<html class="gs_el_sm gs_pfcs"><head><title>‪dean fennell‬ - ‪Google Scholar‬</title><meta http-equiv="Content-Type" content="text/html;charset=UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=Edge"><meta name="referrer" content="origin-when-cross-origin"><meta name="viewport" content="width=device-width,initial-scale=1,minimum-scale=1,maximum-scale=2"><meta name="format-detection" content="telephone=no"><link rel="shortcut icon" href="/favicon.ico"><link rel="canonical" href="https://scholar.google.co.uk/citations?user=IHT1G6gAAAAJ&amp;hl=en"><meta name="description" content="‪University of Leicester‬ - ‪‪Cited by 12,349‬‬"><meta property="og:description" content="‪University of Leicester‬ - ‪‪Cited by 12,349‬‬"><meta property="og:title" content="dean fennell"><meta property="og:image" content="https://scholar.googleusercontent.com/citations?view_op=medium_photo&amp;user=IHT1G6gAAAAJ&amp;citpid=1"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><style>html,body,form,table,div,h1,h2,h3,h4,h5,h6,img,ol,ul,li,button{margin:0;padding:0;border:0;}table{border-collapse:collapse;border-width:0;empty-cells:show;}html,body{height:100%}#gs_top{position:relative;box-sizing:border-box;min-height:100%;min-width:964px;-webkit-tap-highlight-color:rgba(0,0,0,0);}#gs_top>*:not(#x){-webkit-tap-highlight-color:rgba(204,204,204,.5);}.gs_el_ph #gs_top,.gs_el_ta #gs_top{min-width:320px;}#gs_top.gs_nscl{position:fixed;width:100%;}body,td,input,button{font-size:13px;font-family:Arial,sans-serif;line-height:1.24;}body{background:#fff;color:#222;-webkit-text-size-adjust:100%;-moz-text-size-adjust:none;}.gs_gray{color:#777777}.gs_red{color:#dd4b39}.gs_grn{color:#006621}.gs_lil{font-size:11px}.gs_med{font-size:16px}.gs_hlt{font-weight:bold;}a:link{color:#1a0dab;text-decoration:none}a:visited{color:#660099;text-decoration:none}a:hover,a:hover .gs_lbl{text-decoration:underline}a:active,a:active .gs_lbl,a .gs_lbl:active{color:#d14836}.gs_el_tc a:hover,.gs_el_tc a:hover .gs_lbl{text-decoration:none}.gs_pfcs a:focus,.gs_pfcs button:focus,.gs_pfcs input:focus,.gs_pfcs label:focus{outline:none}.gs_a,.gs_a a:link,.gs_a a:visited{color:#006621}.gs_a a:active{color:#d14836}a.gs_fl:link,.gs_fl a:link{color:#1a0dab}a.gs_fl:visited,.gs_fl a:visited{color:#660099}a.gs_fl:active,.gs_fl a:active{color:#d14836}.gs_fl{color:#777777}.gs_ctc,.gs_ctu{vertical-align:middle;font-size:11px;font-weight:bold}.gs_ctc{color:#1a0dab}.gs_ctg,.gs_ctg2{font-size:13px;font-weight:bold}.gs_ctg{color:#1a0dab}a.gs_pda,.gs_pda a{padding:7px 0 5px 0}.gs_alrt{background:#f9edbe;border:1px solid #f0c36d;padding:0 16px;text-align:center;box-shadow:0 2px 4px rgba(0,0,0,.2);border-radius:2px;}.gs_spc{display:inline-block;width:12px}.gs_br{width:0;font-size:0}.gs_ibl{display:inline-block;}.gs_scl:after{content:"";display:table;clear:both;}.gs_ind{padding-left:8px;text-indent:-8px}.gs_ico,.gs_icm{display:inline-block;background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png);background-position:-23px -161px;background-size:169px;width:21px;height:21px;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){.gs_ico,.gs_icm{background-image:url(/intl/en/scholar/images/2x/sprite_20161020.png);}}.gs_el_ta .gs_nta,.gs_ota,.gs_el_ph .gs_nph,.gs_oph{display:none}.gs_el_ta .gs_ota,.gs_el_ph .gs_oph{display:inline}.gs_el_ta div.gs_ota,.gs_el_ph div.gs_oph{display:block}.gs_sth_g{visibility:hidden;max-height:0;}.gs_sth_vis .gs_sth_g{max-height:1000px;}.gs_sth_vis .gs_sth_b{position:fixed;top:0;}@keyframes gs_anm_spin{0%{transform:rotate(0deg);}100%{transform:rotate(360deg);}}.gs_rimg{display:block;background-color:#e5e5e5;border-radius:50%;overflow:hidden;position:relative;z-index:1;}.gs_rimg>img{position:absolute;margin:auto;left:0;top:0;bottom:0;right:0;}.gs_in_txtw{display:inline-block;vertical-align:middle;}.gs_in_txtb{display:block;}.gs_in_txt{color:#000;background-color:#fff;font-size:16px;box-sizing:border-box;height:29px;line-height:23px;border:1px solid #d9d9d9;border-top-color:#c0c0c0;padding:3px 6px 1px 8px;border-radius:1px;outline:none;-webkit-appearance:none;-moz-appearance:none;}.gs_el_tc .gs_in_txt{font-size:18px;}.gs_in_txtb .gs_in_txt{width:100%;}.gs_in_txt:hover{border-color:#b9b9b9;border-top-color:#a0a0a0;box-shadow:inset 0 1px 2px rgba(0,0,0,.1);}.gs_in_txte .gs_in_txt{border-color:#dd4b39;}.gs_in_txt:focus{border-color:#4d90fe;box-shadow:inset 0 1px 2px rgba(0,0,0,.3);}.gs_in_txt:disabled{color:#b8b8b8;border-color:#f1f1f1;box-shadow:none;}.gs_in_txtm .gs_in_txt{font-size:13px;height:24px;line-height:16px;padding:3px 6px;}.gs_el_tc .gs_in_txtm .gs_in_txt{height:29px;line-height:21px;}.gs_in_txts{font-size:13px;line-height:18px;color:#666;}.gs_in_txte .gs_in_txts{color:#dd4b39;}button{position:relative;z-index:1;box-sizing:border-box;font-size:13px;cursor:pointer;height:29px;line-height:normal;min-width:72px;padding:0 8px;color:#444;border:1px solid rgba(0,0,0,.1);border-radius:3px;text-align:center;background-color:#f5f5f5;-webkit-user-select:none;user-select:none;}button.gs_btn_rnd{border-radius:14px;padding:0 12px;}button.gs_btn_rnd.gs_btn_rndci{padding-left:4px;}button.gs_btn_lrge{height:41px;min-width:82px;padding:0 9px;}button.gs_btn_lrge.gs_btn_rnd{border-radius:20px;padding:0 16px;}button.gs_btn_lrge.gs_btn_rnd.gs_btn_rndci{padding-left:10px;}button.gs_btn_cir{border-radius:14.5px;min-width:29px;}button.gs_btn_lrge.gs_btn_cir{border-radius:20.5px;min-width:41px;}button.gs_btn_mini{padding:0;border:0;}.gs_el_ph button.gs_btn_mph,.gs_el_ta button.gs_btn_mta{height:41px;}button .gs_wr{position:relative;display:inline-block;width:100%;height:100%;}button .gs_wr:before{content:"";width:0;height:100%;}button .gs_wr:before,button .gs_ico,button .gs_rdt,button .gs_lbl,button .gs_icm{display:inline-block;vertical-align:middle;}button .gs_wr{font-size:13px;text-transform:none;}.gs_btn_lrge .gs_wr{font-size:15px;}.gs_btn_lsb .gs_wr{font-size:11px;font-weight:bold;}.gs_btn_lsu .gs_wr{font-size:11px;text-transform:uppercase;}.gs_btn_lrge.gs_btn_lsb .gs_wr,.gs_btn_lrge.gs_btn_lsu .gs_wr{font-size:13px;}.gs_btn_half,.gs_el_ta .gs_btn_hta,.gs_el_ph .gs_btn_hph{min-width:36px;}.gs_btn_lrge.gs_btn_half,.gs_el_ta .gs_btn_lrge.gs_btn_hta,.gs_el_ph .gs_btn_lrge.gs_btn_hph,.gs_el_ta .gs_btn_mta,.gs_el_ph .gs_btn_mph{min-width:41px;}.gs_btn_slt{border-radius:3px 0 0 3px;}.gs_btn_srt{margin-left:-1px;border-radius:0 3px 3px 0;}.gs_btn_smd{margin-left:-1px;border-radius:0;}button:hover{z-index:2;color:#222;border-color:rgba(0,0,0,.2);background-color:#f8f8f8;}button.gs_sel{background-color:#dcdcdc;}button:active{z-index:2;background-color:#f1f1f1;}button:focus{z-index:2;}button::-moz-focus-inner{padding:0;border:0}button:-moz-focusring{outline:1px dotted ButtonText}.gs_pfcs button:-moz-focusring{outline:none}a.gs_in_ib{position:relative;display:inline-block;line-height:16px;padding:6px 0 7px 0;-webkit-user-select:none;user-select:none;}a.gs_btn_lrge{height:40px;padding:0;}a.gs_in_ib .gs_lbl{display:inline-block;padding-left:21px;color:#222;}a.gs_in_ib .gs_lbl:not(:empty){padding-left:29px;}button.gs_in_ib .gs_lbl:not(:empty){padding-left:4px;}a.gs_in_ib:active .gs_lbl,a.gs_in_ib .gs_lbl:active,a.gs_in_ib :active~.gs_lbl{color:#d14836;}.gs_el_ta .gs_btn_hta .gs_lbl,.gs_el_ph .gs_btn_hph .gs_lbl,.gs_el_ta .gs_btn_mta .gs_lbl,.gs_el_ph .gs_btn_mph .gs_lbl,.gs_el_ta .gs_btn_cta .gs_lbl,.gs_el_ph .gs_btn_cph .gs_lbl{display:none;}a.gs_in_ib .gs_ico{position:absolute;top:3px;left:0;}.gs_in_ib.gs_md_li .gs_ico{left:14px;}.gs_el_tc .gs_in_ib.gs_md_li .gs_ico{top:11px;}.gs_in_ib.gs_md_li.gs_md_lix .gs_ico{top:10px;left:16px;}a.gs_btn_lrge .gs_ico{top:50%;left:50%;margin:-10.5px 0 0 -10.5px;}.gs_in_ib .gs_ico{opacity:.55;}.gs_in_ib:hover .gs_ico{opacity:.72;}.gs_in_ib:active .gs_ico,.gs_in_ib .gs_ico:active,.gs_in_ib :active~.gs_ico{opacity:1;}.gs_in_ib:disabled .gs_ico,.gs_in_ib.gs_dis .gs_ico{opacity:.28;}.gs_in_ib.gs_btn_act .gs_ico,.gs_in_ib.gs_btn_cre .gs_ico{opacity:1;}.gs_btn_act:disabled .gs_ico,.gs_btn_cre:disabled .gs_ico{opacity:.72;}.gs_rdt{position:relative;width:0;height:21px;}.gs_rdt:before{content:"";position:absolute;top:2px;right:1px;width:5px;height:5px;border-radius:50%;background-color:#dd4b39;}button.gs_btn_flat{border-color:transparent;background-color:transparent;}button.gs_btn_flat:hover{background-color:rgba(0,0,0,.05);}button.gs_btn_flat:active{background-color:rgba(0,0,0,.1);}button.gs_btn_flat.gs_btn_flact{color:#1a0dab;}button.gs_btn_act{color:#fff;-webkit-font-smoothing:antialiased;background-color:#4d90fe;}button.gs_btn_act:hover{color:#fff;background-color:#3983fe;}button.gs_btn_act.gs_sel{background-color:#2f6bcc;}button.gs_btn_act:active{background-color:#357ae8;}button.gs_btn_cre{color:#fff;-webkit-font-smoothing:antialiased;background-color:#d14836;}button.gs_btn_cre:hover{color:#fff;background-color:#c53727;}button.gs_btn_cre.gs_sel{background-color:#992b1e;}html:not(.gs_pfcs) .gs_btn_act:focus:not(:active){box-shadow:inset 0 0 0 1px rgba(255,255,255,.5);}button.gs_btn_cre:active{background-color:#b0281a;}button:disabled,button:disabled:hover,button:disabled:active{cursor:default;color:#b8b8b8;border-color:rgba(0,0,0,.05);background-color:transparent;z-index:0;}button.gs_btn_flat:disabled{color:#b8b8b8;border-color:transparent;}button.gs_btn_act:disabled{color:#fff;background-color:#a6c8ff;}button.gs_btn_cre:disabled{color:#fff;background-color:#e8a49b;}a.gs_in_ib.gs_dis{cursor:default;pointer-events:none}a.gs_in_ib.gs_dis .gs_lbl{color:#b8b8b8;text-decoration:none}.gs_ttp{position:absolute;top:100%;right:50%;z-index:10;pointer-events:none;visibility:hidden;opacity:0;transition:visibility 0s .13s,opacity .13s ease-out;}button:hover .gs_ttp,button:focus .gs_ttp,a:hover .gs_ttp,a:focus .gs_ttp{transition:visibility 0s .3s,opacity .13s ease-in .3s;visibility:visible;opacity:1;}.gs_md_tb.gs_sel .gs_ttp{transition:none;visibility:hidden;}button.gs_btn_lrge.gs_btn_cir .gs_ttp{top:75%;}.gs_ttp .gs_aro,.gs_ttp .gs_aru{position:absolute;top:-2px;right:-5px;width:0;height:0;line-height:0;font-size:0;border:5px solid transparent;border-top:none;border-bottom-color:#595959;z-index:1;}.gs_ttp .gs_aro{top:-3px;right:-6px;border-width:6px;border-top:none;border-bottom-color:white;}.gs_ttp .gs_txt{display:block;position:relative;top:2px;right:-50%;padding:4px 6px;background:#595959;color:white;font-size:11px;font-weight:bold;line-height:normal;white-space:nowrap;border:1px solid white;border-radius:3px;box-shadow:inset 0 1px 4px rgba(0,0,0,.2);}.gs_press,.gs_in_se,.gs_tan{touch-action:none;}.gs_in_se .gs_lbl:not(:empty){padding-right:14px;}.gs_in_se .gs_icm{position:absolute;top:50%;margin-top:-5.5px;right:0;width:7px;height:11px;background-position:-21px -88px;opacity:.55;}.gs_in_se:hover .gs_icm{opacity:.72;}.gs_in_se:active .gs_icm{opacity:1;}.gs_in_se:disabled .gs_icm{opacity:.28;}.gs_el_ta .gs_btn_hta .gs_icm,.gs_el_ph .gs_btn_hph .gs_icm,.gs_el_ta .gs_btn_mta .gs_icm,.gs_el_ph .gs_btn_mph .gs_icm,.gs_el_ta .gs_btn_cta .gs_icm,.gs_el_ph .gs_btn_cph .gs_icm{display:none;}.gs_btn_mnu .gs_icm{margin-top:-3.5px;height:7px;background-position:0 -110px;}.gs_in_se.gs_btn_act .gs_icm,.gs_in_se.gs_btn_cre .gs_icm{margin-top:-3.5px;height:7px;background-position:-42px -44px;opacity:1;}.gs_btn_act:disabled .gs_icm,.gs_btn_cre:disabled .gs_icm{opacity:.72;}button.gs_btnG .gs_ico{width:21px;height:21px;background-position:-92px -253px;}button .gs_bs{position:absolute;top:50%;left:50%;margin-top:-10px;margin-left:-10px;box-sizing:border-box;width:20px;height:20px;border-radius:50%;border:2px solid #eee;border-top-color:#4d90fe;visibility:hidden;animation:gs_anm_spin .8s linear infinite;}button.gs_bsp .gs_bs{visibility:visible;transition:visibility 0s .4s;}.gs_md_d{text-transform:none;white-space:nowrap;position:absolute;top:0;left:0;border:1px solid #ccc;border-color:rgba(0,0,0,.2);background:#fff;box-shadow:0 2px 4px rgba(0,0,0,.2);z-index:1100;text-align:left;visibility:hidden;max-height:0;margin-top:-1000px;opacity:0;transition:opacity .13s,visibility 0s .13s,max-height 0s .13s,margin-top 0s .13s;}.gs_md_d.gs_vis{visibility:visible;max-height:10000px;margin-top:0;opacity:1;transition:all 0s;}.gs_el_tc .gs_md_d{transform-origin:100% 0;transform:scale(1,0);transition:opacity .218s ease-out,transform 0s .218s,visibility 0s .218s,max-height 0s .218s,margin-top 0s .218s;}.gs_el_ios .gs_md_d{-webkit-backface-visibility:hidden;}.gs_el_tc .gs_md_d.gs_ttzi{transform-origin:50% 50%;transform:scale(0,0);}.gs_el_tc .gs_md_d.gs_ttzr{transform:scale(0,0);}.gs_el_tc .gs_md_d.gs_vis{transform:scale(1,1);transition:transform .218s ease-out;}.gs_md_r{position:relative;display:inline-block;}.gs_md_rmb>.gs_md_d{top:29px}.gs_md_rmbl>.gs_md_d{top:41px}.gs_md_ul{list-style-type:none;word-wrap:break-word;display:inline-block;vertical-align:top;}.gs_md_ul.gs_md_ul_tb{display:block;}.gs_md_li,.gs_in_cb.gs_md_li,.gs_md_li:link,.gs_md_li:visited{display:block;padding:6px 44px 6px 16px;font-size:13px;line-height:16px;color:#222;cursor:pointer;text-decoration:none;position:relative;z-index:0;}a.gs_md_li:hover .gs_lbl,a.gs_md_li:active .gs_lbl{text-decoration:none}.gs_el_tc .gs_md_li{padding-top:14px;padding-bottom:10px;}.gs_md_li.gs_md_lix{font-size:16px;line-height:20px;padding:12px 16px 8px 16px;}.gs_md_li:before{content:"";background-color:#f1f1f1;position:absolute;left:0;right:0;top:0;bottom:0;opacity:0;transition:opacity .13s;z-index:-1;}.gs_md_li:hover:before,.gs_md_li:focus:before{opacity:1;transition:all 0s;}a.gs_in_ib.gs_md_li .gs_lbl{color:#222}a.gs_in_ib.gs_md_li.gs_in_gray .gs_lbl{color:#444}.gs_md_li:active:before{background-color:#ddd}.gs_md_li.gs_sel,a.gs_in_ib.gs_md_li.gs_sel .gs_lbl{color:#d14836}.gs_md_d:focus,.gs_md_li:focus{outline:none}a.gs_md_lix .gs_lbl,a.gs_md_lix .gs_lbl:not(:empty){padding:0 0 0 40px;}a.gs_in_cb:link,a.gs_in_cb:visited,a.gs_in_cb:active,a.gs_in_cb:hover{cursor:pointer;color:#222;text-decoration:none;}.gs_in_cb,.gs_in_ra{position:relative;line-height:16px;display:inline-block;-webkit-user-select:none;user-select:none;}.gs_in_cb.gs_md_li{padding:6px 44px 6px 16px;}.gs_in_cb input,.gs_in_ra input{position:absolute;top:1px;left:1px;width:15px;height:15px;margin:0;padding:0;opacity:0;z-index:2;}.gs_in_ra input{top:0;left:0}.gs_el_tc .gs_in_cb input{top:9px}.gs_el_tc .gs_in_ra input{top:8px}.gs_in_cb.gs_in_cbj input{top:15px;left:15px}.gs_in_cb label,.gs_in_cb .gs_lbl,.gs_in_ra label{display:inline-block;padding-left:21px;min-height:16px;}.gs_in_cb label:empty:before,.gs_in_cb .gs_lbl:empty:before,.gs_in_ra label:empty:before{content:"\200b";}.gs_el_tc .gs_in_cb label,.gs_el_tc .gs_in_cb .gs_lbl,.gs_el_tc .gs_in_ra label{padding-top:8px;padding-bottom:5px;}.gs_in_cb.gs_in_cbj label,.gs_in_cb.gs_in_cbj .gs_lbl{padding:13px 0 12px 41px;}.gs_in_cbb,.gs_in_cbb label,.gs_in_cbb .gs_lbl{display:block;}.gs_in_cb .gs_cbx,.gs_in_ra .gs_cbx{position:absolute}.gs_in_cb .gs_cbx{top:2px;left:2px;width:11px;height:11px;border:1px solid #c6c6c6;border-radius:1px;}.gs_md_li .gs_cbx{top:8px;left:18px}.gs_el_tc .gs_in_cb .gs_cbx{top:10px}.gs_el_tc .gs_md_li .gs_cbx{top:16px}.gs_in_cb.gs_in_cbj .gs_cbx{top:15px;left:15px}.gs_el_tc .gs_in_ra .gs_cbx{top:8px}.gs_in_ra .gs_cbx{top:0;left:0;border:1px solid #c6c6c6;width:13px;height:13px;border-radius:7px;}.gs_in_cb:hover .gs_cbx,.gs_in_ra:hover .gs_cbx{border-color:#666;box-shadow:inset 0 1px 1px rgba(0,0,0,.1);}button.gs_in_cb:hover .gs_cbx{border-color:#c6c6c6;}.gs_in_cb :focus~label,.gs_in_ra :focus~label{outline:1px dotted #222;outline:auto -webkit-focus-ring-color;}.gs_pfcs .gs_in_cb :focus~label,.gs_pfcs .gs_in_ra :focus~label{outline:none;}.gs_in_cb:active .gs_cbx,.gs_in_ra:active .gs_cbx,.gs_in_cb .gs_cbx:active,.gs_in_ra .gs_cbx:active,.gs_in_cb :active~.gs_cbx,.gs_in_ra :active~.gs_cbx{border-color:#666;background-color:#ebebeb;}button.gs_in_cb:active .gs_cbx{border-color:#a6a6a6;}.gs_in_cb :disabled~.gs_cbx,.gs_in_ra :disabled~.gs_cbx,button.gs_in_cb:disabled .gs_cbx{border-color:#f1f1f1;box-shadow:none;}.gs_in_cb :disabled~label,.gs_in_ra :disabled~label{color:#b8b8b8;}.gs_in_cb.gs_err .gs_cbx{border-color:#eda29b;}.gs_in_cb .gs_chk,.gs_in_ra .gs_chk{position:absolute;z-index:1;top:-3px;left:-2px;width:21px;height:21px;}.gs_md_li .gs_chk{top:3px;left:14px}.gs_el_tc .gs_in_cb .gs_chk{top:5px}.gs_el_tc .gs_md_li .gs_chk{top:11px}.gs_in_cb.gs_in_cbj .gs_chk{top:10px;left:11px}.gs_in_ra .gs_chk{top:4px;left:4px;width:7px;height:7px;border-radius:4px;}.gs_el_tc .gs_in_ra .gs_chk{top:12px}.gs_in_cb input:checked~.gs_chk,.gs_in_cb.gs_sel .gs_chk{background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png) -69px -67px;opacity:.62;}.gs_in_ra input:checked~.gs_chk{background-color:#666}.gs_in_cb.gs_par .gs_chk{background:no-repeat url(/intl/en/scholar/images/1x/sprite_20161020.png) -21px -44px;opacity:.55;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){.gs_in_cb input:checked~.gs_chk,.gs_in_cb.gs_sel .gs_chk,.gs_in_cb.gs_par .gs_chk{background-image:url(/intl/en/scholar/images/2x/sprite_20161020.png);background-size:169px;}}.gs_in_cb input:checked:disabled~.gs_chk{opacity:.22}.gs_in_ra input:checked:disabled~.gs_chk{background-color:#f1f1f1}.gs_ico_x{background-position:-113px -22px;opacity:.55;}.gs_ico_x:hover{opacity:.72;}.gs_ico_x:active{opacity:1;}.gs_ico_X{background-position:-71px 0;opacity:.55;}.gs_ico_X:hover{opacity:.72;}.gs_ico_X:active{opacity:1;}.gs_el_tc .gs_ico_Xt{background-origin:content-box;background-clip:content-box;padding:10px 6px 10px 14px;}.gs_ico_P{background-position:0 0;opacity:.55;}.gs_ico_P:hover{opacity:.72;}.gs_ico_P:active{opacity:1;}.gs_btnP .gs_ico{background-position:-21px 0;}.gs_btnC .gs_ico{background-position:0 -66px;}.gs_btnL .gs_ico{background-position:-92px -44px;}.gs_ico_LB{background-position:-50px -44px;height:16px;}.gs_btnJ .gs_ico{background-position:-92px -22px;}.gs_btnM .gs_ico{background-position:-92px 0;}.gs_btnMW .gs_ico{background-position:-21px -22px;}.gs_btnSB .gs_ico{background-position:0 -44px;}.gs_btnTSB .gs_ico{background-position:-115px -253px;}.gs_btnPL .gs_ico{background-position:-148px -66px;}.gs_btnPR .gs_ico{background-position:-21px -66px;}.gs_btnPLW .gs_ico{background-position:-0 -230px;}.gs_btnPRW .gs_ico{background-position:-23px -230px;}.gs_btnZI .gs_ico{background-position:-148px -22px;}.gs_btnZO .gs_ico{background-position:-127px -44px;}.gs_btnDE .gs_ico{background-position:-134px 0;}.gs_btnFI .gs_ico{background-position:-50px -66px;}.gs_btnAD .gs_ico{background-position:-141px -88px;opacity:.55;}.gs_btnAD:hover .gs_ico{opacity:.72;}.gs_btnAD:active .gs_ico,.gs_btnAD .gs_ico:active,.gs_btnAD :active~.gs_ico{opacity:1;}.gs_btnBA .gs_ico{background-position:-50px -22px;}.gs_btnADD .gs_ico{background-position:-92px -66px;}.gs_btnMRG .gs_ico{background-position:-113px 0;}.gs_btnLBL .gs_ico{background-position:0 -161px;}.gs_btnCNCL .gs_ico{background-position:-71px 0;}.gs_btnDWL .gs_ico{background-position:-28px -88px;}.gs_btnMNU .gs_ico{background-position:0 -88px;}.gs_btnMNT .gs_ico{background-position:-46px -161px;}.gs_btnALT .gs_ico{background-position:-92px -161px;}.gs_btnART .gs_ico{background-position:-115px -161px;}.gs_btnGSL .gs_ico{background-position:-69px -161px;}.gs_btnCLS .gs_ico{background-position:-138px -161px;}.gs_btnXBLU .gs_ico{background-position:-138px -253px;}.gs_btnSSB .gs_ico{background-position:0 -276px;}.gs_btnSSW .gs_ico{background-position:-23px -276px;}.gs_btnFLT .gs_ico{background-position:0 -184px;}.gs_btnXT .gs_ico{background-position:-46px -184px;}.gs_btnPD .gs_ico{background-position:-69px -184px;}.gs_btnPU .gs_ico {background-position:-92px -276px;}.gs_btnCP .gs_ico{background-position:-92px -184px;}.gs_btnTP .gs_ico{background-position:-138px -184px;}.gs_btnML .gs_ico{background-position:-115px -276px;}.gs_btnCHK .gs_ico{background-position:-71px -66px;}.gs_btnDNB .gs_ico{background-position:-115px -230px;}.gs_btnDNW .gs_ico{background-position:0 -207px;}.gs_btnACA .gs_ico{background-position:-23px -207px;}.gs_btnAPT .gs_ico{background-position:-46px -207px;}.gs_btnAPTW .gs_ico{background-position:-92px -230px;}.gs_btnAFL .gs_ico{background-position:-69px -207px;}.gs_btnAN .gs_ico{background-position:-46px -276px;}.gs_btnAI .gs_ico{background-position:-69px -276px;}.gs_btnPBL .gs_ico{background-position:-92px -207px;}.gs_btnUCT .gs_ico{background-position:-115px -207px;}.gs_btnVRF .gs_ico{background-position:-138px -207px;}.gs_btnLSI .gs_ico{background-position:-46px -230px;}.gs_btnLSG .gs_ico{background-position:-69px -230px;}.gs_btnMOR .gs_ico{background-position:-23px -253px;}.gs_btnADV .gs_ico{background-position:-46px -253px;}.gs_btnPRO .gs_ico{background-position:-69px -253px;}.gs_ico_star{background-position:-71px -44px;width:13px;height:13px;}.gs_btnPLSW .gs_ico{background-position:-138px -230px;}.gs_btnPDF .gs_ico{background-position:0 -253px;}.gs_btnS .gs_ico{background-position:-138px -276px;}.gs_btnUNS .gs_ico{background-position:0 -299px;}.gs_btnMORR .gs_ico{background-position:-23px -299px;}.gs_btnTW .gs_ico{background-position:-46px -299px;}.gs_btnIN .gs_ico{background-position:-69px -299px;}.gs_btnFB .gs_ico{background-position:-92px -299px;}#gs_hdr_drs,#gs_hdr_drw{position:fixed;top:0;left:0;width:100%;height:100%;z-index:1200;visibility:hidden;}#gs_hdr_drs{opacity:0;background-color:#fff;transition:opacity .15s,visibility 0s .15s;}.gs_el_ta #gs_hdr_drs,.gs_el_ph #gs_hdr_drs{background-color:#666;}#gs_hdr_drs.gs_vis{visibility:visible;opacity:.5;transition:opacity .15s,visibility 0s;}.gs_el_tc #gs_hdr_drs{transition:opacity .218s,visibility 0s .218s;}.gs_el_tc #gs_hdr_drs.gs_vis{transition:opacity .218s,visibility 0s;}#gs_hdr_drw{overflow:auto;width:228px;background-color:#fff;box-shadow:2px 2px 4px rgba(0,0,0,.15);outline:none;transform:translate(-100%,0);transition:transform .15s ease-in-out,visibility 0s .15s;}#gs_hdr_drw.gs_vis{visibility:visible;transform:translate(0,0);transition:transform .15s ease-in-out,visibility 0s;}.gs_el_tc #gs_hdr_drw{transition:transform .3s cubic-bezier(.4,0,.6,1),visibility 0s .3s;}.gs_el_tc #gs_hdr_drw.gs_vis{transition:transform .225s cubic-bezier(0,0,.2,1),visibility 0s;}#gs_hdr_drw.gs_abt,.gs_el_tc #gs_hdr_drw.gs_abt{transition:none;}#gs_hdr_drw_in{position:relative;box-sizing:border-box;min-height:100%;padding:0 0 8px 0;}.gs_el_ta #gs_hdr_drw_in,.gs_el_ph #gs_hdr_drw_in{padding:0 0 65px 0;}#gs_hdr_drw_top{position:relative;height:63px;border-bottom:1px solid #e5e5e5;margin-bottom:8px;}.gs_el_ta #gs_hdr_drw_top,.gs_el_ph #gs_hdr_drw_top{height:57px;}#gs_hdr_drw_mnu,#gs_hdr_drw_lgo{position:absolute;top:0;height:100%;}#gs_hdr_drw_mnu{left:0;width:55px;}#gs_hdr_drw_lgo{left:56px;}.gs_hdr_drw_sec:before{display:block;content:" ";height:0;border-bottom:1px solid #e5e5e5;margin:8px 0;}.gs_hdr_drw_sec:first-child:before{display:none;}#gs_hdr_drw_bot{display:none;}.gs_el_ta #gs_hdr_drw_bot,.gs_el_ph #gs_hdr_drw_bot{display:block;position:absolute;left:0;bottom:0;width:100%;height:65px;}#gs_hdr_drw_bot .gs_md_li:before{opacity:0;}#gs_hdr_drw_bot .gs_hdr_pp{display:block;position:absolute;bottom:14px;left:15px;pointer-events:none;}#gs_hdr_drw_bot .gs_lbl{display:block;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;}#gs_hdr{position:relative;height:63px;background-color:#f5f5f5;border-bottom:1px solid #e5e5e5;display:flex;}.gs_el_ta #gs_hdr,.gs_el_ph #gs_hdr{height:57px;}#gs_hdr_mnu,#gs_hdr_bck,#gs_hdr_lgo,#gs_hdr_lgt,#gs_hdr_md,#gs_hdr_sre,#gs_hdr_act{display:inline-block;vertical-align:top;position:relative;height:100%;flex:0 0 auto;}#gs_hdr_md{flex:1 1 auto;}#gs_hdr .gs_hdr_mbo,#gs_hdr .gs_hdr_mbo,.gs_el_ta #gs_hdr .gs_hdr_dso,.gs_el_ph #gs_hdr .gs_hdr_dso{display:none;}.gs_el_ta #gs_hdr .gs_hdr_mbo,.gs_el_ph #gs_hdr .gs_hdr_mbo{display:inline-block;}#gs_hdr_mnu,#gs_hdr_bck,#gs_hdr_sre{width:55px;margin-right:1px;}#gs_hdr_lgo,#gs_hdr_drw_lgo{width:149px;background:no-repeat url('/intl/en/scholar/images/1x/scholar_logo_24dp.png') 0% 50%;background-size:149px;}@media(-webkit-min-device-pixel-ratio:1.5),(min-resolution:144dpi){#gs_hdr_lgo,#gs_hdr_drw_lgo{background-image:url('/intl/en/scholar/images/2x/scholar_logo_24dp.png');}}#gs_hdr_lgo{margin-right:31px;}.gs_el_ph #gs_hdr_lgo{margin-right:0;}#gs_hdr_lgt{min-width:164px;margin-right:16px;}#gs_hdr_lgt:empty{display:none;}#gs_hdr_md{margin-right:16px;min-width:1px;}#gs_hdr_lgt,#gs_hdr_md h1{padding:19px 0 0 0;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;font-size:20px;line-height:25px;font-weight:normal;color:#666;max-width:100%;text-align:left;}.gs_el_ta #gs_hdr_md h1,.gs_el_ph #gs_hdr_md h1{padding:16px 0 0 0;}#gs_hdr_srch{padding:14px 0 0 0;max-width:600px;}.gs_el_ta #gs_hdr_srch,.gs_el_ph #gs_hdr_srch{padding:10px 0 0 0;max-width:none;}#gs_hdr_frm{position:relative;padding-right:39px;}#gs_hdr_tsi{height:38px;border-radius:2px 0 0 2px;}#gs_hdr_tsi::-ms-clear{display:none;}#gs_hdr_tsc{display:none;position:absolute;top:3px;right:41px;width:21px;height:21px;padding:6px 10px 7px 10px;}.gs_in_acw[dir="rtl"]~#gs_hdr_tsc{right:auto;left:1px;}#gs_hdr_tsb{position:absolute;top:0;right:0;width:40px;height:38px;border-radius:0 2px 2px 0;}#gs_hdr_frm_ac{top:37px;right:40px;}.gs_el_ph #gs_hdr_frm_ac{right:0;}.gs_el_ph .gs_hdr_ifc #gs_hdr_mnu,.gs_el_ph .gs_hdr_ifc #gs_hdr_bck,.gs_hdr_src #gs_hdr_srch,.gs_hdr_src #gs_hdr_lgt,.gs_hdr_srx #gs_hdr_sre,.gs_hdr_srx #gs_hdr_md h1,.gs_hdr_srx #gs_hdr_md h1.gs_hdr_mbo,.gs_hdr_srx #gs_hdr_md h1.gs_hdr_dso,.gs_el_ta .gs_hdr_srx #gs_hdr_lgo,.gs_el_ph .gs_hdr_srx #gs_hdr_lgo,.gs_el_ph .gs_hdr_srx #gs_hdr_mnu,.gs_el_ph .gs_hdr_srx #gs_hdr_bck{display:none;}.gs_el_ph .gs_hdr_ifc #gs_hdr_md,.gs_el_ph .gs_hdr_srx #gs_hdr_md{margin-left:16px;}.gs_el_tc .gs_hdr_tsc #gs_hdr_tsi[dir="ltr"]{padding-right:41px;}.gs_el_tc .gs_hdr_tsc #gs_hdr_tsi[dir="rtl"]{padding-left:41px;}.gs_el_tc .gs_hdr_tsc .gs_in_acw~#gs_hdr_tsc{display:block;}#gs_hdr_act{min-width:64px;max-width:200px;text-align:right;float:right;}.gs_el_ta #gs_hdr_act,.gs_el_ph #gs_hdr_act{display:none;}#gs_hdr_act_i,#gs_hdr_act_s{display:inline-block;padding:23px 24px 23px 16px;max-width:100%;box-sizing:border-box;font-size:13px;line-height:17px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;color:#444;}#gs_hdr_act_s{text-transform:uppercase;}.gs_el_sm #gs_hdr_act_i,.gs_el_sm #gs_hdr_act_s{padding:23px 16px;}.gs_el_ta #gs_hdr_act_i,.gs_el_ta #gs_hdr_act_s,.gs_el_ph #gs_hdr_act_i,.gs_el_ph #gs_hdr_act_s{padding:20px 16px;}#gs_hdr_act_i:active,#gs_hdr_act_s:active{color:#d14836;}#gs_hdr_act_i,.gs_el_sm #gs_hdr_act_i{padding-top:15px;padding-bottom:16px;}.gs_el_ta #gs_hdr_act_i,.gs_el_ph #gs_hdr_act_i{padding-top:12px;padding-bottom:13px;}#gs_hdr_act_i .gs_hdr_pp{vertical-align:top;}#gs_hdr_act_d{top:63px;left:auto;right:24px;min-width:288px;max-width:400px;}.gs_el_sm #gs_hdr_act_d{right:16px;}.gs_el_ta #gs_hdr_act_d{top:57px;}.gs_el_ph #gs_hdr_act_d{top:57px;min-width:280px;max-width:280px;max-width:90vw;}/* Account dialog body. */#gs_hdr_act_aw,#gs_hdr_act_ap,.gs_hdr_act_am,#gs_hdr_act_ab{display:block;padding:10px 20px;word-wrap:break-word;white-space:normal;}#gs_hdr_act_aw{background-color:#fef9db;font-size:11px;}#gs_hdr_act_ap,.gs_hdr_act_am{border-bottom:1px solid #ccc;}#gs_hdr_act_ap{padding:20px;}.gs_el_ph #gs_hdr_act_ap{padding:10px;}#gs_hdr_act_apb{margin-top:12px;}#gs_hdr_act_aa:link,#gs_hdr_act_aa:visited{float:right;margin-left:8px;color:#1a0dab;}#gs_hdr_act_aa:active{color:#d14836}.gs_hdr_act_am:link,.gs_hdr_act_am:visited{color:#222;text-decoration:none;background:#fbfbfb;}.gs_hdr_act_am:hover,.gs_hdr_act_am:focus{background:#f1f1f1;}.gs_hdr_act_am:active{background:#eee;}#gs_hdr_act_ab{background:#fbfbfb;padding:10px 0;display:table;width:100%;white-space:nowrap;}#gs_hdr_act_aba,#gs_hdr_act_abs{display:table-cell;padding:0 20px;}#gs_hdr_act_abs{text-align:right;}.gs_el_ph #gs_hdr_act_aba,.gs_el_ph #gs_hdr_act_abs{display:block;padding:10px;text-align:center;}.gs_el_ph #gs_hdr_act_aba button,.gs_el_ph #gs_hdr_act_abs button{width:100%;}#gs_hdr_act_a1,#gs_hdr_act_a2{position:absolute;top:-9px;right:7.5px;width:0;height:0;z-index:1;border:8.5px solid transparent;border-top:none;border-bottom-color:#333;border-bottom-color:rgba(0,0,0,.2);}#gs_hdr_act_a2{top:-8px;border-bottom-color:#fff;}.gs_hdr_act_mw #gs_hdr_act_a2{border-bottom-color:#fef9db;}.gs_hdr_pp{border-radius:50%;overflow:hidden;}#gs_hdr_act_ap .gs_hdr_pp,.gs_hdr_act_am .gs_hdr_pp{float:left;}#gs_hdr_act_ap .gs_hdr_pm{margin-left:116px;}.gs_hdr_act_am .gs_hdr_pm{margin:6px 0 0 58px;}#gs_ab{position:relative;height:41px;border-bottom:1px solid #e5e5e5;display:flex;white-space:nowrap;background-color:#fff;z-index:1000;}.gs_el_ta #gs_ab.gs_nta,.gs_el_ph #gs_ab.gs_nph{display:none;}#gs_ab_g{height:42px;}.gs_sth_vis #gs_ab{position:fixed;}#gs_ab_ico,#gs_ab_ttl,#gs_ab_md,#gs_ab_btns{display:inline-block;vertical-align:top;position:relative;height:100%;flex:0 0 auto;}.gs_el_ph #gs_ab_md{display:block;}#gs_ab_ico{width:55px;margin-right:1px;}#gs_ab_ico .gs_ico{position:absolute;top:50%;left:50%;margin:-10.5px 0 0 -10.5px;}#gs_ab_ttl{min-width:172px;padding-right:8px;}.gs_el_sm #gs_ab_ttl{min-width:68px;}.gs_el_ta #gs_ab_ttl,.gs_el_ph #gs_ab_ttl{min-width:0;}#gs_ab_ttl,#gs_ab_ttll{font-size:18px;color:#666;text-transform:none;}.gs_el_sm #gs_ab_ttl,.gs_el_sm #gs_ab_ttll{font-size:16px;}#gs_ab_ttll{overflow:hidden;text-overflow:ellipsis;max-width:200px;}#gs_ab_md{flex:1 0 auto;}.gs_ab_st #gs_ab_md{flex:1 1 auto;font-size:13px;line-height:17px;padding:0 8px;color:#999;overflow:hidden;text-overflow:ellipsis;}.gs_el_ph .gs_ab_st #gs_ab_md{visibility:hidden;padding:0;}#gs_ab_btns{margin-right:8px;}.gs_el_sm #gs_ab_btns{margin-right:0;}.gs_el_ta #gs_ab_btns,.gs_el_ph #gs_ab_btns{margin-right:4px;}#gs_ab_ttl:before,#gs_ab_md:before,#gs_ab_btns:before{content:"";display:inline-block;width:0;height:100%;vertical-align:middle;}#gs_ab_md>button,#gs_ab_btns>button,#gs_ab_md>.gs_in_ib,#gs_ab_btns>.gs_in_ib,#gs_ab_md>.gs_md_r,#gs_ab_btns>.gs_md_r,#gs_ab .gs_ab_mdw,#gs_ab .gs_ab_btw{margin:0 8px;vertical-align:middle;}#gs_ab .gs_ab_mdw,.gs_ab_btw{display:inline-block;margin:0;}#gs_ab_btns>.gs_in_ib{margin:0 16px 0 8px;}#gs_ab .gs_ab_btw{margin:0 12px 0 16px;}.gs_el_ta .gs_ab_sel #gs_ab_ico,.gs_el_ph .gs_ab_sel #gs_ab_ico,.gs_el_ta .gs_ab_sel #gs_ab_ttl,.gs_el_ph .gs_ab_sel #gs_ab_ttl,.gs_el_ta .gs_ab_sel #gs_ab_btns,.gs_el_ph .gs_ab_sel #gs_ab_btns{display:none;}#gs_bdy{display:table;table-layout:fixed;width:100%;}#gs_bdy_sb{vertical-align:top;width:228px;word-wrap:break-word;display:none;}.gs_el_sm #gs_bdy_sb{}.gs_el_ta #gs_bdy_sb,.gs_el_ph #gs_bdy_sb{}.gs_bdy_sb_sec{margin:0 40px 0 56px;}.gs_bdy_sb_sec:before{display:block;content:" ";height:0;margin:13px 0;border-top:1px solid #eee;}.gs_bdy_sb_sec:first-child:before{margin:21px 0 0 0;border:none;}#gs_bdy_sb ul{list-style-type:none;}.gs_bdy_sb_sec a:link,.gs_bdy_sb_sec a:visited{color:#222;}.gs_bdy_sb_sec a:active{color:#d14836;}.gs_bdy_sb_sel a:link,.gs_bdy_sb_sel a:visited{color:#d14836;text-decoration:none;}.gs_el_tc .gs_bdy_sb_sec li.gs_ind,.gs_el_tc .gs_bdy_sb_sec li.gs_ind a{padding-top:8px;padding-bottom:5px;}.gs_el_tc .gs_bdy_sb_sec:first-child li.gs_ind:first-child{margin-top:-8px;}#gs_bdy_sb .gs_ind,#gs_bdy_sb .gs_inw{margin-bottom:4px;}.gs_el_tc #gs_bdy_sb .gs_ind,.gs_el_tc #gs_bdy_sb .gs_inw{margin-bottom:0;}#gs_bdy_ccl{display:table-cell;vertical-align:top;padding:0 24px 0 16px;}.gs_el_sm #gs_bdy_ccl{padding:0 16px;}.gs_el_ta #gs_bdy_ccl,.gs_el_ph #gs_bdy_ccl{padding:0 16px;}.gs_el_ph #gs_bdy_ccl{padding:0;}#gs_ftr_sp{height:62px;}.gs_el_sm #gs_ftr_sp{height:57px;}#gs_ftr{position:absolute;bottom:0;left:0;width:100%;white-space:nowrap;border-top:1px solid #e4e4e4;background-color:#f2f2f2;display:flex;}#gs_ftr_rt{box-sizing:border-box;max-width:100%;overflow-x:auto;margin-left:auto;padding:0 12px;}.gs_el_sm #gs_ftr_rt{padding:0 8px;}.gs_el_ph #gs_ftr_rt:after{content:" ";position:absolute;top:0;right:0;width:16px;height:100%;background-image:linear-gradient(to right,rgba(242,242,242,0),rgba(242,242,242,1) 80%);}#gs_ftr_rt a{display:inline-block;line-height:16px;padding:12px;white-space:nowrap;}.gs_el_sm #gs_ftr_rt a{padding:12px 8px;}#gs_ftr_rt a:link,#gs_ftr_rt a:visited{color:#666}#gs_ftr_rt a:active{color:#d14836}#gsc_a_t{width:100%;table-layout:fixed;}#gsc_a_tr0,#gsc_a_trh{box-sizing:border-box;}#gsc_a_tr0 th.gsc_a_x,#gsc_a_tr0 th.gsc_a_t,#gsc_a_tr0 th.gsc_a_c,#gsc_a_tr0 th.gsc_a_y{height:0;}#gsc_a_trh{z-index:700;background-color:#f5f5f5;height:42px;}.gs_el_ta #gsc_a_trh,.gs_el_ph #gsc_a_trh,.gs_el_ta #gsc_a_t td,.gs_el_ph #gsc_a_t td{background-color:#fff;border-bottom:1px solid #e5e5e5;}#gsc_a_t th.gsc_a_x,#gsc_a_t th.gsc_a_t,#gsc_a_t th.gsc_a_c,#gsc_a_t th.gsc_a_y{box-sizing:border-box;text-transform:uppercase;vertical-align:middle;padding-top:0;padding-bottom:0;}#gsc_x_all{z-index:1;}.gsc_a_x,.gsc_a_t,.gsc_a_c,.gsc_a_y,.gsc_a_e{font-weight:normal;padding:16px 16px 0 16px;vertical-align:top;text-align:right;}.gsc_a_c{padding:16px 8px 0 8px;}.gs_el_sm .gsc_a_x,.gs_el_sm .gsc_a_t,.gs_el_sm .gsc_a_c{padding:12px 8px 0 8px;}.gs_el_ta .gsc_a_x,.gs_el_ta .gsc_a_t,.gs_el_ta .gsc_a_c,.gs_el_ph .gsc_a_x,.gs_el_ph .gsc_a_t,.gs_el_ph .gsc_a_c{padding:12px 8px;}.gs_el_sm .gsc_a_y{padding:12px 8px 0 8px;}.gs_el_ta .gsc_a_y{padding-bottom:12px;}.gsc_a_x{width:41px;padding:4px 0 0 0;}.gs_el_sm .gsc_a_x{padding:0;}.gsc_a_t{text-align:left;}.gs_el_ph .gsc_a_t{padding-left:16px;}#gsc_a_ta{display:inline-block;vertical-align:middle;margin-right:16px;}.gs_el_ph #gsc_a_ta{display:none}.gs_el_ph .gsc_a_c{padding-right:16px;}th.gsc_a_c{width:64px;white-space:nowrap;}.gsc_art_sel #gsc_a_ta,.gsc_art_sel #gsc_a_ca,.gsc_art_sel .gsc_a_h{display:none;}.gsc_a_ac,.gsc_a_hc{margin-top:3px;}th.gsc_a_y{width:88px;white-space:nowrap;}.gs_el_sm th.gsc_a_y{width:58px;}.gs_el_ph th.gsc_a_y,.gs_el_ph td.gsc_a_y{width:0;padding:0;}.gs_el_ph .gsc_a_h{display:none}@media print{#gs_top th.gsc_a_y{width:58pt;}#gs_top #gsc_a_tr0{display:none}#gs_top #gsc_a_trh{position:static}}.gsc_a_e{padding:16px;text-align:center;}.gsc_a_a{padding:8px 0}.gsc_a_at{padding:8px 0;font-size:16px}a.gsc_a_acm{text-decoration:line-through;}a.gsc_a_acm:hover,a.gs_a_acm:active{text-decoration:underline;}.gsc_a_m{position:absolute;}.gs_el_ph .gsc_a_m{display:block;position:static;}.gsc_a_am{font-size:24px;position:absolute;top:-18px;left:-2px;padding:8px 12px 4px 8px;}.gs_el_ph .gsc_a_am{display:inline-block;position:static;padding:6px 16px;margin-bottom:-6px;}#gsc_a_sp{visibility:hidden;}#gsc_a_sp.gs_vis{visibility:visible;padding:16px 0;height:25px;border-bottom:1px solid #ccc;}#gsc_a_sp:after{display:block;height:100%;content:" ";background:url('/intl/en/scholar/images/spinner.gif') no-repeat 50% 50%;opacity:0;}#gsc_a_sp.gs_vis:after{opacity:1;transition:opacity 0s .4s;}#gsc_a_err{display:none;padding:28px 0;}#gsc_a_err.gs_vis{display:block;}#gsc_md_iad{width:800px;max-width:94%;}.gs_el_ph #gsc_md_iad{width:100%;max-width:100%;}#gsc_md_iad .gs_md_prg{min-height:400px;}.gs_el_ph #gsc_iads_res .gs_md_prg{margin:0 16px;}#gsc_iad_tart,.gsc_iad_tsel.gsc_iad_tart #gsc_iad_tart,.gsc_iad_tart #gsc_iad_tgrp,.gsc_iad_tsel #gsc_iad_tgrp,#gsc_iad_tsel,#gsc_napb_hdr #gsc_iad_tart,#gsc_napb_hdr #gsc_iad_tgrp{display:none;}#gsc_iad_tgrp,.gsc_iad_tart #gsc_iad_tart,.gsc_iad_tsel #gsc_iad_tsel,#gsc_napb_hdr #gsc_iad_tsel{display:inline-block;}#gsc_iad_t:not(.gsc_iad_tsel) #gsc_iad_tsel{pointer-events:none;color:#b5b5b5;}.gs_el_ph #gsc_napb #gsc_iads_frm{margin:0 16px;}#gsc_iads_res{position:relative;margin:8px 0 16px 0;min-height:80px;border-bottom:1px solid #e5e5e5;}.gs_el_ph #gsc_md_iad #gsc_iads_res{margin:8px -16px 16px -16px;}.gs_el_ph #gsc_napb #gsc_iads_pp{margin-right:16px;}#gsc_iadb_hdr{display:table;table-layout:fixed;width:100%;}#gsc_iadb_hdr_cb,#gsc_iadb_hdr_instr{display:table-cell;vertical-align:middle;height:41px;}#gsc_iadb_hdr_cb{width:41px;}#gsc_iadb_hdr_cb:empty{width:0;}.gs_el_ph #gsc_iadb_hdr_cb:empty{width:16px;}#gsc_iadb_hdr_instr{font-size:16px;}.gs_el_ph #gsc_iadb_hdr_instr{padding-right:16px;}.gsc_oic{position:relative;}.gsc_oic_cb{font-weight:normal;border-top:1px solid #e5e5e5;border-bottom:1px solid #e5e5e5;background-color:#fcfcfc;padding-right:16px;}.gsc_oict{display:block;overflow:hidden;}.gsc_oict_name{display:block;font-size:16px;line-height:20px;word-wrap:break-word;}.gsc_oict_inf{display:block;float:right;margin-left:16px;white-space:nowrap;}.gsc_oict_all,.gsc_oict_prf{font-size:13px;text-transform:uppercase;line-height:20px;}.gsc_oict_all[data-a]{color:#1a0dab;cursor:pointer;}.gsc_oict_all[data-a]:hover{text-decoration:underline;}.gsc_oict_all[data-a]:active{color:#d14836;}.gsc_oict_prf{padding-left:8px;margin-left:8px;border-left:1px solid #e0e0e0;}.gsc_oict_prf:empty{display:none;}.gs_el_ph .gsc_oict_all,.gs_el_ph .gsc_oict_prf{float:right;clear:both;margin:0;padding:0;border:none;}.gs_el_ph .gsc_oict_prf{margin-top:2px;}.gsc_oic_res{margin:8px 0 12px 41px;}.gs_el_ph .gsc_oic_res{margin-right:16px;}.gsc_oic_res h4{font-size:13px;font-weight:normal;}.gsc_oic_dis .gsc_oic_name,.gsc_oic_dis .gsc_oic_all,.gsc_oic_dis .gsc_oic_prf{color:#777;}.gsc_oic_dis .gsc_oict_all[data-a]{color:#1a0dab;opacity:.66;}.gsc_oic_dis .gsc_oic_res{opacity:.5;}.gsc_iadb_art{border-top:1px solid #e5e5e5;overflow:hidden;}.gsc_iadb_art_cb{float:left;}.gsc_iadb_art_added{float:right;margin:12px;font-size:11px;text-transform:uppercase;color:#777;}.gs_el_ph .gsc_iadb_art_added{display:block;float:none;text-align:right;margin:8px 16px;}.gsc_iadb_art_added:empty{display:none;}.gsc_iadb_art_body{margin:12px 0 12px 41px;}.gs_el_ph .gsc_iadb_art_body{margin:12px 16px 12px 41px;}.gsc_iadb_art_body h3{font-size:13px;font-weight:normal;}.gsc_iadb_art_dis .gsc_iadb_art_body{opacity:.5;}#gsc_md_mopt,#gsc_md_cbyd,#gsc_md_cbym{width:600px;}.gs_el_ta #gsc_md_mopt,.gs_el_ta #gsc_md_cbyd,.gs_el_ta #gsc_md_cbym{width:500px;}.gs_el_ph #gsc_md_mopt,.gs_el_ph #gsc_md_cbyd,.gs_el_ph #gsc_md_cbym{width:100%;}.gsc_mob_art{vertical-align:top;padding:8px 0;}.gs_el_tc .gsc_mob_art>.gs_in_ra{margin-top:-8px;}.gsc_mob_cby{vertical-align:top;text-align:right;padding:8px 12px;position:relative;}.gsc_mob_ttl,.gsc_mob_pub{display:block;}.gsc_mob_pub{color:#666;}.gsc_mob_cbym{text-decoration:line-through}.gsc_mob_cbm{font-size:24px;position:absolute;padding:4px 0 0 4px;line-height:16px;}.gs_fsvg line{stroke:#222222}a:link .gs_fsvg{fill:#1a0dab;}a:link .gs_fsvg line{stroke:#1a0dab;}a:visited .gs_fsvg{fill:#660099;}a:visited .gs_fsvg line{stroke:#660099;}a:active .gs_fsvg{fill:#d14836;}a:active .gs_fsvg line{stroke:#d14836;}a .gs_fsvg{border-bottom:1px solid transparent;}a:hover .gs_fsvg,a:focus .gs_fsvg{border-bottom-color:inherit;}.gs_fsml{font-size:13px}.gs_fscp{font-variant:small-caps}.gsh_clim{display:table-row}.gsh_clil,.gsh_clic{display:table-cell;padding-bottom:8px}.gsh_clil{padding-right:8px;}.gsh_lla{list-style-type:lower-alpha}.gsh_lua{list-style-type:upper-alpha}.gsh_llr{list-style-type:lower-roman}.gsh_lur{list-style-type:upper-roman}.gsh_l>li{margin-left:32px;}.gsh_h3{font-size:inherit;font-weight:normal}.gsh_h3,.gsh_csp{margin:16px 0}.gsh_h3+.gsh_csp{margin-top:-8px}.gsh_ovln{text-decoration:overline}.gsh_small .gsh_l .gsh_csp{margin:8px 0}.gsh_small .gsh_csp:first-child,.gsh_small .gsh_h3:first-child{margin-top:0}.gsh_small .gsh_csp:last-child{margin-bottom:0}.gsh_dspfr{text-align:center}.gsh_dspfr svg{margin:8px 0}.gs_pp_tn,.gs_el_ta .gs_pp_mo_tn,.gs_el_ph .gs_pp_mo_tn{width:32px;height:32px;}.gs_pp_sm,.gs_el_ta .gs_pp_mo_sm,.gs_el_ph .gs_pp_mo_sm{width:56px;height:56px;}.gs_pp_nm,.gs_el_ta .gs_pp_mo_nm,.gs_el_ph .gs_pp_mo_nm{width:128px;height:128px;}.gs_ai_pho{float:left;}.gs_ai_t{margin-left:72px;}.gs_ai_pho_pst+.gs_ai_t{margin-left:48px;}.gs_ai_t.gs_ai_pss{margin-left:64px;}.gs_ai_pho_pst+.gs_ai_t.gs_ai_pss{margin-left:40px;}.gs_ai_name{font-size:17px;font-weight:normal;margin-bottom:4px;}.gs_ai_name a{padding:6px 0 4px 0;}.gs_ai_name.gs_ai_name_nlsb{font-size:15px;}.gs_ai_name.gs_ai_name_nlsb a:link,.gs_ai_name.gs_ai_name_nlsb a:visited{padding:7px 0 5px 0; color:#222;}.gs_ai_name.gs_ai_name_nlsb a:active{color:#d14836;}.gs_ai_int{margin-top:5px;}.gs_ai_eml:empty,.gs_ai_int:empty,.gs_ai_cby:empty{display:none;}.gs_ai_one_int{vertical-align:top;font-size:13px;margin-right:8px;white-space:nowrap;display:inline-block;max-width:200px;text-overflow:ellipsis;overflow:hidden;}.gs_el_tc a.gs_ai_one_int{padding:8px 0 5px 0;}.gs_el_ph .gs_ai_eml,.gs_el_ph .gs_ai_cby{margin-top:8px;}.gs_ai_ilnl .gs_ai_int,.gs_ai_ilnl .gs_ai_cby{margin-top:8px;color:#666;}.gs_ai.gs_ai_chpr{position:relative;}.gs_ai_chpr .gs_ai_t{margin-right:276px;}.gs_el_sm .gs_ai_chpr .gs_ai_t{margin-right:156px;}.gs_el_ph .gs_ai_chpr .gs_ai_t{margin-right:0;}.gs_ai_chpr .gs_ai_cby{position:absolute;top:4px;right:0;text-align:right;}.gs_el_sm .gs_ai_chpr .gs_ai_cby,.gs_el_ta .gs_ai_chpr .gs_ai_cby{width:132px;word-wrap:break-word;}.gs_el_ph .gs_ai_chpr .gs_ai_cby{text-align:left;position:static;width:auto;}#gsc_bdy{position:relative;max-width:1200px;margin:0 auto;}.gs_el_ph #gsc_bdy,.gs_el_ta #gsc_bdy{display:flex;flex-flow:column;}.gsc_lcl{position:relative;margin:0 350px 0 0;order:3;}.gs_el_sm .gsc_lcl{margin-right:334px;}.gs_el_ta .gsc_lcl,.gs_el_ph .gsc_lcl{margin:0;}#gsc_prf_t_wrp{position:relative;order:2;overflow:hidden;}.gs_el_tc #gsc_prf_t_wrp:after{display:block;content:"";position:absolute;z-index:100;top:0;right:0;width:12px;height:100%;background-image:linear-gradient(to right,rgba(247,247,247,0),rgba(247,247,247,1) 80%);}#gsc_prf_t{width:100%;background-color:#f5f5f5;display:none;white-space:nowrap;overflow-x:auto;padding:0 4px;}.gs_el_ta #gsc_prf_t,.gs_el_ph #gsc_prf_t{display:block;}#gsc_prf_t:after{content:"\00A0";padding:0 4px;}.gsc_prf_tab,.gsc_prf_tab:link{font-size:13px;text-transform:uppercase;padding:13px 12px;display:inline-block;color:#666;cursor:pointer;}.gsc_prf_tab:hover{color:#000;text-decoration:none}.gsc_prf_tab:active{color:#4d90fe;}.gsc_prf_tab[aria-selected="true"]{border-bottom:2px solid #4d90fe;color:#0461f9;cursor:default;}.gs_el_ta #gsc_art,.gs_el_ph #gsc_art,.gs_el_ta #gsc_rsb_cit,.gs_el_ph #gsc_rsb_cit,.gs_el_ta #gsc_rsb_mnd,.gs_el_ph #gsc_rsb_mnd,.gs_el_ta #gsc_rsb_awd,.gs_el_ph #gsc_rsb_awd,.gs_el_ta #gsc_rsb_co,.gs_el_ph #gsc_rsb_co{display:none;}#gsc_bdy[data-tab="gsc_prf_t-art"] #gsc_art,#gsc_bdy[data-tab="gsc_prf_t-cit"] #gsc_rsb_cit,#gsc_bdy[data-tab="gsc_prf_t-mnd"] #gsc_rsb_mnd,#gsc_bdy[data-tab="gsc_prf_t-awd"] #gsc_rsb_awd,#gsc_bdy[data-tab="gsc_prf_t-ath"] #gsc_rsb_co{display:block;}.gsc_rsb{float:right;width:317px;order:4;border-left:1px solid #eee;margin-top:32px;}.gs_el_sm .gsc_rsb{margin-top:16px;}.gs_el_ph .gsc_rsb,.gs_el_ta .gsc_rsb{float:none;width:auto;border:none;margin:0;}.gsc_rsb_s{margin:0 0 48px 16px;position:relative;}.gs_el_sm .gsc_rsb_s{margin:0 0 32px 16px;}.gs_el_ph .gsc_rsb_s,.gs_el_ta .gsc_rsb_s{margin:0;}.gsc_rsb_s:last-child{margin-bottom:0;}.gsc_rsb_header{padding:8px 8px 12px 8px;border-bottom:1px solid #e5e5e5;font-weight:normal;font-size:15px;}.gs_el_sm .gsc_rsb_header{padding:4px 8px 9px 8px;}.gs_el_ph .gsc_rsb_header,.gs_el_ta .gsc_rsb_header{display:none;}.gsc_rsb_action{position:absolute;top:-3px;right:-2px;}.gs_el_sm .gsc_rsb_action{top:-8px;}.gsc_rsb_tap{display:block;position:absolute;right:2px;top:12px;opacity:.5;z-index:1;}.gs_el_ta .gsc_rsb_tap,.gs_el_ph .gsc_rsb_tap{top:24px;right:10px;}.gsc_rsb_hm{border-bottom:1px solid #e5e5e5;padding:3px 6px;}#gsc_rsb_gpl{display:block;margin-top:3px;padding:6px 16px;line-height:15px;color:#0461f9;border:1px solid #4d90fe;border-radius:2px;text-align:center;text-transform:uppercase;}.gs_el_sm #gsc_rsb_gpl{margin-top:0;}.gs_el_ta #gsc_rsb_gpl,.gs_el_ph #gsc_rsb_gpl{display:none;}#gsc_rsb_st{width:100%;}.gsc_rsb_std{text-align:right;padding-right:8px;}.gs_el_ta .gsc_rsb_std,.gs_el_ph .gsc_rsb_std{padding-right:16px;}.gsc_rsb_sc1{text-align:left;padding:2px 8px;}.gs_el_sm .gsc_rsb_sc1{padding:0 8px;}.gs_el_ta .gsc_rsb_sc1,.gs_el_ph .gsc_rsb_sc1{padding:4px 16px;}.gsc_rsb_sth{font-weight:normal;padding:8px 8px 8px 0;border-bottom:1px solid #e5e5e5;text-align:right;}.gs_el_sm .gsc_rsb_sth{padding:4px 8px 4px 0;}.gs_el_ta .gsc_rsb_sth,.gs_el_ph .gsc_rsb_sth{padding:16px 16px 16px 0;}#gsc_rsb_st tbody:before,#gsc_rsb_st tbody:after{content:'';display:block;height:8px;}.gs_el_sm #gsc_rsb_st tbody:before,.gs_el_sm #gsc_rsb_st tbody:after{height:4px;}.gs_el_ph #gsc_hist_opn,.gs_el_ta #gsc_hist_opn{display:none;}.gsc_rsb_f{max-width:118px;word-wrap:break-word;white-space:normal;}.gs_el_ta .gsc_rsb_f{max-width:none;}.gsc_rsb_f:link,.gsc_rsb_f:visited{color:#222;}.gsc_rsb_m_na{color:#dd4b39;}.gsc_rsb_m_a{color:#006621;float:right;position:relative;}.gsc_rsb_m_bar{width:100%;height:4px;margin:8px 0 8px 0;background:#006621;}.gsc_rsb_m_bar_na{background:#dd4b39;width:100%;height:100%;z-index:1;}.gsc_rsb_m{padding:8px;}.gs_el_ta .gsc_rsb_m,.gs_el_ph .gsc_rsb_m{padding:8px 16px;}.gsc_rsb_m_desc{padding-top:16px;color:#777;}.gsc_rsb_m_s{font-size:24px;position:absolute;line-height:0.3;}#gsc_lwp_mndt_lnk{text-transform:uppercase;margin-left:16px;margin-right:-9px;text-align:right;font-size:13px;padding:12px 9px;border-radius:3px;}#gsc_lwp_mndt_lnk:hover,#gsc_lwp_mndt_lnk:active,#gsc_lwp_mndt_lnk:visited{text-decoration:none;color:#1a0dab;}#gsc_lwp_mndt_lnk:hover{background-color:rgba(0,0,0,.05);}#gsc_lwp_mndt_lnk:active{background-color:rgba(0,0,0,.1);}.gsc_rsb_m_title{padding-bottom:12px;}.gsc_rsb_m_header{display:flex;align-items:flex-end;justify-content:space-between;padding:0 8px;}.gs_el_sm .gsc_rsb_m_header{padding:0 8px;}.gsc_rsb_hmv{text-align:center;padding-top:16px;}.gsc_rsb_a{list-style:none;}.gsc_rsb_a>li{position:relative;}.gs_el_ta .gsc_rsb_a>li,.gs_el_ph .gsc_rsb_a>li{border-bottom:1px solid #e5e5e5;}.gsc_rsb_a>li:first-child{margin-top:8px;}.gsc_rsb_a_pht{float:left;width:32px;height:32px;}.gsc_rsb_a_desc{margin:0 33px 0 48px;min-height:32px;display:block;}.gs_el_ph .gsc_rsb_a_desc,.gs_el_ta .gsc_rsb_a_desc{margin:0 33px 0 64px;min-height:56px;}.gsc_rsb_a_desc a{color:#222;}.gsc_rsb_a_ext{display:block;color:#777;font-size:13px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;}.gs_el_ph .gsc_rsb_a_ext,.gs_el_ta .gsc_rsb_a_ext{white-space:normal;}.gsc_rsb_a_ext2{display:none;}.gs_el_ph .gsc_rsb_a_ext2,.gs_el_ta .gsc_rsb_a_ext2{display:block;}.gsc_rsb_aa{display:block;padding:8px;line-height:normal;cursor:pointer;}.gs_el_ph .gsc_rsb_aa,.gs_el_ta .gsc_rsb_aa{font-size:17px;padding:12px 16px;}.gsc_rsb_aa:hover,.gsc_rsb_aa:active{text-decoration:none;background:#f1f1f1;}.gsc_rsb_aa a:hover{text-decoration:none;}#gsc_prf_w{order:1;padding:32px 0;overflow:hidden;}.gs_el_sm #gsc_prf_w{padding:16px 0;}#gsc_prf_pu{float:left;width:128px;height:128px;text-align:center;}.gs_el_ph #gsc_prf_pu{float:none;width:100%;margin:0 0 8px 0;}#gsc_prf_pua{line-height:0;width:128px;height:128px;}.gs_el_ph #gsc_prf_pua{margin:0 auto;}#gsc_prf_pufi{width:0;height:0;overflow:hidden;}.gsc_prf_pufo #gsc_prf_pufi{width:auto;height:auto;overflow:visible;position:relative;z-index:10;}.gsc_prf_pufo #gsc_prf_pufi2{display:inline-block;background:#fcfcfc;padding:8px 8px 8px 0;}.gsc_prf_puic{position:absolute;bottom:0;width:100%;padding:8px 0;background-color:#000;opacity:.6;}.gsc_prf_pel{cursor:pointer;}#gsc_prf_i{margin:0 16px 0 160px;}.gs_el_sm #gsc_prf_i{margin:0 16px 0 144px;}.gs_el_ph #gsc_prf_i{margin:0 16px;text-align:center;}#gsc_prf_btne{vertical-align:top;margin:-9px 4px;}.gs_el_ph #gsc_prf_btne{position:absolute;top:60px;right:8px;margin:0;}#gsc_prf_btnf{float:right;margin:3px 0 16px 16px;}.gs_el_sm #gsc_prf_btnf{margin-top:0;}.gs_el_ph #gsc_prf_btnf{float:none;margin:0;position:absolute;top:8px;right:8px;border-radius:50%;}#gsc_prf_btnf .gs_lbl{padding:0 4px;}#gsc_prf_in{font-size:24px;line-height:24px;padding:3px 0 12px 0;word-wrap:break-word;}.gs_el_sm #gsc_prf_in{font-size:22px;padding:3px 0 8px 0;}.gs_el_ph #gsc_prf_in{font-size:20px;padding:0 0 2px 0;}.gsc_prf_il{font-size:15px;line-height:18px;padding:1px 0;}.gs_el_ph .gsc_prf_il{font-size:13px;line-height:16px;}.gsc_prf_ila:link,.gsc_prf_ila:visited{text-decoration:underline;color:#222;}#gsc_prf_int{margin-top:5px;}#gsc_prf_int:empty{display:none;}.gsc_prf_inta{margin-right:16px;white-space:nowrap;max-width:200px;text-overflow:ellipsis;overflow:hidden;vertical-align:top;}.gsc_prf_inta:last-child{margin:0}.gs_el_tc .gsc_prf_ila,.gs_el_tc .gsc_prf_inta{padding:8px 0 5px 0;}.gsc_md_pro_tt,.gsc_md_pro_ch #gsc_md_pro_lgtm,#gsc_md_pro_save{display:none;}.gsc_md_pro_ed #gsc_md_pro_ted,.gsc_md_pro_aa #gsc_md_pro_taa,.gsc_md_pro_ra #gsc_md_pro_tra,.gsc_md_pro_an #gsc_md_pro_tan,.gsc_md_pro_ai #gsc_md_pro_tai,.gsc_md_pro_ch #gsc_md_pro_save{display:inline-block;}.gsc_md_pro_el{color:#777;}.gsc_md_pro_ev{padding:4px 0 16px 0;}#gsc_dd_add-d,#gsc_dd_exp-d,#gsc_dd_sort-d,#gsc_dd_mor-d{top:42px;}#gsc_dd_add-d,#gsc_dd_mor-d,#gsc_dd_sort-d{white-space:normal;word-wrap:break-word;width:208px;width:-webkit-max-content;width:max-content;min-width:100px;max-width:208px;}.gs_el_ph #gsc_dd_add-d{left:-9px;}.gs_el_ph #gsc_dd_exp-d{left:auto;right:12px;}.gs_el_ph #gsc_dd_mor-d{left:-58px;}.gs_el_ph #gsc_dd_sort-d{left:10px;}.gs_el_ph #gsc_dd_sort-r{margin-left:-10px;}.gsc_dd_sec,#gsc_dd_exp-d{padding:8px 0;}.gs_el_tc .gsc_dd_sec,.gs_el_tc #gsc_dd_exp-d{padding:4px 0 8px 0;}.gsc_dd_sep{border-top:1px solid #ebebeb;}#gsc_dd_mor-s .gsc_dd_mor-sel,#gsc_dd_sort-s .gsc_dd_sort-sel{color:#dd4b39;}#gsc_dd_mor-p{padding:14px 44px 14px 16px;color:#777;}.gs_el_tc #gsc_dd_mor-p{padding:18px 44px 18px 16px;}.gsc_art_sel #gsc_dd_add-r,.gsc_art_sel #gsc_dd_mor-r,#gsc_btn_mer,#gsc_btn_del,#gsc_dd_exp-r{display:none;}#gsc_dd_mor-r,.gsc_art_sel #gsc_btn_mer,.gsc_art_sel #gsc_btn_del,.gsc_art_sel #gsc_dd_exp-r{display:inline-block;}html:not(.gs_el_ph) #gsc_dd_sort-r{display:none;}#gsc_lwp{margin:24px 0;text-align:center;}.gs_el_sm #gsc_lwp{margin:16px 0;}#gsc_bpf{display:inline-block;verticle-align:middle;}#gsc_a_nn{display:inline-block;vertical-align:middle;padding-right:16px;font-size:13px;}.gs_el_ph #gsc_a_nn{display:none;}@media print{#gs_top #gs_md_s,#gs_top #gs_md_w,#gs_top #gs_hdr,#gs_top #gs_hdr_drs,#gs_top #gs_hdr_drw,#gs_top #gs_ftr,#gs_top #gsc_nag,#gs_top #gsc_prf_nbar_btns,#gs_top #gsc_prf_btne,#gs_top #gsc_prf_btnf,#gs_top #gsc_prf_ivh,#gs_top #gsc_prf_puf,#gs_top #gsc_rsb_co,#gs_top #gsc_bdy #gsc_rsb_co,#gs_top .gsc_g_hist_wrp,#gs_top #gsc_prf_t_wrp,#gs_top .gsc_rsb_header,#gs_top .gsc_a_tb,#gs_top .gsc_a_x,#gs_top #gsc_lwp,#gs_top .gsc_prf_puic,#gs_top #gsc_dd_add-r,#gs_top #gsc_dd_mor-r,#gs_top #gsc_dd_sort-r{display:none;}#gs_top,#gs_top #gsc_bdy,#gs_top #gsc_prf_w,#gs_top #gsc_prf,#gs_top #gsc_prf_pu,#gs_top #gsc_prf_pua,#gs_top #gsc_prf_i,#gs_top .gsc_rsb_s,#gs_top .gsc_lcl,#gs_top .gsc_rsb,#gs_top #gsc_a_tw,#gs_top #gsc_a_t,#gs_top .gsc_prf_il,#gs_top .gsc_prf_ila,#gs_top .gsc_prf_inta,#gs_top #gsc_rsb_st{background:none;border:none;padding:0;margin:0;height:auto;width:auto;min-width:0;max-width:none;float:none;display:block;position:static;color:black;font-weight:normal;font-size:12pt;text-decoration:none;}#gs_top .gsc_a_ac,#gs_top .gsc_a_a,#gs_top #gsc_a_ca,#gs_top .gsc_a_at,#gs_top .gsc_rsb_sc1,#gs_top .gsc_rsb_sth,#gs_top .gsc_rsb_std,#gs_top #gsc_bdy .gsc_a_x,#gs_top #gsc_bdy .gsc_a_t,#gs_top #gsc_bdy .gsc_a_c,#gs_top #gsc_bdy .gsc_a_y,#gs_top #gsc_a_trh,#gs_top .gsc_a_m,#gs_top .gsc_a_am{color:black;font-weight:normal;font-size:12pt;padding:0;margin:0;background:none;border:none;}#gs_top #gsc_a_trh,#gs_top #gsc_a_trh th{height:0;}#gs_top #gsc_a_ta,#gs_top #gsc_a_ca,#gs_top #gsc_a_ha,#gs_top .gsc_a_a{font-size:11pt;}#gs_top .gsc_a_ac{font-size:10pt}#gs_top #gsc_prf_pu{width:80pt;height:auto;float:left;margin:0 7pt 7pt 0;}#gs_top #gsc_prf_pua{left:auto;transform:none;border-radius:0;}#gs_top #gsc_prf_pua>img{position:static;}#gs_top #gsc_prf_i{margin:0 7pt 7pt 87pt;text-align:left;}#gs_top #gsc_prf_in{font-size:18pt;line-height:18pt;padding:0 0 4pt 0;}#gs_top .gsc_prf_il{padding:2pt 0;}#gs_top #gsc_prf_w{float:left;width:64%;}#gs_top .gsc_rsb{float:right;width:35%;}#gs_top #gsc_art{clear:both;}#gs_top #gsc_rsb_st{display:table;width:100%;max-width:none;margin-top:3pt;}#gs_top .gsc_rsb_sc1,#gs_top .gsc_rsb_sth,#gs_top .gsc_rsb_std{font-size:10pt;}#gs_top th.gsc_rsb_sc1,#gs_top .gsc_rsb_sth{border-bottom:1pt solid #ccc;}#gs_top .gsc_rsb_f{max-width:60pt;}#gs_top .gsc_rsb_sth{padding-left:14pt;}#gs_top #gsc_bdy .gsc_a_x,#gs_top #gsc_bdy .gsc_a_t,#gs_top #gsc_bdy .gsc_a_c,#gs_top #gsc_bdy .gsc_a_y,#gs_top #gsc_a_trh{padding:6pt 0;}#gs_top #gsc_a_trh{border-bottom:1pt solid #ccc;}#gs_top #gsc_a_ca{display:block;width:auto;}#gs_top #gsc_a_ta{display:inline-block;vertical-align:middle;margin-right:12pt;}#gs_top .gsc_a_h{display:inline;font-size:10pt;}#gs_top .gsc_a_at{color:#008;}#gs_top .gsc_a_m,#gs_top .gsc_a_am{display:inline;position:absolute;}#gs_top .gsc_a_am{padding: 11pt 0 0 8pt;}#gs_top .gsc_a_t .gs_gray{color:black;font-size:10pt;}}.gsc_lwpds_frm{position:relative;height:29px;}.gsc_lwpds_tsiw{position:absolute;top:0;left:0;right:38px;}.gsc_lwpds_tsiw input{border-radius:3px 0 0 3px;}.gsc_lwpds_tsbw{position:absolute;top:0;right:0;}.gsc_lwpds_tsbw button{border-radius:0 3px 3px 0;}.gsc_pgn{text-align:right;font-weight:bold;line-height:29px;}.gsc_pgn_ppn{margin:0 8px;}.gsc_ccb_ck{padding:11px 10px 9px 10px;}.gsc_ccb_svg{stroke:#666;stroke-width:2px;fill:#fff;width:21px;height:21px;vertical-align:top;}.gsc_ccb_lim .gsc_ccb_svg,.gsc_ccb_dis .gsc_ccb_svg{fill:#e2e2e2;stroke:#fff;}.gsc_ccb_lim .gsc_ccb_svg>circle,.gsc_ccb_dis .gsc_ccb_svg>circle{stroke:#e2e2e2;}.gsc_ccb_on .gsc_ccb_svg{fill:#4d90fe;stroke:#fff;}.gsc_ccb_on .gsc_ccb_svg>circle{stroke:#4d90fe;}.gsc_ccb_del:active .gsc_ccb_svg>circle,.gsc_ccb_add:active .gsc_ccb_svg>circle{fill:#2f6de1;}#gsc_md_cod{width:800px;max-width:94%;}.gs_el_ph #gsc_md_cod{width:100%;max-width:100%;}#gsc_md_cod .gs_md_prg{min-height:400px;}.gsc_codb_instr{font-size:16px;margin:1em 0;}#gsc_cods_res{position:relative;margin-bottom:24px;min-height:80px;border-bottom:1px solid #e5e5e5;}.gs_el_ph #gsc_cods_res{margin-bottom:16px;}.gsc_cods_hide,.gsc_cod_sugg #gsc_cod_tedit,.gsc_cod_sugg #gsc_cods_frm,.gsc_cod_sugg #gsc_cods_pp,.gsc_cod_lc #gsc_cod_tadd,.gsc_cod_changed #gsc_cod_tedit,.gsc_cod_changed #gsc_cod_tadd,.gsc_cod_lim #gsc_cod_tedit,.gsc_cod_lim #gsc_cod_tadd{display:none;}#gsc_cods_frm{margin:0 0 24px 0;}.gs_el_ph #gsc_cods_frm{margin:0 0 16px 0;}.gsc_ucoar{padding:24px 0;border-bottom:1px solid #eee;}.gs_el_ph .gsc_ucoar{padding:16px 0px;}.gsc_ucoar:first-child{padding-top:0;}.gsc_ucoar:last-child{border-bottom:none;}.gsc_ucoar_cb{float:right;margin-top:-8px;}#gsc_cod_trev{display:none;color:#666;pointer-events:none;}.gsc_cod_changed #gsc_cod_trev,.gsc_cod_lim #gsc_cod_trev{display:inline-block;}.gsc_cod_changed #gsc_cod_trev{color:#1a0dab;pointer-events:auto;}.gsc_fol_cr{margin:0 0 8px 0;}.gs_el_tc .gsc_fol_cr{margin:0;}.gs_el_tc .gsc_fol_cr:first-child{margin-top:-8px;}#gsc_fol_ml{display:block;color:#777;padding:12px 0 4px 0;}</style><script>!function(GSP){/*

 Copyright The Closure Library Authors.
 SPDX-License-Identifier: Apache-2.0
*/
var aa="function"==typeof Object.create?Object.create:function(a){var b=function(){};b.prototype=a;return new b},ba;if("function"==typeof Object.setPrototypeOf)ba=Object.setPrototypeOf;else{var da;a:{var ea={a:!0},fa={};try{fa.__proto__=ea;da=fa.a;break a}catch(a){}da=!1}ba=da?function(a,b){a.__proto__=b;if(a.__proto__!==b)throw new TypeError(a+" is not extensible");return a}:null}
var ha=ba,ia=function(a,b){a.prototype=aa(b.prototype);a.prototype.constructor=a;if(ha)ha(a,b);else for(var c in b)if("prototype"!=c)if(Object.defineProperties){var d=Object.getOwnPropertyDescriptor(b,c);d&&Object.defineProperty(a,c,d)}else a[c]=b[c];a.na=b.prototype},ja=function(){},ka=function(a,b){var c=Array.prototype.slice.call(arguments,1);return function(){var d=c.slice();d.push.apply(d,arguments);return a.apply(this,d)}};var g=function(){this.o=this.o;this.F=this.F};g.prototype.o=!1;g.prototype.isDisposed=function(){return this.o};g.prototype.T=function(){this.o||(this.o=!0,this.H())};g.prototype.H=function(){if(this.F)for(;this.F.length;)this.F.shift()()};function la(a){var b=[],c=0,d;for(d in a)b[c++]=d;return b};function l(a,b){a.classList.add(b)}function n(a,b){a.classList.remove(b)}function p(a,b){return a.classList?a.classList.contains(b):!1}function q(a,b,c){c=void 0!==c?c:!p(a,b);(c?l:n)(a,b)};function r(a){return 0<=(navigator.userAgent||"").indexOf(a)}var ma=r("iPhone")||r("iPad")||r("iPod"),na=r("iPhone")||r("Android")&&r("Mobile");function oa(){if(void 0===b){var a=window.screen;a={width:window.innerWidth,height:window.innerHeight,ma:a.width,la:a.height}}else a=b;var b=a;a=b.width;var c=b.height,d=b.ma;b=b.la;var e=4;if(600>a||48E4>d*b||na)e=1;else if(982>a)e=2;else if(1136>a||590>c)e=3;return e}var pa,qa=/[?&]tc=([01])/.exec(location.search||"");
pa=qa?0<+qa[1]:r("Android")?!0:window.matchMedia&&window.matchMedia("(pointer)").matches?window.matchMedia("(pointer:coarse)").matches:!r("Firefox")||r("Mobile")||r("Tablet")?ma||"ontouchstart"in window||0<(navigator.msMaxTouchPoints||0):!1;function ra(){if(void 0==sa){sa=!1;try{var a=Object.defineProperty({},"passive",{get:function(){sa=!0}});window.addEventListener("testPassive",ja,a);window.removeEventListener("testPassive",ja,a)}catch(b){}}return sa}var sa;var ta=function(a){this.Y=a},ua=new ta("INPUT"),va=new ta("TABLE");function t(a){return document.getElementById(a)}function x(a){return a.id||(a.id="gs_id"+wa++)}function xa(a){a=(void 0===a?null:a)||document.body;return"rtl"==(a?window.getComputedStyle(a,null):null).direction}
function ya(a){var b=[];a=a.elements;for(var c=a.length,d=0;d<c;d++){var e=a[d],f=encodeURIComponent(e.name||""),h=e.type;!f||e.disabled||!("checkbox"!=h&&"radio"!=h||e.checked)||b.push(f+"="+encodeURIComponent(e.value||""))}return b.join("&")}function za(a,b){var c=a.elements[b];c||(c=document.createElement(ua.Y),c.type="hidden",c.name=b,a.appendChild(c));return c}function Aa(a){t("gsc_md_cbyd_c").href=a&&a.match(Ba)?a:"javascript:void(0)"}function Ca(a){a.match(Ba)&&(window.location.href=a)}
var wa=100,Da=/\S+/g,Ba=/^(?:https?:|[^:/?#]*(?:[/?#]|$))/i,Ea=/^(?:#|\/[a-z0-9_-]*(?:[?].*)?$)/i;function y(a){return a.hasOwnProperty("gs_uid")?a.gs_uid:a.gs_uid=++Fa}var Fa=0;var z=function(){this.i=[];this.A={};this.O=this.v=0};z.prototype.add=function(a){var b=y(a);this.A[b]||(this.i.push(a),this.A[b]=this.i.length,++this.v)};z.prototype.remove=function(a){a=y(a);var b=this.A[a];b&&(this.i[b-1]=null,delete this.A[a],2*--this.v<this.i.length&&!this.O&&Ga(this))};z.prototype.notify=function(a){var b=this.i;try{++this.O;for(var c=0;c<b.length;c++){var d=b[c];d&&d.apply(null,arguments)}}finally{!--this.O&&2*this.v<b.length&&Ga(this)}};
var Ga=function(a){var b=a.i,c=b.length;a=a.A;for(var d=0,e=0;e<c;e++){var f=b[e];f&&(b[d]=f,a[y(f)]=++d)}b.length=d};function B(a,b,c,d,e){Ha(a,b,c,void 0===d?!1:d,void 0===e?!1:e,Ia)}function C(a,b,c,d){Ha(a,b,c,void 0===d?!1:d,!1,Ja)}function Ka(a,b,c,d){function e(h){C(f,a,e,c);b(h)}var f=document;c=void 0===c?!1:c;B(f,a,e,c,void 0===d?!1:d)}function D(a){La?La.add(a):a()}var Ma=window.requestAnimationFrame?function(a){window.requestAnimationFrame(a)}:function(a){setTimeout(a,33)};function Na(a){a.stopPropagation();a.preventDefault()}
function Oa(a){return(a.ctrlKey?1:0)|(a.altKey?2:0)|(a.metaKey?4:0)|(a.shiftKey?8:0)}function Ia(a,b,c,d,e){var f=a.addEventListener;e=e&&ra();f.call(a,b,c,e?{passive:e,capture:d}:d)}function Ja(a,b,c,d){a.removeEventListener(b,c,d)}function Ha(a,b,c,d,e,f){if("string"===typeof b)f(a,b,c,d,e);else for(var h=b.length,k=0;k<h;k++)f(a,b[k],c,d,e)}function Pa(){La.notify();La=null}function Qa(){"complete"==document.readyState&&(C(document,"readystatechange",Qa),Pa())}
var La,Ra=!!document.attachEvent,Sa=document.readyState;if(Ra?"complete"!=Sa:"loading"==Sa)La=new z,Ra?B(document,"readystatechange",Qa):Ka("DOMContentLoaded",Pa);function Ta(){Ka(["mousedown","touchstart"],function(){q(document.documentElement,"gs_pfcs",!0);B(document,"keydown",Ua,!0)},!0,!0)}function Ua(a){9==a.keyCode&&(q(document.documentElement,"gs_pfcs",!1),C(document,"keydown",Ua,!0),Ta())}Ta();function Va(a,b,c,d,e){var f=t(a);Wa(f,function(){l(f,"gs_vis");b&&b()},function(){n(f,"gs_vis");c&&c()},d,e)}function Wa(a,b,c,d,e){var f=x(a);if(!E[f]){var h=document.activeElement;Xa(Ya(a),!0);b&&b();G.push(function(k){delete E[f];try{k||(e||h).focus()}catch(m){}c&&c()});E[f]=G.length;h&&a.contains(h)||setTimeout(function(){var k=d,m=k&&"text"==k.type;if(!k||m&&pa)k=a;try{k.focus(),m&&(k.value=k.value)}catch(w){}},0)}}function H(a){Xa((E[a]||1E6)-1,!1)}
function Za(a){a=void 0===a?!1:a;G.pop()(a)}function Xa(a,b){for(b=void 0===b?!1:b;G.length>a;)Za(b||G.length>a+1)}function Ya(a){for(var b=0;a&&!(b=E[a.id]||0);)a=a.parentNode;return b}var G=[],E={};B(document,"click",function(a){var b=G.length;b&&!Oa(a)&&b>Ya(a.target)&&Za(!0)});B(document,"keydown",function(a){27==a.keyCode&&!Oa(a)&&G.length&&Za()});
B(document,"focus",function(a){var b=G.length;if(b)for(var c=Ya(a.target);c<b;){var d="",e;for(e in E)if(E[e]==b){d=e;break}a:{d=(t(d).getAttribute("data-wfc")||"").match(Da)||[];for(var f=0;f<d.length;f++){var h=t(d[f]);if(h&&h.offsetWidth){d=h;break a}}d=void 0}if(d){Na(a);d.focus();break}else Za(!0),--b}},!0);var $a={},ab={},bb;try{bb=window.sessionStorage}catch(a){};function J(a){return"object"==typeof a?a:null}function cb(a,b){b=db(b);a=eb(a);a=fb(a)||"#";gb=J(b);hb?window.history.pushState(b,"",a):window.location.assign(a)}function ib(a,b){b=db(b);a=eb(a);a=fb(a)||"#";gb=J(b);hb?window.history.replaceState(b,"",a):window.location.replace(a)}function fb(a){var b=[],c;for(c in a)b.push(encodeURIComponent(c)+"="+encodeURIComponent(a[c]));return(a=b.sort().join("&"))?"#"+a:""}
function jb(a){var b={};a=a.split("&");for(var c=0;c<a.length;c++){var d=a[c],e=d.indexOf("=");if(e+1){var f=d.substr(0,e);d=d.substr(e+1)}else f=d,d="";f&&(b[decodeURIComponent(f)]=decodeURIComponent(d))}return b}function kb(a){var b=a.indexOf("#")+1;return jb(b?a.substr(b):"")}function lb(a){var b=a.indexOf("?")+1;a=b?a.substr(b):"";b=a.indexOf("#");return jb(b+1?a.substr(0,b):a)}function mb(a,b){for(var c in b){var d=b[c];void 0!==d?a[c]=d:delete a[c]}}
function eb(a){var b=kb(window.location.hash);mb(b,a);return b}function db(a){var b=gb||J(window.history.state),c={},d;for(d in b)c[d]=b[d];mb(c,a);return c}function nb(){setTimeout(function(){if(!ob){var a=window.history.state;ob=!0;gb=J(a);rb.notify()}sb=!1},0)}var rb=new z,gb,ob=!1,sb=!0,hb="pushState"in window.history,tb;
if("undefined"==typeof GSP)tb=!1;else{var ub=.001*Date.now(),vb=GSP.eventId,wb=!1,K,xb=bb;if(!("nh"in $a)){var yb=xb&&xb.getItem("nh"),zb;if(yb)try{zb=JSON.parse(yb)}catch(a){}ab.nh=zb}K=ab.nh;K instanceof Array||(K=[]);for(var Ab=K.length,Bb=0,Cb=0;Cb<Ab;Cb++){var Db=K[Cb];if(Db instanceof Array&&2==Db.length){var Eb=Db[1]==vb;wb=wb||Eb;10>=Ab-Cb&&+Db[0]>ub-86400&&!Eb&&(K[Bb++]=Db)}}K.length=Bb;K.push([ub,vb]);var Fb=K,Gb=bb;ab.nh=Fb;try{Gb&&Gb.setItem("nh",JSON.stringify(Fb))}catch(a){}tb=wb}
var Hb=tb;"onpageshow"in window?B(window,"pageshow",nb):D(nb);B(window,hb?"popstate":"hashchange",function(a){"loading"!=document.readyState&&(a=a.state,ob=!0,gb=J(a),rb.notify())});function Ib(){Jb&&(C(t("gs_alrt_l"),"click",Jb),Jb=void 0)}function Kb(){var a=Lb();l(a,"gs_anm");l(a,"gs_vis");B(document,"click",Mb);clearTimeout(Nb);Nb=setTimeout(Mb,4E3);++Ob;setTimeout(Pb,0)}function Mb(){Ob||(C(document,"click",Mb),clearTimeout(Nb),Nb=void 0,Ib(),n(Lb(),"gs_vis"))}function Lb(){return t("gs_alrt")}function Pb(){Ob=0}var Nb,Ob=0,Jb;D(function(){var a=t("gs_alrt_m");a&&(a.innerHTML&&!Hb&&Kb(),B(window,"pagehide",function(){Ob=0;Mb();n(Lb(),"gs_anm")}))});function Qb(a,b,c){var d=new XMLHttpRequest;d.onreadystatechange=function(){if(4==d.readyState){var e=d.status,f=d.responseText,h=d.responseURL,k=window.location,m=k.protocol;k="//"+k.host+"/";h&&h.indexOf(m+k)&&h.indexOf("https:"+k)&&(e=0,f="");c(e,f)}};d.open(b?"POST":"GET",a,!0);d.setRequestHeader("X-Requested-With","XHR");b&&d.setRequestHeader("Content-Type","application/x-www-form-urlencoded");b?d.send(b):d.send();return d}function Rb(a){a&&(a.onreadystatechange=ja,a.abort())};var Sb=function(a,b,c){this.type=a;this.currentTarget=this.target=b;this.g=void 0===c?null:c;this.P=!1};Sb.prototype.stopPropagation=function(){this.g&&this.g.stopPropagation();this.P=!0};var L=function(a){a.g&&Na(a.g);a.P=!0};var M=function(a,b){this.R=a;this.ka=b},Tb=function(a,b,c){this.R=a;this.types=b;this.listener=c};function Ub(a,b){var c=b.length;if(c){var d=y(a),e=Vb[d];if(!e){e=Vb[d]=[];d=Wb(b[0].R);for(var f in d){var h=Xb[f];h||(h=Xb[f]=Object.create(null));for(var k in d[f]){var m=h[k];m||(m=h[k]=[]);m.push(a)}}Yb(a,e,b[0],Zb);for(f=1;f<c;f++)Yb(a,e,b[f],$b)}}}function O(a,b,c){ac(new Sb(a,b,void 0===c?null:c))}
function P(a,b,c){var d=bc;"string"===typeof b&&(cc[0]=b,b=cc);var e=b.length;a=Wb(a);for(var f in a)for(var h in a[f])for(var k=0;k<e;k++)d(f,h,b[k],c)}function Wb(a){"string"===typeof a&&(dc[0]=a,a=dc);for(var b=a.length,c=Object.create(null),d=0;d<b;d++){var e=a[d],f=e.charAt(0),h=e.substr(1);if("#"!=f&&"."!=f||!h)throw Error("bad selector: "+e);(e=c[f])||(e=c[f]=Object.create(null));e[h]=!0}return c}
function bc(a,b,c,d){var e=ec[c];e||("touchstart"!=c&&"mouseover"!=c&&"mouseout"!=c&&B(document,c,fc,"focus"==c||"blur"==c),e=ec[c]=Object.create(null));(c=e[a])||(c=e[a]=Object.create(null));(a=c[b])||(a=c[b]=new z);a.add(d)}function fc(a){var b=a.target;b&&3==b.nodeType&&(b=b.parentNode);ac(new Sb(a.type,b,a))}
function ac(a){for(var b=a.target;b&&b!=document&&!b.disabled&&!p(b,"gs_dis");){a.currentTarget=b;var c=b.id;if(c&&!gc("#",c,a))break;c=b.classList||[];for(var d=c.length,e=0;e<d;e++)if(!gc(".",c[e],a))return;b=b.parentNode}}function gc(a,b,c){var d=ec[c.type];(b=(a=d&&d[a])&&a[b])&&b.notify(c);return!c.P}function Yb(a,b,c,d){var e=c.R;c=c.ka;for(var f in c){var h=ka(d,a,c[f]);P(e,f,h);b.push(new Tb(e,f,h))}}function Zb(a,b,c){var d=c.currentTarget;a=hc(a,d)||a;a=ic(a,d);b.call(a,c)}
function $b(a,b,c){a:{for(var d=c.currentTarget;d&&d!=document;){var e=hc(a,d);if(e){a=ic(e,d);break a}d=d.parentNode}a=void 0}a&&b.call(a,c)}function ic(a,b){var c=jc(b),d=kc[c];d||(d=kc[c]=[]);for(var e=d.length,f=0;f<e;f++){var h=d[f];if(h instanceof a)return h}b=new a(b);d.push(b);a=y(a);(d=lc[a])||(d=lc[a]=[]);d.push(c);return b}function hc(a,b){var c,d=b.id;d&&(c=mc(a,c,"#",d));b=b.classList||[];d=b.length;for(var e=0;e<d;e++)c=mc(a,c,".",b[e]);return c}
function mc(a,b,c,d){c=(d=(c=Xb[c])&&c[d])?d.length:0;for(var e=0;e<c;e++){var f=d[e];!(f===a||f.prototype instanceof a)||b&&!(f===b||f.prototype instanceof b)||(b=f)}return b}function jc(a){var b=a.getAttribute("data-duid");b||a.setAttribute("data-duid",b=""+nc++);return b}var ec=Object.create(null),dc=[""],cc=[""],Xb=Object.create(null),Vb=Object.create(null),lc=Object.create(null),kc=Object.create(null),nc=100;window.gs_evt_dsp=fc;function oc(){var a=".gs_md_li";if("string"===typeof a){var b=a.charAt(0),c=a.slice(1);if("#"==b)a=function(d){return d.id==c&&0<d.offsetWidth};else if("."==b)a=function(d){return p(d,c)&&0<d.offsetWidth};else throw Error("bad selector: "+a);}return a}function pc(a,b){return a&&((void 0===b?0:b)?a.lastElementChild:a.firstElementChild)}function qc(a,b){return a&&((void 0===b?0:b)?a.previousElementSibling:a.nextElementSibling)}function rc(a,b,c){c=void 0===c?!1:c;return sc(a,b,oc(),c,!1)}
function sc(a,b,c,d,e){for(var f;b&&a;){if(c(b)){if(e)return b}else for(f=pc(b,d);f;f=qc(f,d))if(e=sc(f,f,c,d,!0))return e;for(e=!0;;){if(b==a)return null;f=b.parentNode;if(b=qc(b,d))break;b=f}}return null};function tc(a){return!!p(a,"gs_sel")+2*!!p(a,"gs_par")}function uc(a){return+a.getAttribute("data-s")}function vc(a,b,c){c=void 0===c?!1:c;q(a,"gs_sel",1==b);q(a,"gs_par",2==b);a.setAttribute("aria-checked",wc[b]);c||a.setAttribute("data-s",""+b)}var wc=["false","true","mixed"];var Q=function(){this.j=Object.create(null);this.l=0};Q.prototype.clear=function(){this.j=Object.create(null);this.l=0};Q.prototype.has=function(a){return a in this.j};Q.prototype.get=function(a){return this.j[a]};Q.prototype.set=function(a,b){this.has(a)||this.l++;this.j[a]=b};Q.prototype.delete=function(a){this.has(a)&&(delete this.j[a],this.l--)};var xc=function(a){var b=window,c=this;this.i=new z;this.V=0;this.S=[b,a,function(){c.V++||Ma(d)},!1];var d=function(){c.V=0;c.i.notify()}};xc.prototype.addListener=function(a){this.i.v||B.apply(null,this.S);this.i.add(a)};xc.prototype.removeListener=function(a){this.i.remove(a);this.i.v||C.apply(null,this.S)};var yc=new xc("scroll"),zc=new xc("resize");var Ac=new z;function Bc(){var a=document.documentElement,b=oa();b={gs_el_ph:1==b,gs_el_ta:2==b,gs_el_sm:4!=b,gs_el_tc:pa||1==b};var c;for(c in b){var d=b[c];if(p(a,c)!=d){var e=!0;q(a,c,d)}}e&&Ac.notify()}q(document.documentElement,"gs_el_ios",ma);Bc();zc.addListener(Bc);B(window,["pageshow","load"],Bc);function R(a,b,c,d){function e(){var u=ca&&p(h,"gs_el_ph");q(F,"gs_vis",!u);h.style.overflowY=Yd&&!u?"scroll":""}function f(){var u=h.clientHeight,I=+A.getAttribute("data-h");I||(w.style.maxHeight="none",I=m.offsetHeight);I=Math.max((u-I)/2,10);u=Math.max(u-48-2*I,10);var Jc=ca&&p(h,"gs_el_ph");m.style.top=Jc?"auto":I+"px";w.style.maxHeight=Jc?"none":u+"px";Cc(w)}b=void 0===b?"":b;c=void 0===c?"":c;d=void 0===d?"":d;var h=document.documentElement,k=t("gs_top"),m=t(a),w=t(a+"-bdy"),v=t(m.getAttribute("data-cid")||
m.id+"-bdy")||m,F=t(m.getAttribute("data-shd")||"gs_md_s"),A=Dc(m),ca=!!A&&p(A,"gs_md_wmw"),N=window.pageYOffset,Yd=k.scrollHeight>h.clientHeight,pb=!!E[a],qb=pb?"":S,Lc=b&&"#"!=b[0]&&!d,$d=a==S&&b==Ec&&c==T;Fc=b;Lc?(pb?q(v,"gs_md_ldg",!0):Gc(m,v,'<div class="gs_md_prg">'+t("gs_md_ldg").innerHTML+"</div>"),O("gs-md-ldin",v)):(d&&Gc(m,v,d),O("gs-md-lded",v));qb&&(++Hc,H(qb),--Hc);S=a;Ec=b;T=c;Ic=d;$d||Hc||(Kc+=1,(qb?ib:cb)(Mc(),Nc()));pb||Wa(m,function(){A&&l(A,"gs_vis");l(m,"gs_vis");q(m,"gs_abt",
sb);Oc(a);Ac.add(e);e();A&&w&&(f(),zc.addListener(f));l(k,"gs_nscl");k.style.top=-N+"px"},function(){Ac.remove(e);zc.removeListener(f);A&&n(A,"gs_vis");n(m,"gs_vis");n(m,"gs_abt");n(F,"gs_vis");h.style.overflowY="";n(k,"gs_nscl");k.style.top="auto";Rb(U);U=null;window.scrollTo(0,N);S=Ec=T=Ic="";var u=Kc;Kc=0;Hc||(0<u?window.history.go(-u):ib(Mc(),Nc()))},Pc(m),Qc(m));Lc&&(Rb(U),U=null,U=Qb(b,c,function(u,I){U=null;u=200==u;Gc(m,v,u?I:Rc());u&&a==S&&b==Ec&&c==T&&(Ic=I,ib(Mc(),Nc()));O("gs-md-lded",
v)}))}function Dc(a){a=a.parentNode;return p(a,"gs_md_wnw")?a:null}function Pc(a){return(a=a.getAttribute("data-ifc"))?t(a):null}function Qc(a){return(a=a.getAttribute("data-cfc"))?t(a):null}
function Gc(a,b,c){q(b,"gs_md_ldg",!1);for(var d=b.querySelectorAll("[data-duid]"),e=d.length,f={},h=0;h<e;h++){for(var k=jc(d[h]),m=kc[k],w=m?m.length:0,v=0;v<w;v++){var F=m[v],A=y(F.constructor),ca=f[A];ca||(ca=f[A]={});ca[k]=!0;F&&"function"==typeof F.T&&F.T()}delete kc[k]}for(var N in f){N=+N;d=f[N];h=(e=lc[N])?e.length:0;for(m=k=0;m<h;m++)w=e[m],w in d||(e[k++]=w);k?e.length=k:delete lc[N]}b.innerHTML=c;Oc(a.id);Rb(U);U=null}
function Oc(a){if(a=document.querySelector("#"+a+">.gs_md_bdy"))a.scrollTop=a.scrollLeft=0,Cc(a)}function Cc(a){var b=a.style,c="padding"+(xa(a)?"Left":"Right");b[c]="";var d=a.offsetWidth-a.clientWidth;2<d&&(a=parseInt(window.getComputedStyle(a,null)[c],10)||0,b[c]=Math.max(a-d,0)+"px")}function Rc(){return'<div class="gs_md_prg"><div class="gs_alrt">'+t("gs_md_err").innerHTML+"</div></div>"}function Mc(){return{d:S||void 0,u:Ec||void 0,p:T?"1":void 0}}function Nc(){return{n:Kc,p:T,h:Ic}}
var U=null,Fc="",S="",Ec="",T="",Ic="",Kc=0,Hc=0;rb.add(function(){var a=kb(window.location.hash),b=a.d||"",c=b?t(b):null;++Hc;if(c){c=a.u||"";a=0<+a.p;var d=gb||J(window.history.state)||{},e=+d.n||0,f=""+(d.p||"");d=""+(d.h||"");c.match(Ea)||(c="");a!=!!f?R(b,"","",Rc()):b==S&&c==Ec&&f==T&&d==Ic||R(b,c,f,d);Kc=e}else S&&H(S);--Hc});var Sc=function(a){g.call(this);this.D=a;this.K=Object.create(null);this.C=null;a=a.querySelectorAll(".gs_in_txtw>input[type=text]");for(var b=a.length;b--;){var c=a[b],d=c.parentNode.querySelector(".gs_in_txts");c=c.name;d&&c&&(this.K[c]=d.innerHTML)}};ia(Sc,g);Sc.prototype.H=function(){Rb(this.C);this.D=this.C=null;g.prototype.H.call(this)};
Sc.prototype.ga=function(a){var b=this;L(a);if((a=this.D)&&!this.C){var c="json=&"+ya(a);Tc(this,!0);this.C=Qb(a.action,c,function(d,e){b.C=null;Tc(b,!1);var f=b.D,h=f.getAttribute("data-alrt");if(h=h?t(h):null)h.innerHTML="";try{var k=200==d&&JSON.parse(e)}catch(A){}k&&"object"==typeof k||(Uc(h,t("gs_md_err").innerHTML),k={});if(d=k.L)Ca(""+d);else{(d=k.M)&&Uc(h,d);d=1E6;if(h&&h.innerHTML){var m=h;d=h.getBoundingClientRect().top}f=f.elements;k=k.E;"object"==typeof k||(k=Object.create(null));for(var w in b.K){h=
f[w];e=void 0;var v=""+(k[w]||""),F=h.parentNode.querySelector(".gs_in_txts");q(h.parentNode,"gs_in_txte",!!v);F&&(F.innerHTML=v||b.K[w]||"");v&&(e=h.getBoundingClientRect().top)<d&&(m=h,d=e)}m&&m.scrollIntoView&&(0>d||d+20>window.innerHeight)&&m.scrollIntoView()}})}};
var Tc=function(a,b){a=a.D;var c=a.getAttribute("data-bsel");a=c?document.querySelectorAll(c):a.querySelectorAll("button");for(c=a.length;c--;){var d=a[c];d.disabled=b;q(d,"gs_bsp",b)}},Uc=function(a,b){if(a)a.innerHTML=b;else{var c=void 0===c?"":c;var d=void 0===d?"":d;var e=void 0===e?[]:e;t("gs_alrt_m").innerHTML=b;Lb().action=d.match(Ba)?d:"";a=t("gs_alrt_l");a.textContent=c;c=t("gs_alrt_h");c.innerHTML="";for(var f in e)b=document.createElement("input"),b.type="hidden",b.name=f,b.value=e[f],
c.appendChild(b);Ib();q(a,"gs_fm_s",!0);Kb()}};Ub(Sc,[new M(".gs_ajax_frm",{submit:Sc.prototype.ga})]);var Vc=[[1,0,1],[2,0,1]];P(".gs_cb_gen","click",function(a){var b=a.currentTarget,c=tc(b),d=2==+b.getAttribute("data-s");vc(b,Vc[+d][c],!0);O("gs-change",b,a.g)});P(".gs_cb_gen",["keydown","keyup"],function(a){var b=a.currentTarget,c=a.g.keyCode;"BUTTON"!=b.tagName||13!=c&&32!=c||(L(a),"keydown"==a.type&&b.click())});P([".gs_cb_gen",".gs_md_li"],"keydown",function(a){var b=a.currentTarget,c=b.tagName,d=a.g.keyCode;"BUTTON"!=c&&(32==d||13==d&&"A"!=c)&&(L(a),b.click())});var Wc=["click","contextmenu","mouseup"].concat(navigator.sendBeacon?[]:["mousedown","touchstart"]),Xc="",Yc=null;function Zc(){Yc=null}function $c(a){navigator.sendBeacon?navigator.sendBeacon(a):Yc&&a==Yc.src||((Yc=new Image).src=a,setTimeout(Zc,1E3))}function ad(){var a=lb(document.location.href).hl||"";a="/scholar_bfnav?url="+encodeURIComponent(document.location.href)+"&hl="+encodeURIComponent(a)+"&ei="+GSP.eventId;$c(a)}D(function(){Xc=Hb?"&bn=1":"";Hb&&ad()});
B(window,"pageshow",function(a){a.persisted&&(Xc="&bn=1",ad())});
B(document,Wc,function(a){if(!("click"==a.type&&a.button||"mouseup"==a.type&&1!=a.button)){var b,c;a:{for(a=a.target;a;){var d=a.nodeName;if("A"==d)break a;if("SPAN"==d||"B"==d||"I"==d||"EM"==d||"IMG"==d)a=a.parentNode;else break}a=null}a&&(b=a.getAttribute("href"))&&(c=a.getAttribute("data-clk"))&&(b="/scholar_url?url="+encodeURIComponent(b)+"&"+c+"&ws="+window.innerWidth+"x"+window.innerHeight+"&at=",c=encodeURIComponent,a=(a=a.getAttribute("data-clk-atid"))&&t(a),b=b+c(a&&a.innerText||"")+Xc,$c(b))}},
!1,!0);P(".gs_fm_s","click",function(a){a=a.currentTarget.getAttribute("data-fm")||"";(a=t(a))&&a.submit()});var V=function(a){this.m=x(a.querySelector(".gs_md_d"));this.G=x(a.querySelector(".gs_md_tb"))};V.prototype.I=function(a){var b=t(this.m);return void 0!==a?rc(b,b,a):null};V.prototype.open=function(a){a=this.I(a);if(p(t(this.G),"gs_sel"))try{a&&a.focus()}catch(c){}else{var b=t(this.G);Va(this.m,function(){l(b,"gs_sel")},function(){n(b,"gs_sel")},a,b)}};V.prototype.close=function(){H(this.m)};V.prototype.Z=function(a){L(a);p(t(this.G),"gs_sel")?this.close():this.open("keydown"==a.g.type?!1:void 0)};
V.prototype.U=function(a){var b=a.g.keyCode;if(38==b||40==b)L(a),this.open(38==b)};V.prototype.aa=function(a){a.target.id==this.m&&this.U(a)};Ub(V,[new M(".gs_md_rmb",{}),new M(".gs_md_tb",{"gs-press":V.prototype.Z,keydown:V.prototype.U}),new M(".gs_md_d",{keydown:V.prototype.aa})]);var W=function(a){V.call(this,a);this.ia=x(a.querySelector(".gs_md_in"));this.ja=x(a.querySelector(".gs_md_tb .gs_lbl"))};ia(W,V);W.prototype.I=function(){return t(this.m).querySelector(".gs_md_li[aria-selected]")};W.prototype.ba=function(a){bd(this,a)};W.prototype.J=function(a){var b=a.g.keyCode;13!=b&&32!=b||bd(this,a)};
var bd=function(a,b){var c=b.currentTarget,d=t(a.ia),e=a.I();c!=e&&(d.value=c.getAttribute("data-v"),t(a.ja).innerHTML=c.innerHTML,e&&cd(e,!1),cd(c,!0));L(b);a.close();O("gs-change",d,b.g)},cd=function(a,b){q(a,"gs_sel",b);b?a.setAttribute("aria-selected","true"):a.removeAttribute("aria-selected")};Ub(W,[new M(".gs_md_ris",{}),new M(".gs_md_li",{click:W.prototype.ba,keydown:W.prototype.J})]);P("#gs_lp","click",function(a){L(a);R("gs_lp_d")});P("#gs_lp_cur","click",function(a){L(a);H("gs_lp_d")});var dd=function(a){this.W=x(a)};dd.prototype.J=function(a){var b=a.currentTarget,c=a.g.keyCode;if(38==c||40==c){var d=t(this.W);d=rc(d,b,38==c)||rc(d,d,38==c)}else if(37==c||39==c)a:{c=!!(37==c^xa(b.parentNode));d=b.parentNode;var e=d.children,f=e.length;if(d.id!=this.W){for(;e[--f]!=b;);d=qc(d,c)||pc(d.parentNode,c);e=d.children;if(f=Math.min(f+1,e.length))if(d=e[f-1],p(d,"gs_md_li")&&d.offsetLeft!=b.offsetLeft)break a}d=void 0}d&&(L(a),d.focus())};
Ub(dd,[new M(".gs_md_ulr",{}),new M(".gs_md_li",{keydown:dd.prototype.J})]);P("#gs_hdr_mnu","click",function(a){L(a);R("gs_hdr_drw")});P("#gs_hdr_drw_mnu","click",function(a){L(a);H("gs_hdr_drw")});P("#gs_hdr_act_i","click",function(a){L(a);1==oa()?Ca(document.querySelector("#gs_hdr_drw_bot>a").href):Va("gs_hdr_act_d")});P("#gs_hdr_drw","keydown",function(a){var b=a.g.keyCode;if(38==b||40==b){var c=a.currentTarget;if(b=rc(c,c,38==b))L(a),b.focus()}});
P("#gs_hdr_tsi",["focus","blur"],function(a){function b(){var h=d.getBoundingClientRect().top-10;10<Math.abs(h)&&window.scrollBy(0,h);clearTimeout(e);c()}function c(){C(window,f,b)}var d=a.target;a="focus"==a.type;q(t("gs_hdr"),"gs_hdr_ifc",a);if(a&&pa&&!(749<window.innerHeight)){var e=setTimeout(c,1E3),f=["scroll","resize"];B(window,f,b)}});P("#gs_hdr_tsi",["input","gs-change"],function(a){q(t("gs_hdr_frm"),"gs_hdr_tsc",!!a.currentTarget.value)});
P("#gs_hdr_tsc","mousedown",function(a){L(a);var b=t("gs_hdr_tsi");b.value="";b.focus();O("input",b,a.g)});P("#gs_hdr_sre","click",function(a){L(a);var b=t("gs_hdr");Va("gs_hdr_frm",function(){n(b,"gs_hdr_src");l(b,"gs_hdr_srx")},function(){l(b,"gs_hdr_src");n(b,"gs_hdr_srx")},t("gs_hdr_tsi"))});P(".gs_md_x","click",function(a){(a=a.currentTarget.getAttribute("data-mdx"))&&H(a)});var X=function(){},ed,fd;X.prototype.$=function(a){a.g.button||(L(a),gd(a))};X.prototype.ca=function(a){hd(a)&&(L(a),gd(a))};X.prototype.da=function(a){hd(a)&&L(a)};X.prototype.ea=function(a){if(!a.g.button){L(a);var b=a.g;b&&(id=b.clientX||0,jd=b.clientY||0,B(document,kd,ld,!0),clearTimeout(ed),ed=setTimeout(md,2E3));gd(a)}};X.prototype.ha=function(a){L(a);if(nd){var b=a.g;if(b=(b=b&&b.touches)&&1==b.length&&b[0])od=b.clientX,pd=b.clientY,B(document,qd,rd,!0),clearTimeout(fd),fd=setTimeout(sd,2E3)}gd(a)};
var hd=function(a){a=a.g.keyCode;return 32==a||13==a},gd=function(a){O("gs-press",a.currentTarget,a.g)},md=function(){C(document,kd,ld,!0);clearTimeout(ed);ed=void 0},ld=function(a){"mousedown"!=a.type&&10>Math.abs(a.clientX-id)&&10>Math.abs(a.clientY-jd)?(Na(a),"click"==a.type&&md()):md()},sd=function(){C(document,qd,rd,!0);clearTimeout(fd);fd=void 0},rd=function(a){"touchstart"!=a.type&&10>Math.abs(a.clientX-od)&&10>Math.abs(a.clientY-pd)?(Na(a),"click"==a.type&&sd()):sd()},id=0,jd=0,kd=["mousedown",
"mouseup","click"],nd=r("Android")&&!r("Chrome"),od=0,pd=0,qd=["touchstart","mousedown","mouseup","click"];Ub(X,[new M(".gs_press",{click:X.prototype.$,keydown:X.prototype.ca,keyup:X.prototype.da,mousedown:X.prototype.ea,touchstart:X.prototype.ha})]);function td(){var a=0>ud.getBoundingClientRect().top;vd!=a&&(vd=a,q(wd,"gs_sth_vis",a),a?xd():(yd.style.left="",yd.style.width="",zd()))}function xd(){if(vd){var a=ud.getBoundingClientRect();yd.style.left=a.left+"px";yd.style.width=a.width+"px";zd()}}function zd(){O("gs-sth-change",t("gs_sth"))}var wd,ud,yd,vd=!1;D(function(){if(wd=t("gs_sth"))ud=wd.querySelector(".gs_sth_g"),yd=wd.querySelector(".gs_sth_b"),yc.addListener(td),zc.addListener(xd),td()});function Ad(){var a=t("gsc_rsb_co");if(a){a=a.querySelectorAll("img.gs_pp_df");for(var b=0;b<a.length;b++){var c=a[b];c.getAttribute("data-srcset")&&(c.setAttribute("srcset",c.getAttribute("data-srcset")),c.removeAttribute("data-srcset"));c.getAttribute("data-src")&&(c.setAttribute("src",c.getAttribute("data-src")),c.removeAttribute("data-src"))}}};var Bd=/\S+@\S+\.\S+/;function Cd(a){return p(a,"gsc_ccb_dis")||p(a,"gsc_ccb_lim")}function Dd(){for(var a=0>=Ed(),b=t("gsc_cods_res").querySelectorAll(".gsc_ccb_add"),c=b.length;c--;){var d=b[c];p(d,"gsc_ccb_on")||q(d,"gsc_ccb_lim",a)}};var Fd=function(a){this.X=a};Fd.prototype.fa=function(a){L(a);a=a.currentTarget.getAttribute("data-a");this.X.setAttribute("data-a",a||"");O("gsc-navigate",this.X)};var Gd=[new M(".gsc_pgn",{}),new M([".gsc_pgn_ppr",".gsc_pgn_pnx"],{click:Fd.prototype.fa})];function Hd(a,b){b=void 0===b?"":b;var c=t("gsc_md_cod");a+=fb({t:Id});R(c.id,a,"",b)}function Jd(a){if(Id!=a){var b=t("gsc_md_cod");n(b,Id);l(b,a);Id=a}}function Kd(){var a=kb(Fc).t;"gsc_cod_sugg"!=a&&"gsc_cod_lc"!=a||Jd(a)}function Ld(){var a=Md();a=a?a.value:"";var b=(t("gsc_cods_urls").getAttribute("data-sa")||"").replace(Nd,"$1"+encodeURIComponent(a));a=a?b:t("gsc_cods_urls").getAttribute("data-lc")||"";Hd(a)}
function Od(a){var b=t("gsc_cods_frm");if(b){b=b.elements;var c=b[1];b[0].disabled=c.disabled=a;q(c,"gs_bsp",a)}a=a?null:t("gsc_codb_data");if(c=t("gsc_cods_pp")){var d=a&&a.getAttribute("data-prev");b=a&&a.getAttribute("data-next");var e=a&&a.getAttribute("data-start"),f=a&&a.getAttribute("data-end");c.querySelector(".gsc_pgn_ppn").textContent=e&&f?e+" - "+f:"";e=c.querySelector(".gsc_pgn_ppr");e.disabled=!d;e.setAttribute("data-a",d||"");c=c.querySelector(".gsc_pgn_pnx");c.disabled=!b;c.setAttribute("data-a",
b||"")}a&&(Pd=+a.getAttribute("data-max")||0,za(t("gsc_cods_save"),"xsrf").value=a.getAttribute("data-xsrf")||"")}function Qd(){var a=0<Y.l||0<Z.l,b=Ed(),c=0>=b;t("gsc_cod_done").disabled=!a||0>b;q(t("gsc_cod_t"),"gsc_cod_changed",a);a=t("gsc_cod_trev");a.textContent=a.getAttribute(c?"data-lim":"data-txt")||"";q(t("gsc_cod_t"),"gsc_cod_lim",c)}function Ed(){return Pd-Y.l+("gsc_cod_sugg"==Id?0:Z.l)}function Md(){return t("gsc_cods_tsi")}
function Rd(a){for(var b="",c=la(a.j),d=c.length;d--;)b+=a.get(c[d]);return b}var Id="gsc_cod_lc",Pd=0,Nd=/([?&]mauthors=)([^&]*)/,Y=new Q,Z=new Q;function Sd(a){q(t("gsc_a_sp"),"gs_vis",0==a);q(t("gsc_a_err"),"gs_vis",2==a)}function Td(){return document.querySelectorAll("#gsc_a_t input[type=checkbox]")}function Ud(){O("gsc-works-change",t("gsc_a_t"))}function Vd(){var a=t("gsc_x_all");if(a){var b=document.querySelectorAll("#gsc_a_t input[type=checkbox]:checked");var c=b.length;var d=Td().length;c=c?c==d?1:2:0;vc(a,c);2==c&&(Wd=b)}Ud()}var Wd=[];var Xd="",Zd=0,ae=0;function be(a){for(var b=[!1,!1,!1],c=0;c<b.length;c++){var d=t(ce[c]);d&&(b[c]=!!a(d))}return b}function de(){var a=t("gsc_fol_m");if(a){var b=t("gsc_fol_b");if(!(a=!Bd.test(a.value))){a:{a=be(tc);for(var c=be(uc),d=0;d<a.length;d++)if(a[d]!=c[d]){a=!0;break a}a=!1}a=!a}b.disabled=a}}var ce=["gsc_fol_a","gsc_fol_c","gsc_fol_r"],ee=["follow_articles_btn","follow_citations_btn","follow_related_btn"];function fe(){p(document.documentElement,"gs_el_ph")||p(document.documentElement,"gs_el_ta")||Ad()};function ge(a){if(a){a.id&&a.removeAttribute("id");for(var b=0;b<a.children.length;b++)ge(a.children[b])}};function he(){var a=t("gsc_prf_pufii");if(r("MSIE ")){var b=t("gsc_prf_puf");Va("gsc_prf_pufi",function(){l(b,"gsc_prf_pufo")},function(){n(b,"gsc_prf_pufo")},a)}else a.click()};function ie(){var a=document.querySelectorAll(".gsc_prf_pnl"),b=document.documentElement;b=p(b,"gs_el_ph")||p(b,"gs_el_ta");for(var c=0;c<a.length;c++)a[c].setAttribute("role",b?"tabpanel":"region")};var je=kb(window.location.hash),ke=je.u||"";"gs_md_cita-d"==je.d&&ke.match(Ea)&&0<=ke.indexOf("view_citation")&&Ca(ke);P("#gsc_md_cod","gs-md-ldin",function(){Kd();Od(!0)});P("#gsc_md_cod","gs-md-lded",function(){Kd();Od(!1);for(var a=t("gsc_cods_res").querySelectorAll(".gsc_ccb_ck"),b=a.length;b--;){var c=a[b];if(!Cd(c)){var d=c.getAttribute("data-authorid")||"";d=(p(c,"gsc_ccb_add")?Y:Z).has(d);q(c,"gsc_ccb_on",d)}}Dd();Qd();a=lb(Fc);(b=Md())&&(b.value=a.mauthors||"")});
P("#gsc_cods_frm","gsc-lwpds-submit",Ld);P("#gsc_cods_pp","gsc-navigate",function(a){(a=a.currentTarget.getAttribute("data-a"))&&Hd(a)});
P([".gsc_ccb_add",".gsc_ccb_del"],"click",function(a){a=a.currentTarget;if(!Cd(a)){var b=!p(a,"gsc_ccb_on");q(a,"gsc_ccb_on",b);var c=p(a,"gsc_ccb_add")?".gsc_ccb_del":".gsc_ccb_add",d=a.parentNode;(c=d&&d.querySelector(c))&&n(c,"gsc_ccb_on");c=a.getAttribute("data-authorid")||"";Y.delete(c);Z.delete(c);b&&(p(a,"gsc_ccb_add")?Y:Z).set(c,t("gsc_ucoar-"+c).outerHTML);Dd();Qd()}});
P("#gsc_cod_trev","click",function(){var a=t("gsc_cods_res").cloneNode(!0),b=a.querySelector("#gsc_codb_content");b||(b=document.createElement("div"),b.id="gsc_codb_content",a.appendChild(b));var c=Rd(Y)+Rd(Z);b.innerHTML=c;(b=Md())&&(b.value="");Hd("",a.innerHTML)});P("#gsc_cod_done","click",function(){var a=t("gsc_cods_save");za(a,"colleague_add").value=la(Y.j).join(",");za(a,"colleague_del").value=la(Z.j).join(",");a.submit()});
P(["#gsc_coauth_opn",".gsc_rsb_btne",".gsc_rsb_btnv"],"click",function(){Jd("gsc_cod_lc");Pd=0;Y.clear();Z.clear();var a=Md();a&&(a.value="");Ld()});P(".gsc_rsb_aa",["click","keydown"],function(a){if("keydown"!=a.type||a.g&&!Oa(a.g)&&13==a.g.keyCode)a.g&&Na(a.g),(a=(a=a.currentTarget.querySelector("a"))?a.getAttribute("href"):"")&&Ca(a)});P("#gsc_prf_t-ath","click",function(){Ad()});D(function(){Ac.add(fe);fe()});P(".gsc_lwpds_frm","submit",function(a){L(a);O("gsc-lwpds-submit",a.target)});
var le=window.location.href.split("#")[0];Xd=le.replace(/([?&])(cstart|pagesize)=[^&]*/g,"$1");Zd=Math.max(+le.replace(/.*[?&]cstart=([^&]*).*/,"$1")||0,0);ae=+le.replace(/.*[?&]pagesize=([^&]*).*/,"$1")||0;ae=Math.max(Math.min(ae,100),20);
P("#gsc_bpf_more","click",function(a){var b=a.currentTarget,c=ae,d=100>c?100-c:100;a=(Xd+"&cstart="+(Zd+c)+"&pagesize="+d).replace(/([?&])&+/g,"$1");Sd(0);b.disabled=!0;Qb(a,"json=1",function(e,f){b.disabled=!1;try{var h=200==e&&JSON.parse(f)}catch(m){}if(h&&"object"==typeof h){ae=c+=d;Sd(1);e=t("gsc_a_b");f=document.createElement(va.Y);f.innerHTML=""+h.B;f=Array.prototype.slice.call(f.rows);for(var k=0;k<f.length;k++)e.appendChild(f[k]);Vd();if(e=t("gsc_a_nn"))f=e.innerHTML.replace(/[0-9]+$/,""+
t("gsc_a_b").rows.length),e.innerHTML=f;b.disabled=!h.N}else Sd(2)})});P(["#gsc_fol_a","#gsc_fol_c","#gsc_fol_r"],"gs-change",de);P("#gsc_fol_m","input",de);P("#gsc_fol_f","submit",function(a){a.g&&a.g.preventDefault();a=t("gsc_fol_f");var b=t("gsc_fol_inp");b.innerHTML="";for(var c=be(tc),d=be(uc),e=0;e<c.length;e++)if(c[e]!=d[e]){var f=ee[e],h=document.createElement("input");h.type="hidden";h.name=c[e]?f:"un"+f;b.appendChild(h)}O("gsc-fol-submit",a)});P("#gsc_fol_f","gsc-fol-submit",function(a){a.currentTarget.submit()});
P("#gsc_md_hist","gs-md-lded",function(){var a=t("gsc_md_hist_c");if(!a.innerHTML){var b=document.getElementsByClassName("gsc_g_hist_wrp");1==b.length&&(a.appendChild(b[0].cloneNode(!0)),ge(a.lastChild))}});P(["#gsc_hist_opn",".gsc_md_hist_b"],"click",function(){var a=document.documentElement;!t("gsc_hist_opn")||p(a,"gs_el_ph")||p(a,"gs_el_ta")||R("gsc_md_hist")});
P("#gsc_lwp_mndt_lnk","click",function(a){var b=a.currentTarget.getAttribute("href")+"&tzom="+(new Date).getTimezoneOffset();window.location.assign(b);a.g.preventDefault()});P("#gsc_prf_btne","click",function(){var a=t("gsc_md_pro-d");a.setAttribute("data-ifc","");R(a.id,fb({t:"gsc_md_pro_ed"}))});P("#gsc_prf_btnf","click",function(){R("gsc_md_fol")});P("#gsc_md_fol_pub","click",function(){t("gsc_fol_mpf").submit()});P("#gsc_prf_iv_tg","click",function(){q(t("gsc_prf_w"),"gsc_prf_why")});
P(".gsc_prf_pel",["click","keydown"],function(a){("keydown"!=a.type||13==a.g.keyCode&&a.g&&!Oa(a.g))&&he()});P("#gsc_prf_pufii","change",function(){t("gsc_prf_puf").submit()});P(".gsc_prf_tab","click",function(a){var b=t("gsc_bdy");b.setAttribute("data-tab",a.currentTarget.id);b=b.querySelectorAll(".gsc_prf_tab");for(var c=0;c<b.length;c++){var d=b[c];d.setAttribute("aria-selected",""+(d==a.currentTarget))}});D(function(){Ac.add(ie);ie()});
P("#gsc_md_cbyd","gs-md-ldin",function(){var a=t("gsc_md_cbyd_merge");a&&(a.disabled=!0);Aa("")});P("#gsc_md_cbyd","gs-md-lded",function(){var a=t("gsc_md_cbyd_f"),b=t("gsc_md_cbyd_merge"),c=Fc,d=lb(c).s||"";c=kb(c).c||"";a.elements.s.value=d;Aa(c);b&&a.elements.choose&&(b.disabled=!1,b.getBoundingClientRect().bottom<window.innerHeight&&b.focus())});
P("#gsc_md_cbym",["gs-md-ldin","gs-md-lded"],function(){var a=lb(Fc).s||"",b=t("gsc_md_cbym_e");b&&a&&0>a.indexOf("&")&&b.setAttribute("data-href",(b.getAttribute("data-href")||"").replace(/(&citation_for_view=)[^&]*/,"$1"+a))});P("#gsc_md_cbym_e","click",function(a){a=a.currentTarget.getAttribute("data-href")||"";R("gs_md_cita-d",a)});Ub(Fd,Gd);D(function(){return setTimeout(Vd,0)});P(".gsc_a_x","change",Vd);
P("#gsc_x_all","gs-change",function(a){a=tc(a.currentTarget);for(var b=2==a?Wd:Td(),c=b.length;c--;)b[c].checked=0!=a;Ud()});P(".gsc_a_acm","click",function(a){L(a);var b=a.currentTarget;a=b.href;var c=b.getAttribute("data-eid")||"";b=b.getAttribute("data-eud")||"";a=t("gsc_md_cbyd_f").action+"&update_op=merge_options&s="+(b+","+c)+fb({c:a});R("gsc_md_cbyd",a)});
P(".gsc_a_am","click",function(a){a=a.currentTarget.getAttribute("data-eid")||"";a=(t("gsc_md_cbym_l").getAttribute("data-act")||"")+"&update_op=merge_options&s="+a;R("gsc_md_cbym",a)});P("#gs_sth","gs-sth-change",function(a){var b=t("gsc_a_tr0"),c=t("gsc_a_trh"),d=b.querySelector(".gsc_a_t"),e=c.querySelector(".gsc_a_t");p(a.currentTarget,"gs_sth_vis")?(e.style.width=d.offsetWidth+"px",b.style.height=c.offsetHeight+"px"):e.style.width=b.style.height="auto"});
P("#gs_md_cita-b-save","click",function(){var a=t("gsc_ecd_form");za(a,"continue").value=window.location.pathname+window.location.search;O("submit",a)});P(".gsc_ecd_form_tsel","click",function(a){var b=t("gsc_ecd_table"),c=za(t("gsc_ecd_form"),"articletype");a=a.currentTarget;c.value=a.getAttribute("data-type")||"";b.className=a.getAttribute("data-class")||"";b=document.querySelectorAll("#gsc_ecd_citation_type button");for(c=b.length;c--;)q(b[c],"gs_sel",b[c]==a)});
}({"customAC":2,"eventId":"DGREYe_2Msi1mwGW7rLoCQ"});</script></head><body><div id="gs_top" onclick=""><style>#gs_md_s,.gs_md_wnw{z-index:1200;position:fixed;top:0;left:0;width:100%;height:100%;visibility:hidden;}#gs_md_s{background-color:#fff;opacity:.5;}.gs_el_ta #gs_md_s,.gs_el_ph #gs_md_s{background-color:#666;}.gs_md_wnw{transition:all 0s .218s;}#gs_md_s.gs_vis,.gs_md_wnw.gs_vis{visibility:visible;transition:all 0s;}.gs_md_wnw>.gs_md_d{position:relative;margin:0 auto;width:464px;box-shadow:2px 2px 8px rgba(0,0,0,.2);white-space:normal;}.gs_el_ta .gs_md_wnw>.gs_md_d,.gs_el_ph .gs_md_wnw>.gs_md_d{box-shadow:2px 2px 8px rgba(0,0,0,.65);}.gs_el_ph .gs_md_wnw>.gs_md_d{width:80%;max-width:440px;}.gs_el_ph .gs_md_wmw>.gs_md_d{width:100%;height:100%;max-width:none;border:none;box-shadow:none;transform:translate(0,100%);transform:translate(0,100vh);transition:transform .27s cubic-bezier(.4,0,.6,1),opacity 0s .27s,visibility 0s .27s,max-height 0s .27s;}.gs_el_ph .gs_md_wmw>.gs_md_d.gs_vis{transform:translate(0,0);transition:transform .3s cubic-bezier(0,0,.2,1);}.gs_md_wmw>.gs_md_d.gs_abt,.gs_el_ph .gs_md_wmw>.gs_md_d.gs_abt{transition:none;}.gs_md_hdr{display:flex;align-items:center;height:47px;border-bottom:1px solid #e0e0e0;border-bottom-color:rgba(0,0,0,.12);background-color:#f5f5f5;}.gs_md_hdr>a,.gs_md_hdr>a.gs_btn_lrge{flex:0 0 auto;width:41px;height:47px;}.gs_el_ph .gs_md_hdr>a{margin:0 2px 0 0;}.gs_el_ph a.gs_md_hdr_c{margin:0 0 0 2px;}.gs_md_hdr_b{margin:0 41px 0 16px;}.gs_el_ph .gs_md_hdr_b{margin:0 16px;}.gs_md_hdr_t:empty~.gs_md_hdr_b{margin-left:0;}.gs_md_hdr_b:empty{width:41px;margin:0;}.gs_el_ph .gs_md_hdr_b:empty{margin-right:2px;}.gs_md_hdr_b:empty:not(:last-child){display:none;}.gs_md_hdr_b>button{min-width:51px;height:33px;}.gs_md_hdr_t{flex:1 1 auto;font-size:18px;font-weight:normal;color:#666;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;text-align:center;}.gs_md_bdy{overflow-y:auto;box-sizing:border-box;padding:24px 41px 0 41px;}.gs_md_bdy:after{display:block;content:"";clear:both;padding-bottom:24px;}.gs_el_ph .gs_md_bdy{padding:16px 16px 0 16px;}.gs_el_ph .gs_md_bdy:after{padding-bottom:16px;}.gs_el_ph .gs_md_wmw .gs_md_bdy{position:absolute;width:100%;top:48px;bottom:0;}.gs_md_lbl{display:block;font-size:16px;margin:0 0 16px 0;word-wrap:break-word;}.gs_md_btns{margin:24px 0 0 0;white-space:nowrap;}.gs_el_ph .gs_md_btns{margin:16px 0 0 0;}.gs_md_btns button{margin-right:16px;}.gs_md_btns button:last-child{margin-right:0;}.gs_md_prg{margin:24px 0;text-align:center;}.gs_md_prg .gs_alrt{padding:4px 16px;}.gs_md_ldg:before{content:"";position:absolute;top:0;left:0;bottom:0;right:0;background-color:#fff;opacity:.5;z-index:100;}</style><div id="gs_md_ldg" style="display:none">Loading...</div><div id="gs_md_err" style="display:none">The system can't perform the operation now. Try again later.</div><div id="gs_md_s"></div><div data-h="0" class="gs_md_wnw"><div id="gsc_md_hist" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_hist-t" data-wfc="gsc_md_hist-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_hist-x" role="button" aria-label="Cancel" data-mdx="gsc_md_hist" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_hist-t" class="gs_md_hdr_t">Citations per year</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_hist-bdy" class="gs_md_bdy"><style>#gsc_md_hist{width:80%;max-width:386px;}#gsc_md_hist_c{position:relative;width:100%;}</style><div id="gsc_md_hist_c"></div></div></div></div><div data-h="600" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cbyd" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cbyd-t" data-cid="gsc_md_cbyd_l" data-wfc="gsc_md_cbyd-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cbyd-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cbyd" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cbyd-t" class="gs_md_hdr_t">Duplicate citations</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_cbyd-bdy" class="gs_md_bdy"><form id="gsc_md_cbyd_f" action="/citations?hl=en&amp;user=IHT1G6gAAAAJ&amp;view_op=list_works" method="post"><input type="hidden" name="s" value=""><div class="gs_md_lbl">The following articles are merged in Scholar. Their <a id="gsc_md_cbyd_c" href="javascript:void(0)">combined citations</a> are counted only for the first article.</div><div id="gsc_md_cbyd_l"></div></form></div></div></div><div data-h="600" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cbym" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cbym-t" data-cid="gsc_md_cbym_l" data-wfc="gsc_md_cbym-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cbym-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cbym" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cbym-t" class="gs_md_hdr_t">Merged citations</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_cbym-bdy" class="gs_md_bdy"><div class="gs_md_lbl">This "Cited by" count includes citations to the following articles in Scholar. The ones marked <span id="gsc_md_cbym_s">*</span> may be different from the article in the profile.</div><div id="gsc_md_cbym_l" data-act="/citations?hl=en&amp;user=IHT1G6gAAAAJ&amp;view_op=list_works"></div></div></div></div><div data-h="900" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_cod" class="gs_md_d gs_ttzi gsc_cod_lc" role="dialog" tabindex="-1" aria-labelledby="gsc_md_cod-t" data-cid="gsc_cods_res" data-wfc="gsc_md_cod-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_cod-x" role="button" aria-label="Cancel" data-mdx="gsc_md_cod" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_cod-t" class="gs_md_hdr_t"><span id="gsc_cod_t"><span id="gsc_cod_tadd">Add co-authors</span><span id="gsc_cod_tedit">Co-authors</span><a id="gsc_cod_trev" href="javascript:void(0)" data-txt="Review" data-lim="Limit reached"></a></span></h2><div class="gs_md_hdr_b"><button type="button" id="gsc_cod_done" aria-label="Add co-authors" disabled="" class="gs_btnDNW gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></div></div><div id="gsc_md_cod-bdy" class="gs_md_bdy"><div id="gsc_cods_urls" class="gsc_cods_hide" data-ls="" data-lc="/citations?view_op=list_colleagues&amp;hl=en&amp;json=&amp;user=IHT1G6gAAAAJ" data-sa=""></div><form id="gsc_cods_save" action="" method="POST"><input type="hidden" name="colleague_add"><input type="hidden" name="colleague_del"></form><div id="gsc_cods_res"></div></div></div></div><div data-h="800" class="gs_md_wnw gs_md_wmw"><div id="gs_md_cita-d" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gs_md_cita-d-t" data-cid="gs_md_cita-l" data-wfc="gs_md_cita-d-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gs_md_cita-d-x" role="button" aria-label="Cancel" data-mdx="gs_md_cita-d" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gs_md_cita-d-t" class="gs_md_hdr_t"></h2><div class="gs_md_hdr_b"><button type="button" id="gs_md_cita-b-save" aria-label="Save" class="gs_btnDNW gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></div></div><div id="gs_md_cita-d-bdy" class="gs_md_bdy"><style>#gs_md_cita-d{width:90%;max-width:1000px;}.gs_el_ph #gs_md_cita-d{width:100%;max-width:none;}#gs_md_cita-d .gs_md_prg{min-height:600px;}</style><div id="gs_md_cita-l" aria-live="assertive"></div></div></div></div><div data-h="0" class="gs_md_wnw gs_md_wmw"><div id="gsc_md_fol" class="gs_md_d gs_ttzi" role="dialog" tabindex="-1" aria-labelledby="gsc_md_fol-t" data-wfc="gsc_md_fol-x"><div class="gs_md_hdr"><a href="javascript:void(0)" id="gsc_md_fol-x" role="button" aria-label="Cancel" data-mdx="gsc_md_fol" class="gs_btnCLS gs_md_x gs_md_hdr_c gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><h2 id="gsc_md_fol-t" class="gs_md_hdr_t">Follow this author</h2><div class="gs_md_hdr_b"></div></div><div id="gsc_md_fol-bdy" class="gs_md_bdy"><form method="post" id="gsc_fol_f" action="/citations?hl=en&amp;user=IHT1G6gAAAAJ&amp;view_op=list_works"><input type="hidden" name="xsrf" value="AMD79ooAAAAAYUW1jFtF22jjYBwFr9PiTQl-UatkHRG3"><input type="hidden" name="user" value="IHT1G6gAAAAJ"><div id="gsc_fol_inp"></div><div id="gsc_fol_cb"><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_a" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New articles by this author</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_c" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New citations to this author</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div><div class="gsc_fol_cr"><a href="javascript:void(0)" id="gsc_fol_r" role="checkbox" aria-checked="false" data-s="0" class="gs_cb_gen gs_in_cb"><span class="gs_lbl">New articles related to this author's research</span><span class="gs_chk"></span><span class="gs_cbx"></span></a></div></div><div id="gsc_fol_email"><label id="gsc_fol_ml" for="gsc_fol_m">Email address for updates</label><div class="gs_in_txtw gs_in_txtb"><input type="text" class="gs_in_txt" name="email_for_op" value="" id="gsc_fol_m" maxlength="100" autocapitalize="off" autocorrect="off"></div></div><div class="gs_md_btns"><button type="submit" id="gsc_fol_b" disabled="" class=" gs_btn_act gs_btn_lrge gs_btn_lsu"><span class="gs_wr"><span class="gs_lbl">Done</span></span></button></div></form></div></div></div><!--[if lte IE 9]><div class="gs_alrt" style="padding:16px"><div>Sorry, some features may not work in this version of Internet Explorer.</div><div>Please use <a href="//www.google.com/chrome/">Google Chrome</a> or <a href="//www.mozilla.com/firefox/">Mozilla Firefox</a> for the best experience.</div></div><![endif]--><div id="gs_hdr_drs"></div><div id="gs_hdr_drw" class="gs_md_ulr" role="dialog" tabindex="-1" data-shd="gs_hdr_drs" data-wfc="gs_hdr_drw_mnu" data-cfc="gs_hdr_mnu"><div id="gs_hdr_drw_in"><div id="gs_hdr_drw_top"><a href="javascript:void(0)" id="gs_hdr_drw_mnu" role="button" aria-controls="gs_hdr_drw" aria-label="Options" class="gs_btnMNT gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><a id="gs_hdr_drw_lgo" href="/schhp?hl=en" aria-label="Homepage"></a></div><div><div class="gs_hdr_drw_sec"><a href="/citations?hl=en" role="menuitem" class="gs_btnPRO gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">My profile</span></a><a href="/scholar?scilib=1&amp;hl=en" role="menuitem" class="gs_btnL gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">My library</span></a><a href="/citations?view_op=metrics_intro&amp;hl=en" role="menuitem" class="gs_btnJ gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Metrics</span></a><a href="/scholar_alerts?view_op=list_alerts&amp;hl=en" role="menuitem" class="gs_btnM gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Alerts</span></a></div><div class="gs_hdr_drw_sec"><a href="/scholar_settings?hl=en" role="menuitem" class="gs_btnP gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Settings</span></a></div></div><div id="gs_hdr_drw_bot" class="gs_hdr_drw_sec"><a href="https://accounts.google.com/Login?hl=en&amp;continue=https://scholar.google.com/schhp%3Fhl%3Den" class=" gs_in_ib gs_md_li gs_md_lix gs_in_gray"><span class="gs_ico"></span><span class="gs_lbl">Sign in</span></a></div></div></div><div id="gs_hdr" role="banner" class="gs_hdr_src"><a href="javascript:void(0)" id="gs_hdr_mnu" role="button" aria-controls="gs_hdr_drw" class="gs_btnMNT gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><a id="gs_hdr_lgo" class="" href="/schhp?hl=en" aria-label="Homepage"></a><div id="gs_hdr_md"><div id="gs_hdr_srch"><form id="gs_hdr_frm" action="/citations"><input type="hidden" name="view_op" value="search_authors"><input type="hidden" name="hl" value="en"><div class="gs_in_txtw gs_in_txtb"><input type="text" class="gs_in_txt" name="mauthors" value="" id="gs_hdr_tsi" placeholder="Search profiles" size="50" maxlength="2048" autocapitalize="off" aria-label="Search"></div><span id="gs_hdr_tsc"><span class="gs_ico gs_ico_X"></span></span><button type="submit" id="gs_hdr_tsb" name="btnG" aria-label="Search" class="gs_btnG gs_in_ib gs_btn_act gs_btn_half gs_btn_lsb"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl"></span></span></button></form></div></div><a href="javascript:void(0)" id="gs_hdr_sre" role="button" aria-controls="gs_hdr_frm" aria-label="Search" class="gs_btnTSB gs_in_ib gs_btn_lrge"><span class="gs_ico"></span><span class="gs_lbl"></span></a><div id="gs_hdr_act"><a id="gs_hdr_act_s" href="https://accounts.google.com/Login?hl=en&amp;continue=https://scholar.google.com/schhp%3Fhl%3Den">Sign in</a></div></div><style>#gs_alrt{position:fixed;bottom:48px;left:16px;max-width:384px;z-index:1250;display:flex;justify-content:space-between;align-items:center;font-size:13px;line-height:16px;color:#e2e2e2;background:#333;text-align:left;border-radius:3px;box-shadow:0 3px 5px -1px rgba(0,0,0,.2),0 6px 10px 0 rgba(0,0,0,.14),0 1px 18px 0 rgba(0,0,0,.12);visibility:hidden;transform-origin:center;transform:scale(0.8,0.8) translate(0,100%);}.gs_el_ph #gs_alrt{bottom:0;left:0;width:100%;max-width:none;border-radius:0;box-shadow:none;transform:scale(1,1) translate(0,100%);}#gs_alrt.gs_vis{visibility:visible;transform:scale(1,1) translate(0,0);}#gs_alrt.gs_anm{transition:transform .067s cubic-bezier(.4,0,1,1),visibility 0s .067s;}#gs_alrt.gs_vis.gs_anm{transition:transform .067s cubic-bezier(0,0,.2,1);}.gs_el_ph #gs_alrt.gs_anm{transition:transform .084s cubic-bezier(.4,0,1,1),visibility 0s .084s;}.gs_el_ph #gs_alrt.gs_vis.gs_anm{transition:transform .1s cubic-bezier(0,0,.2,1);}#gs_alrt_m{display:block;padding:16px;}#gs_alrt_l{display:block;padding:8px;margin:0 8px 0 -8px;border-radius:3px;color:#fcc934;text-transform:uppercase;text-decoration:none;}#gs_alrt_l:hover{background-color:rgba(255,255,255,.05)}#gs_alrt_l:active{background-color:rgba(255,255,255,.1)}#gs_alrt_l:empty{display:none}#gs_alrt_m a{padding:8px 0;color:#e2e2e2;text-decoration:underline;}#gs_alrt_m a:active{color:#f6aea9}</style><form action="" method="post" id="gs_alrt"><span id="gs_alrt_m"></span><span id="gs_alrt_h"></span><a id="gs_alrt_l" href="javascript:void(0)" class="gs_fm_s" data-fm="gs_alrt"></a></form><div id="gs_bdy"><div id="gs_bdy_sb" role="navigation"><div id="gs_bdy_sb_in"></div></div><div id="gs_bdy_ccl" role="main"><div id="gsc_bdy" class="gs_scl" data-tab="gsc_prf_t-art"><div class="gsc_rsb" role="navigation"><a id="gsc_rsb_gpl" class="gsc_rsb_s" href="/citations?hl=en">Get my own profile</a><div class="gsc_rsb_s gsc_prf_pnl" id="gsc_rsb_cit" role="region" aria-labelledby="gsc_prf_t-cit"><h3 class="gsc_rsb_header"><span class="gsc_rsb_title">Cited by</span><button type="button" id="gsc_hist_opn" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_half gs_btn_lsu gsc_rsb_action"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></h3><table id="gsc_rsb_st"><thead><tr><th class="gsc_rsb_sth"></th><th class="gsc_rsb_sth">All</th><th class="gsc_rsb_sth">Since 2016</th></tr></thead><tbody><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="This is the number of citations to all publications. The second column has the &quot;recent&quot; version of this metric which is the number of new citations in the last 5 years to all publications.">Citations</a></td><td class="gsc_rsb_std">12349</td><td class="gsc_rsb_std">9023</td></tr><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="h-index is the largest number h such that h publications have at least h citations. The second column has the &quot;recent&quot; version of this metric which is the largest number h such that h publications have at least h new citations in the last 5 years.">h-index</a></td><td class="gsc_rsb_std">55</td><td class="gsc_rsb_std">41</td></tr><tr><td class="gsc_rsb_sc1"><a href="javascript:void(0)" class="gsc_rsb_f gs_ibl" title="i10-index is the number of publications with at least 10 citations. The second column has the &quot;recent&quot; version of this metric which is the number of publications that have received at least 10 new citations in the last 5 years.">i10-index</a></td><td class="gsc_rsb_std">124</td><td class="gsc_rsb_std">100</td></tr></tbody></table><style>.gsc_g_t{position:absolute;bottom:0;color:#777;font-size:11px;}.gsc_g_a{position:absolute;bottom:13px;width:15px;background:#777;}.gsc_g_a:hover,.gsc_g_a:focus,.gsc_g_a:active{text-decoration:none;cursor:default;}.gsc_g_al{position:absolute;bottom:15px;left:7px;color:#222;background:white;font-size:11px;padding:1px;border:1px solid #777;border-radius:1px;visibility:hidden;opacity:0;transition:opacity .218s,visibility 0s .218s;}.gsc_g_a:hover .gsc_g_al,.gsc_g_a:focus .gsc_g_al,.gsc_g_a:active .gsc_g_al{visibility:visible;opacity:1;transition:all 0s;}#gsc_md_hist{max-width:678px;}.gsc_md_hist_w{position:relative;overflow:hidden;margin-right:43px;}.gs_md_bdy .gsc_md_hist_w,.gs_el_ph .gsc_md_hist_w,.gs_el_ta .gsc_md_hist_w{overflow-x:auto;padding-bottom:16px;}.gsc_md_hist_b{position:relative;height:174px;width:100%;}.gsc_md_hist_b .gsc_g_a{bottom:auto;}.gsc_md_hist_b .gsc_g_t{bottom:auto;top:161px;}.gsc_md_hist_b:after{position:absolute;right:632px;content:"\00A0";}.gsc_g_hist_x{position:relative;margin-right:45px;}.gsc_g_hist_xl{position:absolute;right:8px;width:35px;}.gs_el_ta .gsc_g_hist_xl,.gs_el_ph .gsc_g_hist_xl{right:16px;}.gsc_g_hist_wrp{padding-top:32px;position:relative;}.gs_el_ta .gsc_g_hist_wrp,.gs_el_ph .gsc_g_hist_wrp{padding-right:8px;}.gs_md_bdy .gsc_g_hist_wrp{border-top:0;}.gs_el_tc .gs_md_bdy .gsc_g_hist_wrp:after,.gs_el_tc.gs_el_ph .gsc_g_hist_wrp:after,.gs_el_tc.gs_el_ta .gsc_g_hist_wrp:after{display:block;content:"";position:absolute;z-index:100;top:0;left:0;width:20px;height:100%;background-image:linear-gradient(to left,rgba(255,255,255,0),rgba(255,255,255,1) 80%);}.gsc_g_x,.gsc_g_xt{position:absolute;left:0;border-bottom:1px solid #eee;width:100%;text-align:right;}.gsc_g_x{border-bottom:1px solid #eee;}.gsc_g_xtl{position:absolute;color:#777;}.gsc_g_gtr{position:absolute;}.gsc_g_a:last-child .gsc_g_al{right:0;left:auto;}</style><div class="gsc_g_hist_wrp" dir="rtl"><div class="gsc_g_hist_x"><div class="gsc_g_x" style="top:160px;"></div><div class="gsc_g_xt" style="top:0px;"></div><div class="gsc_g_xt" style="top:80px;"></div><div class="gsc_g_xt" style="top:120px;"></div><div class="gsc_g_xt" style="top:40px;"></div></div><div class="gsc_g_hist_xl"><div class="gsc_g_xtl" style="top:153px;">0</div><div class="gsc_g_xtl" style="top:-7px;">2200</div><div class="gsc_g_xtl" style="top:73px;">1100</div><div class="gsc_g_xtl" style="top:113px;">550</div><div class="gsc_g_xtl" style="top:33px;">1650</div></div><div class="gsc_md_hist_w"><div class="gsc_md_hist_b"><span class="gsc_g_t" style="right:579px">2003</span><span class="gsc_g_t" style="right:547px">2004</span><span class="gsc_g_t" style="right:515px">2005</span><span class="gsc_g_t" style="right:483px">2006</span><span class="gsc_g_t" style="right:451px">2007</span><span class="gsc_g_t" style="right:419px">2008</span><span class="gsc_g_t" style="right:387px">2009</span><span class="gsc_g_t" style="right:355px">2010</span><span class="gsc_g_t" style="right:323px">2011</span><span class="gsc_g_t" style="right:291px">2012</span><span class="gsc_g_t" style="right:259px">2013</span><span class="gsc_g_t" style="right:227px">2014</span><span class="gsc_g_t" style="right:195px">2015</span><span class="gsc_g_t" style="right:163px">2016</span><span class="gsc_g_t" style="right:131px">2017</span><span class="gsc_g_t" style="right:99px">2018</span><span class="gsc_g_t" style="right:67px">2019</span><span class="gsc_g_t" style="right:35px">2020</span><span class="gsc_g_t" style="right:3px">2021</span><a href="javascript:void(0)" class="gsc_g_a" style="right:584px;top:158px;height:2px;z-index:19"><span class="gsc_g_al">32</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:552px;top:157px;height:3px;z-index:18"><span class="gsc_g_al">44</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:520px;top:155px;height:5px;z-index:17"><span class="gsc_g_al">78</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:488px;top:155px;height:5px;z-index:16"><span class="gsc_g_al">73</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:456px;top:155px;height:5px;z-index:15"><span class="gsc_g_al">81</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:424px;top:152px;height:8px;z-index:14"><span class="gsc_g_al">119</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:392px;top:151px;height:9px;z-index:13"><span class="gsc_g_al">129</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:360px;top:147px;height:13px;z-index:12"><span class="gsc_g_al">188</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:328px;top:143px;height:17px;z-index:11"><span class="gsc_g_al">236</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:296px;top:130px;height:30px;z-index:10"><span class="gsc_g_al">426</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:264px;top:125px;height:35px;z-index:9"><span class="gsc_g_al">489</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:232px;top:117px;height:43px;z-index:8"><span class="gsc_g_al">596</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:200px;top:113px;height:47px;z-index:7"><span class="gsc_g_al">656</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:168px;top:109px;height:51px;z-index:6"><span class="gsc_g_al">714</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:136px;top:91px;height:69px;z-index:5"><span class="gsc_g_al">954</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:104px;top:53px;height:107px;z-index:4"><span class="gsc_g_al">1483</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:72px;top:33px;height:127px;z-index:3"><span class="gsc_g_al">1759</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:40px;top:5px;height:155px;z-index:2"><span class="gsc_g_al">2132</span></a><a href="javascript:void(0)" class="gsc_g_a" style="right:8px;top:24px;height:136px;z-index:1"><span class="gsc_g_al">1882</span></a></div></div></div></div><div class="gsc_rsb_s gsc_prf_pnl" id="gsc_rsb_mnd" role="region" aria-labelledby="gsc_prf_t-mnd"><div class="gsc_rsb_header gsc_rsb_m_header"><div class="gsc_rsb_m_title">Public access</div><a href="/citations?view_op=list_mandates&amp;hl=en&amp;user=IHT1G6gAAAAJ" id="gsc_lwp_mndt_lnk">View all</a></div><div class="gsc_rsb_hm gs_ota gs_oph"><button type="button" onclick="window.location='/citations?view_op\x3dlist_mandates\x26hl\x3den\x26user\x3dIHT1G6gAAAAJ'" class=" gs_btn_flat gs_btn_flact gs_btn_lrge gs_btn_half gs_btn_lsu"><span class="gs_wr"><span class="gs_lbl">View all</span></span></button></div><div class="gsc_rsb_m"><div class="gsc_rsb_m_a"><span>55 articles</span></div><div class="gsc_rsb_m_na"><div>4 articles</div></div><div class="gsc_rsb_m_bar"><div class="gsc_rsb_m_bar_na" style="width:7%"></div></div><div class="gsc_rsb_m_a"><span>available</span></div><div class="gsc_rsb_m_na"><span>not available</span></div><div class="gsc_rsb_m_desc">Based on funding mandates</div></div></div></div><div class="gsc_lcl" role="main" id="gsc_prf_w"><div id="gsc_prf"><button type="button" id="gsc_prf_btnf" class="gs_btnMW gs_in_ib gs_btn_act gs_btn_lsu gs_btn_mph"><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl">Follow</span></span></button><div id="gsc_prf_pu"><div id="gsc_prf_pua" class="gs_rimg"><style>#gsc_prf_pup-img{width:91px;height:128px;}@media print{#gs_top #gsc_prf_pup-img{width:56pt;height:80pt;}}</style><img alt="dean fennell" sizes="print 56px,91px" src="https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=IHT1G6gAAAAJ&amp;citpid=1" id="gsc_prf_pup-img" srcset="https://scholar.googleusercontent.com/citations?view_op=view_photo&amp;user=IHT1G6gAAAAJ&amp;citpid=1 91w,https://scholar.googleusercontent.com/citations?view_op=medium_photo&amp;user=IHT1G6gAAAAJ&amp;citpid=1 183w"></div></div><div id="gsc_prf_i"><div id="gsc_prf_in">dean fennell</div><div class="gsc_prf_il"><a href="/citations?view_op=view_org&amp;hl=en&amp;org=4637542799464793309" class="gsc_prf_ila">University of Leicester</a></div><div class="gsc_prf_il" id="gsc_prf_ivh">Verified email at le.ac.uk - <a href="http://www.mesothelioma-research-leicester.com/" rel="nofollow" class="gsc_prf_ila">Homepage</a></div><div class="gsc_prf_il" id="gsc_prf_int"></div></div></div></div><div id="gsc_prf_t_wrp" role="navigation"><div id="gsc_prf_t" role="tablist"><a id="gsc_prf_t-art" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_art" aria-selected="true">Articles</a><a id="gsc_prf_t-cit" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_rsb_cit">Cited by</a><a id="gsc_prf_t-mnd" class="gsc_prf_tab" href="javascript:void(0)" role="tab" aria-controls="gsc_rsb_mnd">Public access</a></div></div><div class="gsc_lcl gsc_prf_pnl" id="gsc_art" role="region" aria-labelledby="gsc_prf_t-art"><form method="post" action="/citations?hl=en&amp;user=IHT1G6gAAAAJ&amp;view_op=list_works"><input type="hidden" name="xsrf" value="AMD79ooAAAAAYUW1jFtF22jjYBwFr9PiTQl-UatkHRG3"><div id="gsc_a_tw"><table id="gsc_a_t"><thead><tr id="gsc_a_tr0" aria-hidden="true"><th class="gsc_a_t"></th><th class="gsc_a_c"></th><th class="gsc_a_y"></th></tr><tr id="gsc_a_trh"><th class="gsc_a_t" scope="col"><span id="gsc_a_ta"><a href="/citations?hl=en&amp;user=IHT1G6gAAAAJ&amp;view_op=list_works&amp;sortby=title" class="gsc_a_a">Title</a></span><div id="gsc_dd_sort-r" class="gs_md_r gs_md_rmb gs_md_rmbl"><button type="button" id="gsc_dd_sort-b" aria-controls="gsc_dd_sort-d" aria-haspopup="true" ontouchstart="gs_evt_dsp(event)" class=" gs_in_se gs_btn_mnu gs_btn_flat gs_btn_lrge gs_btn_half gs_btn_lsu gs_press gs_md_tb"><span class="gs_wr"><span class="gs_lbl">Sort</span><span class="gs_icm"></span></span></button><div id="gsc_dd_sort-d" class="gs_md_d gs_md_ulr" role="menu" tabindex="-1"><div id="gsc_dd_sort-s" class="gs_oph gsc_dd_sec gsc_dd_sep"><a role="menuitem" href="/citations?hl=en&amp;user=IHT1G6gAAAAJ&amp;view_op=list_works" tabindex="-1" class="gs_md_li gsc_dd_sort-sel">Sort by citations</a><a role="menuitem" href="/citations?hl=en&amp;user=IHT1G6gAAAAJ&amp;view_op=list_works&amp;sortby=pubdate" tabindex="-1" class="gs_md_li">Sort by year</a><a role="menuitem" href="/citations?hl=en&amp;user=IHT1G6gAAAAJ&amp;view_op=list_works&amp;sortby=title" tabindex="-1" class="gs_md_li">Sort by title</a></div></div></div></th><th class="gsc_a_c" scope="col" dir="rtl"><span id="gsc_a_ca"><div class="gs_nph">Cited by</div><div class="gs_oph">Cited by</div></span></th><th class="gsc_a_y" scope="col"><span class="gsc_a_h" id="gsc_a_ha"><a href="/citations?hl=en&amp;user=IHT1G6gAAAAJ&amp;view_op=list_works&amp;sortby=pubdate" class="gsc_a_a">Year</a></span></th></tr></thead><tbody id="gsc_a_b"><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:sgsej9ZJWHMC" class="gsc_a_at">Tracking the evolution of non–small-cell lung cancer</a><div class="gs_gray">M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ...</div><div class="gs_gray">New England Journal of Medicine 376 (22), 2109-2121<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5739709269093218260" class="gsc_a_ac gs_ibl">1334</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:tBlTYpvFGQIC" class="gsc_a_at">Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution</a><div class="gs_gray">C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ...</div><div class="gs_gray">Nature 545 (7655), 446-451<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9800736349444847161,8961103359358553507" class="gsc_a_ac gs_ibl">928</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:w1MjKQ0l0TYC" class="gsc_a_at">Small-cell lung cancer</a><div class="gs_gray">JP Van Meerbeeck, DA Fennell, DKM De Ruysscher</div><div class="gs_gray">The Lancet 378 (9804), 1741-1755<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10330345138494590747" class="gsc_a_ac gs_ibl">828</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:Tfl4UtY-dJUC" class="gsc_a_at">Allele-specific HLA loss and immune escape in lung cancer evolution</a><div class="gs_gray">N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ...</div><div class="gs_gray">Cell 171 (6), 1259-1271. e11<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11587979082744295559" class="gsc_a_ac gs_ibl">563</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:mUJArPsKIAAC" class="gsc_a_at">Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer</a><div class="gs_gray">B Delage, DA Fennell, L Nicholson, I McNeish, NR Lemoine, T Crook, ...</div><div class="gs_gray">International journal of cancer 126 (12), 2762-2772<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13497691455935336295" class="gsc_a_ac gs_ibl">322</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:oi2SiIJ9l4AC" class="gsc_a_at">MicroRNA regulation of core apoptosis pathways in cancer</a><div class="gs_gray">RT Lima, S Busacca, GM Almeida, G Gaudino, DA Fennell, ...</div><div class="gs_gray">European journal of cancer 47 (2), 163-174<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7129832306840595366" class="gsc_a_ac gs_ibl">296</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:pUxgyZctzPYC" class="gsc_a_at">Fc effector function contributes to the activity of human anti-CTLA-4 antibodies</a><div class="gs_gray">FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ...</div><div class="gs_gray">Cancer cell 33 (4), 649-663. e4<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17800639634673901367" class="gsc_a_ac gs_ibl">279</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:cRMvf6lLvU8C" class="gsc_a_at">Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled&nbsp;…</a><div class="gs_gray">M Maio, A Scherpereel, L Calabrò, J Aerts, SC Perez, A Bearz, ...</div><div class="gs_gray">The Lancet Oncology 18 (9), 1261-1273<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18022431394407900675" class="gsc_a_ac gs_ibl">279</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:Xz60mAmATU4C" class="gsc_a_at">Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</a><div class="gs_gray">P Baas, D Fennell, KM Kerr, PE Van Schil, RL Haas, S Peters</div><div class="gs_gray">Annals of oncology 26, v31-v39<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5554510026906684158" class="gsc_a_ac gs_ibl">267</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:kzcSZmkxUKAC" class="gsc_a_at">Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature</a><div class="gs_gray">MP Barr, SG Gray, AC Hoffmann, RA Hilger, J Thomale, JD O’Flaherty, ...</div><div class="gs_gray">PloS one 8 (1), e54193<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5922564350972604945" class="gsc_a_ac gs_ibl">246</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:Gpwnp1kGG20C" class="gsc_a_at">Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors</a><div class="gs_gray">FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ...</div><div class="gs_gray">Immunity 46 (4), 577-586<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7152760589631382009" class="gsc_a_ac gs_ibl">243</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:rTD5ala9j4wC" class="gsc_a_at">Tracking genomic cancer evolution for precision medicine: the lung TRACERx study</a><div class="gs_gray">M Jamal-Hanjani, A Hackshaw, Y Ngai, J Shaw, C Dive, S Quezada, ...</div><div class="gs_gray">PLoS biology 12 (7), e1001906<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14237473761913890520" class="gsc_a_ac gs_ibl">220</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:isU91gLudPYC" class="gsc_a_at">Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer</a><div class="gs_gray">DA Fennell, Y Summers, J Cadranel, T Benepal, DC Christoph, R Lal, ...</div><div class="gs_gray">Cancer treatment reviews 44, 42-50<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6552320454617816200" class="gsc_a_ac gs_ibl">219</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:7VEv-pLvLSsC" class="gsc_a_at">Novel insights into mesothelioma biology and implications for therapy</a><div class="gs_gray">TA Yap, JG Aerts, S Popat, DA Fennell</div><div class="gs_gray">Nature Reviews Cancer 17 (8), 475-488<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6739249683896310825" class="gsc_a_ac gs_ibl">203</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:raTqNPD5sRQC" class="gsc_a_at">Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer</a><div class="gs_gray">JD O’Flaherty, S Gray, D Richard, D Fennell, JJ O’Leary, FH Blackhall, ...</div><div class="gs_gray">Lung cancer 76 (1), 19-25<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6361712879557363976" class="gsc_a_ac gs_ibl">181</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:kF1pexMAQbMC" class="gsc_a_at">In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion</a><div class="gs_gray">PW Szlosarek, A Klabatsa, A Pallaska, M Sheaff, P Smith, T Crook, ...</div><div class="gs_gray">Clinical cancer research 12 (23), 7126-7131<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10519057481317835385" class="gsc_a_ac gs_ibl">172</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:WAzi4Gm8nLoC" class="gsc_a_at">The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma</a><div class="gs_gray">J Stebbing, T Powles, K McPherson, J Shamash, P Wells, MT Sheaff, ...</div><div class="gs_gray">Lung Cancer 63 (1), 94-97<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9626203885867071926" class="gsc_a_ac gs_ibl">165</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:ziOE8S1-AIUC" class="gsc_a_at">BCL-2 family regulation by the 20S proteasome inhibitor bortezomib</a><div class="gs_gray">DA Fennell, A Chacko, L Mutti</div><div class="gs_gray">Oncogene 27 (9), 1189-1197<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9693453892895438145" class="gsc_a_ac gs_ibl">165</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:Xl6nMSl579sC" class="gsc_a_at">Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo&nbsp;…</a><div class="gs_gray">LM Krug, HL Kindler, H Calvert, C Manegold, AS Tsao, D Fennell, ...</div><div class="gs_gray">The Lancet Oncology 16 (4), 447-456<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17995376643472263552" class="gsc_a_ac gs_ibl">161</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;citation_for_view=IHT1G6gAAAAJ:YsrPvlHIBpEC" class="gsc_a_at">Advances in the systemic therapy of malignant pleural mesothelioma</a><div class="gs_gray">DA Fennell, G Gaudino, KJ O'byrne, L Mutti, J Van Meerbeeck</div><div class="gs_gray">Nature clinical practice Oncology 5 (3), 136-147<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14326715807479447583" class="gsc_a_ac gs_ibl">143</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:Ic1VZgkJnDsC" class="gsc_a_at">The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC</a><div class="gs_gray">C Manegold, AMC Dingemans, JE Gray, K Nakagawa, M Nicolson, ...</div><div class="gs_gray">Journal of Thoracic Oncology 12 (2), 194-207<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14345180861628087435" class="gsc_a_ac gs_ibl">139</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:5bg8sr1QxYwC" class="gsc_a_at">Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials</a><div class="gs_gray">DA Fennell, A Parmar, J Shamash, MT Evans, MT Sheaff, R Sylvester, ...</div><div class="gs_gray">Journal of Clinical Oncology 23 (1), 184-189<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11951472465128653865" class="gsc_a_ac gs_ibl">127</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:pS0ncopqnHgC" class="gsc_a_at">The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy</a><div class="gs_gray">JD O’Flaherty, M Barr, D Fennell, D Richard, J Reynolds, J O’Leary, ...</div><div class="gs_gray">Journal of thoracic oncology 7 (12), 1880-1890<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14063051430176141513" class="gsc_a_ac gs_ibl">121</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:oYLFIHfuHKwC" class="gsc_a_at">British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma</a><div class="gs_gray">I Woolhouse, L Bishop, L Darlison, D De Fonseka, A Edey, J Edwards, ...</div><div class="gs_gray">Thorax 73 (Suppl 1), i1-i30<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=281704369646657377" class="gsc_a_ac gs_ibl">116</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:ukw-9cB-YDkC" class="gsc_a_at">Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1–deficient malignant pleural mesothelioma: a randomized clinical trial</a><div class="gs_gray">PW Szlosarek, JP Steele, L Nolan, D Gilligan, P Taylor, J Spicer, M Lind, ...</div><div class="gs_gray">JAMA oncology 3 (1), 58-66<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16430384579860433120" class="gsc_a_ac gs_ibl">110</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:8uzoZH4hB9AC" class="gsc_a_at">Prognostic factors in mesothelioma</a><div class="gs_gray">JPC Steele, DA Fennell</div><div class="gs_gray">Malignant Mesothelioma, 416-429<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18132831680383166375" class="gsc_a_ac gs_ibl">104</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:v6i8RKmR8ToC" class="gsc_a_at">A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)</a><div class="gs_gray">S Ramalingam, G Goss, R Rosell, G Schmid-Bindert, B Zaric, Z Andric, ...</div><div class="gs_gray">Annals of Oncology 26 (8), 1741-1748<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=632213006748932646" class="gsc_a_ac gs_ibl">102</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:mWEH9CqjF64C" class="gsc_a_at">New advances in the second‐line treatment of small cell lung cancer</a><div class="gs_gray">JL Hurwitz, F McCoy, P Scullin, DA Fennell</div><div class="gs_gray">The oncologist 14 (10), 986-994<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5316166354107606865" class="gsc_a_ac gs_ibl">101</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:BrOSOlqYqPUC" class="gsc_a_at">Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma</a><div class="gs_gray">A Sartore-Bianchi, F Gasparri, A Galvani, L Nici, JW Darnowski, ...</div><div class="gs_gray">Clinical Cancer Research 13 (19), 5942-5951<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12827267964961183660" class="gsc_a_ac gs_ibl">100</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:SGW5VrABaM0C" class="gsc_a_at">Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids</a><div class="gs_gray">TM Yang, D Barbone, DA Fennell, VC Broaddus</div><div class="gs_gray">American journal of respiratory cell and molecular biology 41 (1), 14-23<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2621621504539446605" class="gsc_a_ac gs_ibl">99</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:DkZNVXde3BIC" class="gsc_a_at">Estrogen receptor-β affects the prognosis of human malignant mesothelioma</a><div class="gs_gray">G Pinton, E Brunelli, B Murer, R Puntoni, M Puntoni, DA Fennell, ...</div><div class="gs_gray">Cancer research 69 (11), 4598-4604<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8710424918173112816" class="gsc_a_ac gs_ibl">92</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:HJSXoJQnj-YC" class="gsc_a_at">Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways</a><div class="gs_gray">HF Yuen, KK Chan, C Grills, JT Murray, A Platt-Higgins, OS Eldin, ...</div><div class="gs_gray">Clinical Cancer Research 18 (2), 380-391<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1686814819944361755" class="gsc_a_ac gs_ibl">90</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:eO3_k5sD8BwC" class="gsc_a_at">Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK</a><div class="gs_gray">F McCoy, J Hurwitz, N McTavish, I Paul, C Barnes, B O'Hagan, ...</div><div class="gs_gray">Cell death &amp; disease 1 (12), e108-e108<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9392230258787479565" class="gsc_a_ac gs_ibl">90</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:2l5NCbZemmgC" class="gsc_a_at">Targeted therapies in the treatment of advanced/metastatic NSCLC</a><div class="gs_gray">AG Pallis, L Serfass, R Dziadziuszko, JP Van Meerbeeck, D Fennell, ...</div><div class="gs_gray">European journal of cancer 45 (14), 2473-2487<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14749166779641769179" class="gsc_a_ac gs_ibl">90</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:An6A6Jpfc1oC" class="gsc_a_at">Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development</a><div class="gs_gray">DA Fennell, RM Rudd</div><div class="gs_gray">The lancet oncology 5 (6), 354-362<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16402692311884436242" class="gsc_a_ac gs_ibl">88</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:T_ojBgVMvoEC" class="gsc_a_at">Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales</a><div class="gs_gray">P Beckett, J Edwards, D Fennell, R Hubbard, I Woolhouse, MD Peake</div><div class="gs_gray">Lung cancer 88 (3), 344-348<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17961534251470263532" class="gsc_a_ac gs_ibl">87</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:EPG8bYD4jVwC" class="gsc_a_at">Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK11195 involves de novo generation of reactive oxygen species</a><div class="gs_gray">DA Fennell, M Corbo, A Pallaska, FE Cotter</div><div class="gs_gray">British journal of cancer 84 (10), 1397-1404<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6680619256586075434" class="gsc_a_ac gs_ibl">84</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:hSRAE-fF4OAC" class="gsc_a_at">Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain</a><div class="gs_gray">MW Richards, EWP Law, PR La’Verne, S Busacca, L O’Regan, AM Fry, ...</div><div class="gs_gray">Proceedings of the National Academy of Sciences 111 (14), 5195-5200<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3141863070556275421" class="gsc_a_ac gs_ibl">77</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:wvYxNZNCP7wC" class="gsc_a_at">Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non–small-cell lung cancer in a prospective blinded assessment phase II&nbsp;…</a><div class="gs_gray">MC Nicolson, DA Fennell, D Ferry, K O'Byrne, R Shah, V Potter, G Skailes, ...</div><div class="gs_gray">Journal of Thoracic Oncology 8 (7), 930-939<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2871357991343654842" class="gsc_a_ac gs_ibl">76</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:NxmKEeNBbOMC" class="gsc_a_at">Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs</a><div class="gs_gray">R Bayliss, J Choi, DA Fennell, AM Fry, MW Richards</div><div class="gs_gray">Cellular and molecular life sciences 73 (6), 1209-1224<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16510746545057098173" class="gsc_a_ac gs_ibl">74</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:k_7cPK9k7w8C" class="gsc_a_at">Guidelines and considerations for conducting experiments using tissue microarrays</a><div class="gs_gray">M Ilyas, H Grabsch, IO Ellis, C Womack, R Brown, D Berney, D Fennell, ...</div><div class="gs_gray">Histopathology 62 (6), 827-839<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12146316026861367541" class="gsc_a_ac gs_ibl">74</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:27LrP4qxOz0C" class="gsc_a_at">Differential affinity of FLIP and procaspase 8 for FADD’s DED binding surfaces regulates DISC assembly</a><div class="gs_gray">J Majkut, M Sgobba, C Holohan, N Crawford, AE Logan, E Kerr, ...</div><div class="gs_gray">Nature communications 5 (1), 1-12<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8498419816862792065" class="gsc_a_ac gs_ibl">73</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:DyXnQzXoVgIC" class="gsc_a_at">Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery</a><div class="gs_gray">F Fay, KM McLaughlin, DM Small, DA Fennell, PG Johnston, DB Longley, ...</div><div class="gs_gray">Biomaterials 32 (33), 8645-8653<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4708618404688336943" class="gsc_a_ac gs_ibl">68</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:j8pvxH-kN2QC" class="gsc_a_at">Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised&nbsp;…</a><div class="gs_gray">GV Scagliotti, R Gaafar, AK Nowak, T Nakano, J van Meerbeeck, S Popat, ...</div><div class="gs_gray">The Lancet Respiratory Medicine 7 (7), 569-580<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14055754504489698553" class="gsc_a_ac gs_ibl">67</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:QUX0mv85b1cC" class="gsc_a_at">Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-XL and Mcl-1 expressing human cholangiocarcinoma cells</a><div class="gs_gray">AC Okaro, DA Fennell, M Corbo, BR Davidson, FE Cotter</div><div class="gs_gray">Gut 51 (4), 556-561<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11398837959580729341" class="gsc_a_ac gs_ibl">65</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:69ZgNCALVd0C" class="gsc_a_at">Caspase regulation in non–small cell lung cancer and its potential for therapeutic exploitation</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Clinical cancer research 11 (6), 2097-2105<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6926119071221833877" class="gsc_a_ac gs_ibl">64</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:2v_ZtQDX9iAC" class="gsc_a_at">Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer</a><div class="gs_gray">JS Riley, R Hutchinson, DG McArt, N Crawford, C Holohan, I Paul, ...</div><div class="gs_gray">Cell death &amp; disease 4 (12), e951-e951<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14427493020738016075" class="gsc_a_ac gs_ibl">62</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:qCaWouos7ogC" class="gsc_a_at">Kinetics of the human leucocyte Na (+)-H+ antiport in essential hypertension.</a><div class="gs_gray">LL Ng, DA Fennell, C Dudley</div><div class="gs_gray">Journal of hypertension 8 (6), 533-537<span class="gs_oph">, 1990</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7206893771468050693" class="gsc_a_ac gs_ibl">62</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1990</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:TlpoogIpr_IC" class="gsc_a_at"><i>In vivo</i> suppression of Bcl‐X<sub>L</sub> expression facilitates chemotherapy‐induced leukaemia cell death in a SCID/NOD‐Hu model</a><div class="gs_gray">DA Fennell, MV Corbo, NM Dean, BP Monia, FE Cotter</div><div class="gs_gray">British journal of haematology 112 (3), 706-713<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15339970345691410810" class="gsc_a_ac gs_ibl">61</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:zGdJYJv2LkUC" class="gsc_a_at">Efficacy and safety of first‐or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma</a><div class="gs_gray">DA Fennell, JPC Steele, J Shamash, MT Evans, P Wells, MT Sheaff, ...</div><div class="gs_gray">Cancer 109 (1), 93-99<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3483553368808338074" class="gsc_a_ac gs_ibl">57</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:adHtZc2wMuEC" class="gsc_a_at">Current and future management of malignant mesothelioma: a consensus report from the national cancer institute thoracic malignancy steering committee, international association&nbsp;…</a><div class="gs_gray">AS Tsao, OW Lindwasser, AA Adjei, PS Adusumilli, ML Beyers, ...</div><div class="gs_gray">Journal of Thoracic Oncology 13 (11), 1655-1667<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6766097933784354692" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:PkcyUWeTMh0C" class="gsc_a_at">Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail‐induced epithelial–mesenchymal transition</a><div class="gs_gray">HF Yuen, YK Chan, C Grills, CM McCrudden, V Gunasekharan, Z Shi, ...</div><div class="gs_gray">The Journal of pathology 224 (1), 78-89<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3977174118869287073" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:IsPWOBWtZBwC" class="gsc_a_at">Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer</a><div class="gs_gray">C Grills, PV Jithesh, J Blayney, SD Zhang, DA Fennell</div><div class="gs_gray">PloS one 6 (1), e14635<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17262284879781578311" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:JTqpx9DYBaYC" class="gsc_a_at">Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM)</a><div class="gs_gray">A Klabatsa, MT Sheaff, JPC Steele, MT Evans, RM Rudd, DA Fennell</div><div class="gs_gray">Lung cancer 51 (1), 53-59<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3444953096557316303" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:DrR-2ekChdkC" class="gsc_a_at">Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma</a><div class="gs_gray">DA Fennell, JPC Steele, J Shamash, MT Sheaff, MT Evans, ...</div><div class="gs_gray">Lung Cancer 47 (2), 277-281<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3995148533484141513" class="gsc_a_ac gs_ibl">55</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:SnGPuo6Feq8C" class="gsc_a_at">PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism</a><div class="gs_gray">DE Banker, JJ Cooper, DA Fennell, CL Willman, FR Appelbaum, ...</div><div class="gs_gray">Leukemia research 26 (1), 91-106<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15261950256055260143" class="gsc_a_ac gs_ibl">53</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:jSAVyFp_754C" class="gsc_a_at">Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells</a><div class="gs_gray">TR Wilson, M McEwan, K McLaughlin, C Le Clorennec, WL Allen, ...</div><div class="gs_gray">Oncogene 28 (1), 63-72<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2534868622608177141" class="gsc_a_ac gs_ibl">51</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:C33y2ycGS3YC" class="gsc_a_at">Tremelimumab as second-or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.</a><div class="gs_gray">HL Kindler, A Scherpereel, L Calabro, J Aerts, S Cedres Perez, A Bearz, ...</div><div class="gs_gray">Journal of Clinical Oncology 34 (15_suppl), 8502-8502<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16602231318659049279" class="gsc_a_ac gs_ibl">50</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:g5Ck-dwhA_QC" class="gsc_a_at">The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance</a><div class="gs_gray">D Barbone, JA Ryan, N Kolhatkar, AD Chacko, DM Jablons, ...</div><div class="gs_gray">Cell death &amp; disease 2 (6), e174-e174<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6699616448938816046" class="gsc_a_ac gs_ibl">50</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:Hck25ST_3aIC" class="gsc_a_at">Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing</a><div class="gs_gray">TR Wilson, KM Redmond, KM McLaughlin, N Crawford, K Gately, ...</div><div class="gs_gray">Cell Death &amp; Differentiation 16 (10), 1352-1361<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18277191855814134951" class="gsc_a_ac gs_ibl">50</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:CYCckWUYoCcC" class="gsc_a_at">Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma</a><div class="gs_gray">DA Fennell, C McDowell, S Busacca, G Webb, B Moulton, A Cakana, ...</div><div class="gs_gray">Journal of Thoracic Oncology 7 (9), 1466-1470<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8410421829514682627" class="gsc_a_ac gs_ibl">49</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:VnuxuLaQPLMC" class="gsc_a_at">Progress in the Management of Malignant PleuraláMesothelioma in 2017</a><div class="gs_gray">AJ McCambridge, A Napolitano, AS Mansfield, DA Fennell, Y Sekido, ...</div><div class="gs_gray">Journal of Thoracic Oncology 13 (5), 606-623<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17963884252872089863" class="gsc_a_ac gs_ibl">47</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:65Yg0jNCQDAC" class="gsc_a_at">In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy</a><div class="gs_gray">BJ Kuss, M Corbo, WM Lau, DA Fennell, NM Dean, FE Cotter</div><div class="gs_gray">International journal of cancer 98 (1), 128-133<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3701813586198206807" class="gsc_a_ac gs_ibl">47</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:UmS_249rOGwC" class="gsc_a_at">Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent</a><div class="gs_gray">JL Hurwitz, I Stasik, EM Kerr, C Holohan, KM Redmond, KM McLaughlin, ...</div><div class="gs_gray">European Journal of Cancer 48 (7), 1096-1107<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11000338654468507892" class="gsc_a_ac gs_ibl">46</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:aIdbFUkbNIkC" class="gsc_a_at">Wnt–β-catenin–Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer</a><div class="gs_gray">A Ravindranath, HF Yuen, KK Chan, C Grills, DA Fennell, TR Lappin, ...</div><div class="gs_gray">British journal of cancer 105 (4), 542-551<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2854648436607112927" class="gsc_a_ac gs_ibl">46</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:u0Mu_IsstPMC" class="gsc_a_at">Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study</a><div class="gs_gray">DA Fennell, P Baas, P Taylor, AK Nowak, D Gilligan, T Nakano, ...</div><div class="gs_gray">Journal of Clinical Oncology 37 (10), 790-798<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12096026668079303463" class="gsc_a_ac gs_ibl">44</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:rbm3iO8VlycC" class="gsc_a_at">Src and ADAM-17–Mediated Shedding of Transforming Growth Factor-α Is a Mechanism of Acute Resistance to TRAIL</a><div class="gs_gray">S Van Schaeybroeck, DM Kelly, J Kyula, S Stokesberry, DA Fennell, ...</div><div class="gs_gray">Cancer research 68 (20), 8312-8321<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10929009562638824615" class="gsc_a_ac gs_ibl">41</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:QsaTk4IG4EwC" class="gsc_a_at">Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Clinical lung cancer 4 (5), 307-313<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8541049609249627971" class="gsc_a_ac gs_ibl">41</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:RJOyoaXV5v8C" class="gsc_a_at">The deubiquitinating enzyme USP17 is associated with nonsmall cell lung cancer (NSCLC) recurrence and metastasis</a><div class="gs_gray">C McFarlane, S McFarlane, I Paul, K Arthur, M Scheaff, K Kerr, ...</div><div class="gs_gray">Oncotarget 4 (10), 1836<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4133948146859131096" class="gsc_a_ac gs_ibl">40</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:LXmCCkuhhTsC" class="gsc_a_at">Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer</a><div class="gs_gray">AG Pallis, DA Fennell, E Szutowicz, NB Leighl, L Greillier, R Dziadziuszko</div><div class="gs_gray">British journal of cancer 105 (1), 1-8<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2743122659749234067" class="gsc_a_ac gs_ibl">40</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:SIv7DqKytYAC" class="gsc_a_at">PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer</a><div class="gs_gray">I Paul, KI Savage, JK Blayney, E Lamers, K Gately, K Kerr, M Sheaff, ...</div><div class="gs_gray">The Journal of pathology 224 (4), 564-574<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10131799986332894015" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:w2UhwfzvF0QC" class="gsc_a_at">Raman microscopy in the diagnosis and prognosis of surgically resected nonsmall cell lung cancer</a><div class="gs_gray">ND Magee, JR Beattie, C Carland, R Davis, K McManus, I Bradbury, ...</div><div class="gs_gray">Journal of biomedical optics 15 (2), 026015<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6148983332312105816" class="gsc_a_ac gs_ibl">39</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:4QKQTXcH0q8C" class="gsc_a_at">Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.</a><div class="gs_gray">MG Zauderer, P Szlosarek, S Le Moulec, S Popat, P Taylor, D Planchard, ...</div><div class="gs_gray">Journal of Clinical Oncology 36 (15_suppl), 8515-8515<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11130615572111133166" class="gsc_a_ac gs_ibl">38</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:UuEBAcK4md4C" class="gsc_a_at">Malignant pleural mesothelioma: current treatments and emerging drugs</a><div class="gs_gray">C Belli, D Fennell, M Giovannini, G Gaudino, L Mutti</div><div class="gs_gray">Expert opinion on emerging drugs 14 (3), 423-437<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13570618198435348340" class="gsc_a_ac gs_ibl">38</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:2ywjKiB__4kC" class="gsc_a_at">Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo</a><div class="gs_gray">AG Manente, D Valenti, G Pinton, PV Jithesh, A Daga, L Rossi, SG Gray, ...</div><div class="gs_gray">Oncogenesis 2 (9), e72-e72<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2712653090093405560" class="gsc_a_ac gs_ibl">37</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:silx2ntsSuwC" class="gsc_a_at">A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).</a><div class="gs_gray">SS Ramalingam, GD Goss, ZG Andric, I Bondarenko, B Zaric, T Ceric, ...</div><div class="gs_gray">Journal of Clinical Oncology 31 (18_suppl), CRA8007-CRA8007<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13900622044934173122" class="gsc_a_ac gs_ibl">36</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:YlPif8NxrbYC" class="gsc_a_at">RanGTPase: a candidate for Myc-mediated cancer progression</a><div class="gs_gray">HF Yuen, VK Gunasekharan, KK Chan, SD Zhang, A Platt-Higgins, ...</div><div class="gs_gray">Journal of the National Cancer Institute 105 (7), 475-488<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3661392634753207414" class="gsc_a_ac gs_ibl">36</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:8Xgff_V0N9gC" class="gsc_a_at">Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression</a><div class="gs_gray">D Barbone, P Cheung, S Battula, S Busacca, SG Gray, DB Longley, ...</div><div class="gs_gray">PLoS One 7 (12), e52753<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14295017298960771507" class="gsc_a_ac gs_ibl">35</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:-DxkuPiZhfEC" class="gsc_a_at">Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer</a><div class="gs_gray">I Paul, AD Chacko, I Stasik, S Busacca, N Crawford, F McCoy, N McTavish, ...</div><div class="gs_gray">Cell death &amp; disease 3 (12), e449-e449<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2668050205496298211" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:ghEM2AJqZyQC" class="gsc_a_at">Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells</a><div class="gs_gray">HF Yuen, O Abramczyk, G Montgomery, KK Chan, YH Huang, T Sasazuki, ...</div><div class="gs_gray">Bioscience reports 32 (4), 413-422<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16781835235400245977" class="gsc_a_ac gs_ibl">34</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:NtGNdKbuCngC" class="gsc_a_at">CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a&nbsp;…</a><div class="gs_gray">DA Fennell, E Kirkpatrick, K Cozens, M Nye, J Lester, G Hanna, N Steele, ...</div><div class="gs_gray">Trials 19 (1), 1-10<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17825822749206924530" class="gsc_a_ac gs_ibl">33</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:SAZ1SQo2q1kC" class="gsc_a_at">SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma</a><div class="gs_gray">N Crawford, I Stasik, C Holohan, J Majkut, M McGrath, PG Johnston, ...</div><div class="gs_gray">Cell death &amp; disease 4 (7), e733-e733<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17780290147791285042" class="gsc_a_ac gs_ibl">31</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:0aBXIfxlw9sC" class="gsc_a_at">Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma</a><div class="gs_gray">JK Blayney, GL Ceresoli, B Castagneto, MER O’Brien, B Hasan, ...</div><div class="gs_gray">European journal of cancer 48 (16), 2983-2992<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=188885863096667492" class="gsc_a_ac gs_ibl">31</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:sA9dB-pw3HoC" class="gsc_a_at">Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis</a><div class="gs_gray">N Crawford, AD Chacko, KI Savage, F McCoy, K Redmond, DB Longley, ...</div><div class="gs_gray">Apoptosis 16 (3), 311-320<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7131361373097057723" class="gsc_a_ac gs_ibl">31</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:5VjbC5aozO0C" class="gsc_a_at">The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer</a><div class="gs_gray">JG Edwards, K Chansky, P Van Schil, AG Nicholson, S Boubia, ...</div><div class="gs_gray">Journal of Thoracic Oncology 15 (3), 344-359<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1525663843166423879" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:qe6vwMD2xtsC" class="gsc_a_at">VANTAGE 014: vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase&nbsp;…</a><div class="gs_gray">LM Krug, H Kindler, H Calvert, C Manegold, AS Tsao, D Fennell, ...</div><div class="gs_gray">European Journal of Cancer, 2-3<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=440369651283258270" class="gsc_a_ac gs_ibl">30</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:G36d5HCDkJYC" class="gsc_a_at">OA 02.01 randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma</a><div class="gs_gray">HL Kindler, S Novello, D Fennell, G Blumenschein, A Bearz, G Ceresoli, ...</div><div class="gs_gray">Journal of Thoracic Oncology 12 (11), S1746<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15200703108290524681" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:qwy9JoKyICEC" class="gsc_a_at">Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8</a><div class="gs_gray">AD Chacko, F Liberante, I Paul, DB Longley, DA Fennell</div><div class="gs_gray">BMC cancer 10 (1), 1-8<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15113726951717433155" class="gsc_a_ac gs_ibl">28</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:1EqfMoDn7-AC" class="gsc_a_at">The IASLC lung cancer staging project: a renewed call to participation</a><div class="gs_gray">DJ Giroux, P Van Schil, H Asamura, R Rami-Porta, K Chansky, ...</div><div class="gs_gray">Journal of Thoracic Oncology 13 (6), 801-809<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6915233282572662391" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:ojlX30-wUrgC" class="gsc_a_at">BTS guideline for the investigation and management of malignant pleural mesothelioma</a><div class="gs_gray">I Woolhouse, L Bishop, L Darlison, D De Fonseka, A Edey, J Edwards, ...</div><div class="gs_gray">BMJ open respiratory research 5 (1), e000266<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12835434866195417467" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:kJDgFkosVoMC" class="gsc_a_at">BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma</a><div class="gs_gray">S Busacca, M Sheaff, K Arthur, SG Gray, KJ O'Byrne, DJ Richard, ...</div><div class="gs_gray">The Journal of pathology 227 (2), 200-208<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6265428997637995595" class="gsc_a_ac gs_ibl">27</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:iKswqCX-FLkC" class="gsc_a_at">A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after&nbsp;…</a><div class="gs_gray">RA Belderbos, P Baas, R Berardi, R Cornelissen, DA Fennell, ...</div><div class="gs_gray">Translational lung cancer research 8 (3), 280<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9237218761890807362" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:c1e4I3QdEKYC" class="gsc_a_at">Resistance to HSP90 inhibition involving loss of MCL1 addiction</a><div class="gs_gray">S Busacca, EWP Law, IR Powley, DA Proia, M Sequeira, J Le Quesne, ...</div><div class="gs_gray">Oncogene 35 (12), 1483-1492<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14231226512743578641" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:zdjWy_NXXwUC" class="gsc_a_at">Strategies for improving outcomes in NSCLC: a look to the future</a><div class="gs_gray">R Stahel, S Peters, P Baas, E Brambilla, F Cappuzzo, D De Ruysscher, ...</div><div class="gs_gray">Lung Cancer 82 (3), 375-382<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11695112425963345420" class="gsc_a_ac gs_ibl">26</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:N4u4nq0IxgcC" class="gsc_a_at">Analysis of gene expression in 3D spheroids highlights a survival role for ASS1 in mesothelioma</a><div class="gs_gray">D Barbone, L Van Dam, C Follo, PV Jithesh, SD Zhang, WG Richards, ...</div><div class="gs_gray">PloS one 11 (3), e0150044<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3456789192074402506" class="gsc_a_ac gs_ibl">25</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:IT1MJ6E3JesC" class="gsc_a_at">Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR L858R, EGFR T790M&nbsp;…</a><div class="gs_gray">R Rosell, BM Sureda, C Costa, MA Molina, A Gimenez-Capitan, ...</div><div class="gs_gray">Annals of Oncology 23, ixe22<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11290825639305732659" class="gsc_a_ac gs_ibl">25</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:ShjGdcaqzI0C" class="gsc_a_at">Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells</a><div class="gs_gray">KK Kolluri, C Alifrangis, N Kumar, Y Ishii, S Price, M Michaut, S Williams, ...</div><div class="gs_gray">Elife 7, e30224<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15220157735721009872" class="gsc_a_ac gs_ibl">24</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:X9ykpCP0fEIC" class="gsc_a_at">Controlling the mitochondrial gatekeeper for effective chemotherapy</a><div class="gs_gray">DA Fennell, FE Cotter</div><div class="gs_gray">British journal of haematology 111 (1), 52-60<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15910633267683102587" class="gsc_a_ac gs_ibl">22</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:I2jIoRS3jIgC" class="gsc_a_at">PS01. 11 nivolumab versus placebo in relapsed malignant mesothelioma: the CONFIRM phase 3 trial</a><div class="gs_gray">D Fennell, C Ottensmeier, R Califano, G Hanna, S Ewings, K Hill, ...</div><div class="gs_gray">Journal of Thoracic Oncology 16 (3), S62<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5389997344980872445" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=20&amp;pagesize=80&amp;citation_for_view=IHT1G6gAAAAJ:iyewoVqAXLQC" class="gsc_a_at">PL03. 09: Phase 3 study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non-small cell lung cancer (GALAXY-2)</a><div class="gs_gray">R Pillai, D Fennell, V Kovcin, T Ciuleanu, R Ramlau, D Kowalski, ...</div><div class="gs_gray">Journal of Thoracic Oncology 12 (1), S7-S8<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2000173697924078894" class="gsc_a_ac gs_ibl">19</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:wE-fMHVdjMkC" class="gsc_a_at">Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line chemotherapy in&nbsp;…</a><div class="gs_gray">TSK Mok, JS Lee, L Zhang, C Yu, S Thongprasert, GEI Ladrera, ...</div><div class="gs_gray">Annals of Oncology 23, ix400-ix401<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15647733161648302287" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:eGYfIraVYiQC" class="gsc_a_at">In arrayed ranks: array technology in the study of mesothelioma</a><div class="gs_gray">SG Gray, DA Fennell, L Mutti, KJ O’Byrne</div><div class="gs_gray">Journal of Thoracic Oncology 4 (3), 411-425<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4670875823107901098" class="gsc_a_ac gs_ibl">18</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:qE4H1tSSYIIC" class="gsc_a_at">BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma</a><div class="gs_gray">S Busacca, AD Chacko, A Klabatsa, K Arthur, M Sheaff, ...</div><div class="gs_gray">PloS one 8 (6), e65489<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4594297523460895343" class="gsc_a_ac gs_ibl">17</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:IyxfXMz2bNAC" class="gsc_a_at">Representative sequencing: unbiased sampling of solid tumor tissue</a><div class="gs_gray">K Litchfield, S Stanislaw, L Spain, LL Gallegos, A Rowan, D Schnidrig, ...</div><div class="gs_gray">Cell reports 31 (5), 107550<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1145187764946444673" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:1tZ8xJnm2c8C" class="gsc_a_at">Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage</a><div class="gs_gray">D Fennell, J Steele, M Sheaff, M Evans, J Shamash, P Wells, R Rudd</div><div class="gs_gray">Lung Cancer 49, S220-S220<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2734900099787158283" class="gsc_a_ac gs_ibl">16</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:hEXC_dOfxuUC" class="gsc_a_at">Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non–Small-Cell Lung Cancer (GALAXY-2)</a><div class="gs_gray">RN Pillai, DA Fennell, V Kovcin, TE Ciuleanu, R Ramlau, D Kowalski, ...</div><div class="gs_gray">Journal of Clinical Oncology 38 (6), 613-622<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6550802847577291880" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:__bU50VfleQC" class="gsc_a_at">Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression</a><div class="gs_gray">HF Yuen, CM McCrudden, C Grills, SD Zhang, YH Huang, KK Chan, ...</div><div class="gs_gray">Cancer science 103 (6), 1145-1154<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17543303173584757243" class="gsc_a_ac gs_ibl">15</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:TiIbgCYny7sC" class="gsc_a_at">ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma</a><div class="gs_gray">I Opitz, A Scherpereel, T Berghmans, I Psallidas, M Glatzer, D Rigau, ...</div><div class="gs_gray">European journal of cardio-thoracic surgery 58 (1), 1-24<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10715872274452014788" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:dAp6zn-oMfAC" class="gsc_a_at">KDM6B histone demethylase is an epigenetic regulator of estrogen receptor β expression in human pleural mesothelioma</a><div class="gs_gray">AG Manente, G Pinton, S Zonca, D Tavian, T Habib, PV Jithesh, D Fennell, ...</div><div class="gs_gray">Epigenomics 8 (9), 1227-1238<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17033170247576720737" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:ZqE1mSdD_DYC" class="gsc_a_at">Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.</a><div class="gs_gray">SS Ramalingam, B Zaric, T Ceric, TE Ciuleanu, JF Spicer, I Bondarenko, ...</div><div class="gs_gray">Journal of Clinical Oncology 32 (15_suppl), TPS8118-TPS8118<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2694839689444443212" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:z6xuaG2dYH0C" class="gsc_a_at">A TMA de-arraying method for high throughput biomarker discovery in tissue research</a><div class="gs_gray">Y Wang, K Savage, C Grills, A McCavigan, JA James, DA Fennell, ...</div><div class="gs_gray">PLoS One 6 (10), e26007<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2559991954396701981" class="gsc_a_ac gs_ibl">14</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:MNNNGtAgD4EC" class="gsc_a_at">EML4–ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7</a><div class="gs_gray">L O'Regan, G Barone, R Adib, CG Woo, HJ Jeong, EL Richardson, ...</div><div class="gs_gray">Journal of cell science 133 (9), jcs241505<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9706058617450924258" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:CNPyR2KL9-0C" class="gsc_a_at">Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European&nbsp;…</a><div class="gs_gray">B Hasan, L Greillier, A Pallis, J Menis, R Gaafar, R Sylvester, DA Fennell, ...</div><div class="gs_gray">European Journal of Cancer 50 (16), 2771-2782<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4877576749372467778" class="gsc_a_ac gs_ibl">13</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:pxXbYLTb8EgC" class="gsc_a_at">Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.</a><div class="gs_gray">MG Zauderer, PW Szlosarek, S Le Moulec, S Popat, P Taylor, ...</div><div class="gs_gray">Journal of Clinical Oncology 38 (15_suppl), 9058-9058<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11240718454486211128" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:natZJ_-F0IUC" class="gsc_a_at">How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?</a><div class="gs_gray">AJ Sharkey, KJ O’Byrne, A Nakas, S Tenconi, DA Fennell, DA Waller</div><div class="gs_gray">Lung Cancer 100, 5-13<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9249001611062244574" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:oPLKW5k6eA4C" class="gsc_a_at">MesobanK UK: an international mesothelioma bioresource</a><div class="gs_gray">RC Rintoul, DM Rassl, J Gittins, SJ Marciniak</div><div class="gs_gray">Thorax 71 (4), 380-382<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15889914501698290377" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:AYInfyleIOsC" class="gsc_a_at">Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma.</a><div class="gs_gray">PW Szlosarek, JP Steele, L Nolan, D Gilligan, P Taylor, JF Spicer, MJ Lind, ...</div><div class="gs_gray">Journal of Clinical Oncology 32 (15_suppl), 7507-7507<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13878769193254408544" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:unp9ATQDT5gC" class="gsc_a_at">Ultra-fast processing of gigapixel Tissue MicroArray images using high performance computing</a><div class="gs_gray">Y Wang, D McCleary, CW Wang, P Kelly, J James, DA Fennell, ...</div><div class="gs_gray">Analytical Cellular Pathology 33 (5-6), 271-285<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8439725102607065607" class="gsc_a_ac gs_ibl">12</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:B2rIPIGFPLEC" class="gsc_a_at">A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed&nbsp;…</a><div class="gs_gray">R Hassan, R Jennens, JP Van Meerbeeck, JJ Nemunaitis, ...</div><div class="gs_gray">Journal of Clinical Oncology 34 (15_suppl), TPS8576-TPS8576<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15994520286257777017" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:A8cqit5AE6sC" class="gsc_a_at">Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer</a><div class="gs_gray">DA Fennell, JPC Steele, J Shamash, SE Slater, MT Sheaff, P Wells, ...</div><div class="gs_gray">International journal of cancer 121 (11), 2575-2577<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11503647198426360375" class="gsc_a_ac gs_ibl">11</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:vVJNg6_NJEsC" class="gsc_a_at">SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells</a><div class="gs_gray">G Pinton, S Zonca, AG Manente, M Cavaletto, E Borroni, A Daga, ...</div><div class="gs_gray">Oncotarget 7 (12), 14366<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12664012828446441675" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:tHtfpZlB6tUC" class="gsc_a_at">Genetics and molecular biology of mesothelioma</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Malignant Mesothelioma, 149-167<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9926742603696013476" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:L_l9e5I586QC" class="gsc_a_at">Dynamical systems analysis of mitochondrial BAK activation kinetics predicts resistance to BH3 domains</a><div class="gs_gray">C Grills, N Crawford, A Chacko, PG Johnston, F O'Rourke, DA Fennell</div><div class="gs_gray">PLoS One 3 (8), e3038<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6263269361896636995" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:eAlLMO4JVmQC" class="gsc_a_at">Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer</a><div class="gs_gray">C Barlow, M Nystrom, C Oesterling, D Fennell, J Ismay, C Gallagher</div><div class="gs_gray">British journal of cancer 90 (7), 1318-1322<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4138524784093616779" class="gsc_a_ac gs_ibl">10</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:nroGzMJTTpEC" class="gsc_a_at">Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment</a><div class="gs_gray">M Zhang, JL Luo, Q Sun, J Harber, AG Dawson, A Nakas, S Busacca, ...</div><div class="gs_gray">Nature communications 12 (1), 1-12<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18263417764795498803" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:JP7YXuLIOvAC" class="gsc_a_at">Perspectives of novel imaging techniques for staging, therapy response assessment, and monitoring of surveillance in lung cancer: Summary of the Dresden 2013 Post WCLC-IASLC&nbsp;…</a><div class="gs_gray">T Henzler, P Goldstraw, F Wenz, R Pirker, W Weder, P Apfaltrer, M Meyer, ...</div><div class="gs_gray">Journal of Thoracic Oncology 10 (2), 237-249<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=946750269516274815" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:MIg0yeAD4ggC" class="gsc_a_at">A randomised phase II trial of pegylated arginine deiminase in patients with malignant pleural mesothelioma</a><div class="gs_gray">PW Szlosarek, J Steele, M Sheaff, T Szyszko, S Ellis, L Nolan, P Taylor, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 8, S308-S308<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6183008525661437584" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:D_tqNUsBuKoC" class="gsc_a_at">Stochastic modeling of apoptosis tolerance distributions measured by multivariate flow analysis of human leukemia cells</a><div class="gs_gray">DA Fennell, FE Cotter</div><div class="gs_gray">Cytometry: The Journal of the International Society for Analytical Cytology&nbsp;…<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17123185588951383156" class="gsc_a_ac gs_ibl">9</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:oH8HCDhqVGsC" class="gsc_a_at">Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy&nbsp;…</a><div class="gs_gray">E Lim, L Darlison, J Edwards, D Elliott, DA Fennell, S Popat, RC Rintoul, ...</div><div class="gs_gray">BMJ open 10 (9), e038892<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=659941574274803310" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:I9gX6wnfuA8C" class="gsc_a_at">A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma</a><div class="gs_gray">EMJ van Brummelen, E Levchenko, M Dómine, DA Fennell, HL Kindler, ...</div><div class="gs_gray">Investigational new drugs 38 (2), 457-467<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7020241814804387637" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:_9Xh93LWpsYC" class="gsc_a_at">Radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials: consensus statement from the NCI thoracic malignancy steering&nbsp;…</a><div class="gs_gray">RR Gill, AS Tsao, HL Kindler, WG Richards, SG Armato III, RJ Francis, ...</div><div class="gs_gray">Journal of Thoracic Oncology 14 (10), 1718-1731<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9107172211412417129" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Wq2b2clWBLsC" class="gsc_a_at">A phase II study of irinotecan, cisplatin, and mitomycin C in malignant pleural mesothelioma</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Lung Cancer 41 (2), S221b<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10764939979536528712" class="gsc_a_ac gs_ibl">8</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:KsTgnNRry18C" class="gsc_a_at">Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial</a><div class="gs_gray">DA Fennell, A King, S Mohammed, A Branson, C Brookes, L Darlison, ...</div><div class="gs_gray">The Lancet Respiratory Medicine 9 (6), 593-600<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15234419807088469022" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:yJjnfzR0HrkC" class="gsc_a_at">ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid&nbsp;…</a><div class="gs_gray">PW Szlosarek, P Baas, GL Ceresoli, DA Fennell, D Gilligan, A Johnston, ...</div><div class="gs_gray">Journal of Clinical Oncology 35 (15_suppl), TPS8582-TPS8582<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13263761343098861875" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:8dzOF9BpDQoC" class="gsc_a_at">Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory&nbsp;…</a><div class="gs_gray">DA Fennell, SP Myrand, TS Nguyen, D Ferry, KM Kerr, P Maxwell, ...</div><div class="gs_gray">PLoS One 9 (9), e107455<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13724825946994327324" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:-6RzNnnwWf8C" class="gsc_a_at">Exploiting BH3 only protein function for effective cancer therapy</a><div class="gs_gray">DA Fennell, A Chacko</div><div class="gs_gray">Front Biosci 13, 6682-6692<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1324523867560750623" class="gsc_a_ac gs_ibl">7</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:wkm4DBaukwsC" class="gsc_a_at">Pathologic considerations and standardization in mesothelioma clinical trials</a><div class="gs_gray">MS Tsao, M Carbone, F Galateau-Salle, AL Moreira, AG Nicholson, ...</div><div class="gs_gray">Journal of Thoracic Oncology 14 (10), 1704-1717<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1780879491026599327" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:d4tt_xEv1X8C" class="gsc_a_at">miR-16: expanding the range of molecular targets in mesothelioma</a><div class="gs_gray">D Fennell</div><div class="gs_gray">The Lancet. Oncology 18 (10), 1296-1297<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1974465469366094328" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:mel-f30kHHgC" class="gsc_a_at">COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that&nbsp;…</a><div class="gs_gray">DA Fennell, P Baas, HL Kindler, LM Krug, A Nowak, M Zauderer, ...</div><div class="gs_gray">Journal of Clinical Oncology 32 (15_suppl), TPS7611-TPS7611<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15170624120134446800" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:RtRctb2lSbAC" class="gsc_a_at">Implications for powering biomarker discovery studies</a><div class="gs_gray">SM Dibben, RJ Holt, TS Davison, CL Wilson, J Taylor, I Paul, K McManus, ...</div><div class="gs_gray">The Journal of Molecular Diagnostics 14 (2), 130-139<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4764711737666125645" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:AzKEL7Gb_04C" class="gsc_a_at">Translational therapies for malignant pleural mesothelioma</a><div class="gs_gray">C Belli, S Anand, G Tassi, D Fennell, L Mutti</div><div class="gs_gray">Expert review of respiratory medicine 4 (2), 249-260<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10471282364544444213" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:H_jBuBxbQIAC" class="gsc_a_at">221 A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma</a><div class="gs_gray">PW Szlosarek, DA Fennell, RM Rudd, M Lind, M Ranson, A Hackshaw, ...</div><div class="gs_gray">Lung Cancer, S54<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10841882863741242797" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:EsEWqaRxkBgC" class="gsc_a_at">Identification of glucose transporter type 1 overexpression as a predictor of survival in patients with malignant pleural mesothelioma</a><div class="gs_gray">DA Fennell, A Klabatsa, MT Sheaff, JPC Steele, MT Evans, JC Strefford, ...</div><div class="gs_gray">Journal of Clinical Oncology 22 (14_suppl), 7199-7199<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13166658065615310273" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:SPgmg5JLkoEC" class="gsc_a_at">Gastrointestinal haemorrhage associated with free-base (crack) cocaine</a><div class="gs_gray">DA Fennell, SS Gandhi, BNC Prichard</div><div class="gs_gray">Postgraduate medical journal 71 (836), 377<span class="gs_oph">, 1995</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16165886879116188425" class="gsc_a_ac gs_ibl">6</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1995</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:bCjgOgSFrM0C" class="gsc_a_at">MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1/BRCA1 deficient relapsed malignant mesothelioma.</a><div class="gs_gray">DA Fennell, L Darlison, P Wells-Jordan, CJ Richards, A Gaba, C Poile, ...</div><div class="gs_gray">Journal of Clinical Oncology 38 (15_suppl), 9057-9057<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7297022729628390956" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:V_vSwabWVtYC" class="gsc_a_at">Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy</a><div class="gs_gray">C Manegold, A Adjei, F Bussolino, F Cappuzzo, L Crino, R Dziadziuszko, ...</div><div class="gs_gray">ESMO open 1 (6), e000118<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8700120490163128350" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:YB4bud6kWLwC" class="gsc_a_at">Will antiangiogenic agents be a future for mesothelioma therapy?</a><div class="gs_gray">C Belli, S Anand, M Panella, M Giovannini, G Tassi, D Fennell, L Mutti</div><div class="gs_gray">Current medicinal chemistry 17 (27), 3069-3079<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5305231415895790380" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:-yGd096yOn8C" class="gsc_a_at">P-518 Second line therapy of malignant pleural mesothelioma with irinotecan, cisplatin, and mitomycin C (IPM): A phase II study</a><div class="gs_gray">DA Fennell, JPC Steele, J Shamash, MT Evans, MT Sheaff, P Wells, ...</div><div class="gs_gray">Lung Cancer, S221<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14178765453742150531" class="gsc_a_ac gs_ibl">5</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:mJbmKSuM8toC" class="gsc_a_at">A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.</a><div class="gs_gray">DA Fennell, AC Casbard, C Porter, R Rudd, JF Lester, M Nicolson, ...</div><div class="gs_gray">Journal of Clinical Oncology 39 (15_suppl), 8507-8507<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11866449253644315600" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:XtJa11BXPS4C" class="gsc_a_at">Cancer-cell death ironed out</a><div class="gs_gray">D Fennell</div><div class="gs_gray">Nature 572 (7769), 314-315<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11495305021012731418" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:zdX0sdgBH_kC" class="gsc_a_at">EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer</a><div class="gs_gray">L O'Regan, G Barone, R Adib, CG Woo, HJ Jeong, EL Richardson, ...</div><div class="gs_gray">Available at SSRN 3377373<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6299691162009274575" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:hKjooKYXoHIC" class="gsc_a_at">When RON MET TAM in mesothelioma: All druggable for one, and one drug for all?</a><div class="gs_gray">AM Baird, D Easty, M Jarzabek, L Shiels, A Soltermann, S Klebe, ...</div><div class="gs_gray">Frontiers in endocrinology 10, 89<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8084898912329528466" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:17ZO-CJnx_8C" class="gsc_a_at">Stem cells and lung cancer: In vitro and in vivo studies</a><div class="gs_gray">DA Fennell, DM Jablons</div><div class="gs_gray">IASLC Thoracic Oncology, 117-120. e2<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11580217595248557678" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:nWoA1JPTheMC" class="gsc_a_at">Management of progressive pulmonary nodules found during and outside of CT lung cancer screening studies</a><div class="gs_gray">M Meyer, R Vliegenthart, T Henzler, D Buergy, FA Giordano, M Kostrzewa, ...</div><div class="gs_gray">Journal of Thoracic Oncology 12 (12), 1755-1765<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1194167441877430918" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:NMlhSUseqAsC" class="gsc_a_at">GALAXY-1: RANDOMIZED PHASE II STUDY OF DOCETAXEL WITH OR WITHOUT GANETESPIB IN ADVANCED LUNG ADENOCARCINOMA: RESULTS IN BIOMARKER SUB-GROUPS AND ALL ADENOCARCINOMA PATIENTS.</a><div class="gs_gray">SS Ramalingam, G Shapiro, V Hirsh, B Zaric, T Ceric, E Poddubskaya, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 8, S139-S139<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16214721319725285025" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:KWzIFqRkAKkC" class="gsc_a_at">Correlation between thymidylate synthetase (TS) expression and progression-free survival (PFS) in patients receiving pemetrexed (pem) for advanced NSCLC: A prospective study.</a><div class="gs_gray">M Nicolson, KM Kerr, RNH Shah, V Potter, S Upadhyay, P Taylor, ...</div><div class="gs_gray">Journal of Clinical Oncology 30 (15_suppl), 7583-7583<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10527932914770287977" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:G1UMdFYMoxkC" class="gsc_a_at">Peripheral benzodiazepine receptor independent superoxide generation</a><div class="gs_gray">F Cotter, D Fennell</div><div class="gs_gray">US Patent App. 11/204,795<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11532385288480617661" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:4aZ_i-5WJEQC" class="gsc_a_at">Arginine depletion upregulates Bax and triggers apoptosis of malignant mesothelioma cells deficient in argininosuccinate synthetase</a><div class="gs_gray">PW Szlosarek, A Klabatsa, A Pallaska, M Sheaff, FR Balkwill, D Fennell</div><div class="gs_gray">Cancer Research 66 (8 Supplement), 521-521<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10980346819304777357" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:RuPIJ_LgqDgC" class="gsc_a_at">Stochastic modelling of apoptosis kinetics</a><div class="gs_gray">DA Fennell, A Pallaska, M Corbo, FE Cotter</div><div class="gs_gray">Apoptosis 10 (2), 447-452<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15809654227226068180" class="gsc_a_ac gs_ibl">4</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:GUYAmugLYisC" class="gsc_a_at">Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial</a><div class="gs_gray">DA Fennell, S Danson, PJ Woll, M Forster, D Talbot, J Child, L Farrelly, ...</div><div class="gs_gray">Clinical Cancer Research 26 (18), 4748-4755<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4826608901221535608" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:LWqeokA2EBkC" class="gsc_a_at">MA12. 05 phase 1 study of HSP90 inhibitor ganetespib with pemetrexed and cisplatin/carboplatin chemotherapy for pleural mesothelioma</a><div class="gs_gray">D Fennell, S Danson, M Forster, D Talbot, P Woll, J Child, Y Ngai, ...</div><div class="gs_gray">Journal of Thoracic Oncology 13 (10), S397<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17412987069183626860" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:vxA22ZmNLkoC" class="gsc_a_at">PL02. 09 nintedanib+ pemetrexed/cisplatin in patients with unresectable MPM: Phase III results from the lume-meso trial</a><div class="gs_gray">G Scagliotti, R Gaafar, A Nowak, T Nakano, J Van Meerbeeck, S Popat, ...</div><div class="gs_gray">Journal of Thoracic Oncology 13 (10), S186<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1011693020942723441" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:3BvdIg-l-ZAC" class="gsc_a_at">Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Journal of Thoracic Oncology 13 (10), 1436-1437<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15273645103369222488" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:M0j1y4EgrScC" class="gsc_a_at">Targeting the tumour vasculature in mesothelioma</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">The Lancet. Oncology 19 (6), 723-724<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5861712602924560379" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:DquSII9TDu4C" class="gsc_a_at">The RON (MST1R)/MSP pathway is a potential therapeutic target in malignant pleural mesothelioma</a><div class="gs_gray">AM Baird, K O'Byrne, D Easty, L Shiels, A Byrne, S Raeppel, ...</div><div class="gs_gray">Lung Cancer 83, S29-S30<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=1370840531300804033" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:8VtEwCQfWZkC" class="gsc_a_at">Apoptotic agents</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Translational lung cancer research 2 (3), 238<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13057920737766608492" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:SxCCDk4iOpsC" class="gsc_a_at">Vinorelbine in mesothelioma (VIM): a randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma (MPM) expressing&nbsp;…</a><div class="gs_gray">DA Fennell, A Casbard, L Nixon, J Lester, G Griffiths</div><div class="gs_gray">Annals of Oncology 23, ix498<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=5593549446580151014" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:hvmnpdAuIbkC" class="gsc_a_at">The GALAXY Trial<sup> </sup>(NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with&nbsp;…</a><div class="gs_gray">GD Goss, C Manegold, R Rosell, DA Fennell, VM Vukovic, I El-Hariry, ...</div><div class="gs_gray">Journal of Clinical Oncology 30 (15_suppl), TPS7613-TPS7613<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17325430648509868932" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:-uzm3Y7AvW0C" class="gsc_a_at">Preliminary results from a randomized 2b/3 study of ganetespib and docetaxel combination versus docetaxel in advanced NSCLC (the GALAXY Trial, NCT01348126)</a><div class="gs_gray">SS Ramalingam, B Zaric, GD Goss, C Manegold Sr, R Rosell, V Vukovic, ...</div><div class="gs_gray">ESMO<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8182837893808138972" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:t-hv7AR41mYC" class="gsc_a_at">Forced vital capacity (FVC) as a reproducible measure of pulmonary function (PF) in chemotherapy-pretreated patients with malignant pleural mesothelioma (MPM).</a><div class="gs_gray">LM Krug, JM Arduino, X Sun, HL Kindler, C Manegold, D Fennell, ...</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), 7028-7028<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12675371624318015608" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Zh0EY9V9P6UC" class="gsc_a_at">Machine vision based stochastic analysis of cancer cell mitochondrial dysfunction induced by a BH3 domain</a><div class="gs_gray">AD Chacko, NT Crawford, PG Johnston, DA Fennell</div><div class="gs_gray">Apoptosis 13 (11), 1386-1393<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12745893017389727588" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:YTuZlYwrTOUC" class="gsc_a_at">Pulmonary toxicity and cancer treatment</a><div class="gs_gray">DA Fennell, RM Rudd</div><div class="gs_gray">Hospital Medicine 65 (8), 462-465<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12761396145208160197" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:BJrgspguQaEC" class="gsc_a_at">Pk11195, a mitochondrial benzodiazepine receptor antagonist radiosensitizes bcl-x (L) and mcl-1 expressing cholangiocarcinoma to apoptosis</a><div class="gs_gray">MC Okaro, DA Fennell, FE Cotter, BR Davidson</div><div class="gs_gray">British Journal of Cancer 83, 58-<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2350111666667535635" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:K4-iKlO5MD4C" class="gsc_a_at">Quantitative antisense dose-response relationships: mathematical modeling of antisense action under steady-state conditions</a><div class="gs_gray">DA FENNELL</div><div class="gs_gray">Antisense and Nucleic Acid Drug Development 7 (1), 49-53<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16650483027719542977" class="gsc_a_ac gs_ibl">3</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:o-PowTg_VKEC" class="gsc_a_at">BRCA1/MAD2L1 deficiency disrupts the spindle assembly checkpoint to confer vinorelbine resistance in mesothelioma</a><div class="gs_gray">S Busacca, L O'Regan, A Singh, AJ Sharkey, AG Dawson, J Dzialo, ...</div><div class="gs_gray">Molecular cancer therapeutics 20 (2), 379-388<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12272753934213961684" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:PZE8UkGerEcC" class="gsc_a_at">Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment</a><div class="gs_gray">S Popat, B Sharma, S MacMahon, AG Nicholson, RK Sharma, K Schuster, ...</div><div class="gs_gray">JCO Precision Oncology 5, 39-43<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4188755449019860825" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:o9ULDYDKYbIC" class="gsc_a_at">Correction: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature</a><div class="gs_gray">MP Barr, SG Gray, AC Hoffmann, RA Hilger, J Thomale, JD O’Flaherty, ...</div><div class="gs_gray">PloS one 15 (5), Article number: e0233739<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7883468912807047554" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:tgTmbKTkO1IC" class="gsc_a_at">Tumour Treating Fields for mesothelioma: controversy versus opportunity</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">The Lancet Oncology 20 (12), 1623-1625<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9634556966433413648" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:GtqhT-R7ZnwC" class="gsc_a_at">P2. 06-02 Mesothelioma Stratified Therapy (MiST): a phase IIa umbrella trial for accelerating the development of precision medicines</a><div class="gs_gray">D Fennell, M Hudka, L Darlison, K Lord, A Bzura, J Dzialo, C Pritchard, ...</div><div class="gs_gray">Journal of Thoracic Oncology 14 (10), S755-S756<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11406887879308126389" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:uoRD4RTSUPoC" class="gsc_a_at">Mesothelioma: Hippo pathway as a target, lessons from COMMAND</a><div class="gs_gray">DA Fennell, EY Baitei</div><div class="gs_gray">Oncotarget 10 (40), 3996<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10667141273983290824" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:a2necdfpwlEC" class="gsc_a_at">State of the art: Advances in Malignant Pleural Mesothelioma in 2017</a><div class="gs_gray">AJ McCambridge, A Napolitano, AS Mansfield, D Fennell, Y Sekido, ...</div><div class="gs_gray">University of Leicester<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15622287406706682227" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:DIubQTN3OvUC" class="gsc_a_at">An update regarding the Prediction of ResIstance to chemotherapy using Somatic copy number variation in Mesothelioma (PRISM) study</a><div class="gs_gray">KG Blyth, AC Kidd, A Winter, W Baird, C Dick, J Hair, M Bylesjo, S Lynagh, ...</div><div class="gs_gray">Lung Cancer 115, S26-S27<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3409700100434947661" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:hfzGNhXhx5MC" class="gsc_a_at">Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM)</a><div class="gs_gray">JMT Perez, E van Brummelen, E Levchenko, MD Gomez, DA Fennell, ...</div><div class="gs_gray">Annals of Oncology 28, v568-v569<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15734828398578107847" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:bVQMTfhMCi4C" class="gsc_a_at">P3. 03-005 inhibition of PRMT5 is synthetic lethal in mesotheliomas harboring MTAP loss: topic: mesothelioma transitional</a><div class="gs_gray">A Sharkey, L Martinson, J Le Quesne, D Moore, A Nakas, P Quirke, ...</div><div class="gs_gray">Journal of Thoracic Oncology 12 (1), S1346<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7034698447434123334" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:qCpRzq7zkD8C" class="gsc_a_at">A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma&nbsp;…</a><div class="gs_gray">R Hassan, D Fennell, A Scherpereel, AK Nowak, J Von Pawel, S Novello, ...</div><div class="gs_gray">Journal of Clinical Oncology 34 (15_suppl), TPS8577-TPS8577<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2667473808718170495" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:BmWJbWwHJAwC" class="gsc_a_at">GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma.</a><div class="gs_gray">DA Fennell, GD Goss, MA Socinski, K Nakagawa, JH Schiller, P Bonomi, ...</div><div class="gs_gray">Journal of Clinical Oncology 31 (15_suppl), TPS8126-TPS8126<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12069573751868686494" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:s9ia6_kGH2AC" class="gsc_a_at">Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer</a><div class="gs_gray">DA Fennell, C Swanton</div><div class="gs_gray">EPMA Journal 3 (1), 1-8<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=4632367194670337872" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:L7vk9XBBNxgC" class="gsc_a_at">The Galaxy Trial (NCT01348126): A Randomized IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone as Second Line Therapy in Patients with&nbsp;…</a><div class="gs_gray">SS Ramalingam, B Zaric, G Goss, C Manegold, R Rosell, V Vukovic, ...</div><div class="gs_gray">Annals of Oncology 23, ixe24<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3603651092986860984" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:z8nqeaKD1nsC" class="gsc_a_at">Thymidylate synthetase (TS) immunohistochemistry (IHC): Feasibility in a routine clinical setting for patients receiving treatment with pemetrexed for advanced nonsquamous NSCLC.</a><div class="gs_gray">KM Kerr, DA Fennell, RN Shah, M Kumar, G Skailes, VA Potter, S Moore, ...</div><div class="gs_gray">Journal of Clinical Oncology 28 (15_suppl), TPS293-TPS293<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8882828300462127181" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:_AeoHAGD03cC" class="gsc_a_at">Small molecule de-repression of BAX and BAK oligomerization as a strategy for treating cancer</a><div class="gs_gray">N Crawford, DA Fennell</div><div class="gs_gray">Letters in Drug Design &amp; Discovery 3 (8), 534-540<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6047060217092664596" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:c_xDhezhKKUC" class="gsc_a_at">Apoptosis: molecular physiology and significance for cancer therapeutics</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Introduction to the cellular and molecular biology of cancer, 210<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=11521284938055928473" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:LGlY6t8CeOMC" class="gsc_a_at">P-516 Expression and prognostic significance of hypoxia-inducible factor 1 alpha in malignant pleural mesothelioma</a><div class="gs_gray">DA Fennell, A Klabatsa, MT Sheaff, MT Evans, J Shamash, JPC Steele, ...</div><div class="gs_gray">Lung Cancer, S221<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13629704496789492969" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:hGdtkIFZdKAC" class="gsc_a_at">O-30 Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials</a><div class="gs_gray">DA Fennell, A Parmar, J Shamash, MT Evans, RJ Sylvester, K Dhaliwal, ...</div><div class="gs_gray">Lung Cancer, S12<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6956870362262640010" class="gsc_a_ac gs_ibl">2</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:yKzB5RS27GgC" class="gsc_a_at">A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.</a><div class="gs_gray">DA Fennell, A King, S Mohammed, A Branson, A Greystoke, S Moody, ...</div><div class="gs_gray">Journal of Clinical Oncology 39 (15_suppl), 8558-8558<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12758952404717042355" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:1_W9tMSvGuwC" class="gsc_a_at">Inclusion of multiple high‐risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma</a><div class="gs_gray">M Sereno, Z He, CR Smith, J Baena, M Das, RK Hastings, G Rake, ...</div><div class="gs_gray">Histopathology 78 (6), 838-848<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3719838244617435095" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:6Zm5LS9gQ5UC" class="gsc_a_at">Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression</a><div class="gs_gray">S Busacca, Q Zhang, A Sharkey, AG Dawson, DA Moore, DA Waller, ...</div><div class="gs_gray">Scientific reports 11 (1), 1-10<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=16559193477127677471" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:QAOzB4mb83kC" class="gsc_a_at">Precision Therapy for Mesothelioma: Feasibility and New Opportunities</a><div class="gs_gray">S Dulloo, A Bzura, DA Fennell</div><div class="gs_gray">Cancers 13 (10), 2347<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12948558851690865293" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:YGhAHpnIhDoC" class="gsc_a_at">Loss of BAP1/BRCA1 counteracts spindle assembly checkpoint activation by the anti-mesothelin antibody drug-conjugate anetumab ravtansine</a><div class="gs_gray">A Singh, J Luo, S Busacca, A Dawson, KK Kolluri, S Janes, A Fry, ...</div><div class="gs_gray">Cancer Research 80 (16 Supplement), 1808-1808<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17712345744868251987" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:eI34FqJmdUoC" class="gsc_a_at">A randomized phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer.</a><div class="gs_gray">DA Fennell, JF Lester, S Danson, FH Blackhall, M Nicolson, LS Nixon, ...</div><div class="gs_gray">Journal of Clinical Oncology 38 (15_suppl), e21649-e21649<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10411283660922535961,1754397246237578208" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=100&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:vD2iS2Kej30C" class="gsc_a_at">Reply to K. Masuda et al.</a><div class="gs_gray">DA Fennell, P Taylor, D Gilligan, T Nakano, A Scherpereel, N Pavlakis, ...</div><div class="gs_gray">Journal of clinical oncology: official journal of the American Society of&nbsp;…<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17451877225419895219" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:GiYFt9mpioMC" class="gsc_a_at">T1 Loss of BAP1 function leads to TRAIL sensitivity in mesothelioma</a><div class="gs_gray">N Kumar, KK Kolluri, C Alifrangis, Y Ishii, S Price, M Michaut, S Williams, ...</div><div class="gs_gray">Thorax 73 (Suppl 4), A1-A1<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17491289938993472331" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:CRzUtm-VnGAC" class="gsc_a_at">P2. 06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma</a><div class="gs_gray">M Krebs, L Carter, S Villa, A King, C Massey, J Lorens, E Darlington, ...</div><div class="gs_gray">Journal of Thoracic Oncology 13 (10), S745<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17883321943929368963" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:rqnDXT1GswoC" class="gsc_a_at">Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).</a><div class="gs_gray">CT Hiley, T Ahmad, M Jamal-Hanjani, C Abbosh, Y Ngai, A Hackshaw, ...</div><div class="gs_gray">Journal of Clinical Oncology 35 (15_suppl), TPS9099-TPS9099<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10964224737523993150" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:AFmTUeZ1pmEC" class="gsc_a_at">Patterns of comorbidity, treatment, resource utilization, and referral in malignant pleural mesothelioma patients in the US.</a><div class="gs_gray">MG Zauderer, AS Tsao, DA Fennell, WB Wong, T Pattipaka, MT Bretscher, ...</div><div class="gs_gray">Journal of Clinical Oncology 35 (15_suppl), 8554-8554<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=9884202597740826894" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:4e5Qn2KL_jwC" class="gsc_a_at">P2. 06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma: Topic: Mesothelioma and SCLC</a><div class="gs_gray">R Hassan, R Jennens, J Van Meerbeeck, J Nemunaitis, G Blumenschein, ...</div><div class="gs_gray">Journal of Thoracic Oncology 12 (1), S1087-S1088<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2110576385119895264" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:SpPTWFSNUtQC" class="gsc_a_at">Mesobank-an international mesothelioma tissue bioresource-now open for tissue requests</a><div class="gs_gray">RC Rintoul, DM Rassl, J Gittins, J Edwards, DA Fennell, N Maskell, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 10 (9), S201-S202<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15730531095113922231" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:as0KMg8qHbkC" class="gsc_a_at">COMMAND: A Phase 2 Randomized, Double-Blind, Study of Defactinib (VS-6063) as Maintenance Therapy in Malignant Pleural Mesothelioma</a><div class="gs_gray">HL Kindler, DA Fennell, P Baas, LM Krug, MG Zauderer, AK Nowak, ...</div><div class="gs_gray">Journal of Thoracic Oncology 10 (9), S748-S749<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=13682898097732993390" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:FsLZdJ3BAzkC" class="gsc_a_at">Circumventing HSP90 inhibitors via apoptosis block</a><div class="gs_gray">DA Fennell, S Busacca</div><div class="gs_gray">Oncoscience 2 (9), 747<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6376449396695658154" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:sbeIDTyQOFgC" class="gsc_a_at">Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line&nbsp;…</a><div class="gs_gray">D Fennell, A Antonov, ML Martins, S Popat, SS Ramalingam, J Spicer, ...</div><div class="gs_gray">Cancer Research 74 (19 Supplement), 4657-4657<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=15670793474185082044" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:0sTkTiv_uMkC" class="gsc_a_at">Novel mechanisms of sensitivity and acquired resistance to Hsp90 inhibition by Ganetespib</a><div class="gs_gray">S Busacca, H Pringle, E Law, L O'Regan, A Fry, KB Matchett, V Reichert, ...</div><div class="gs_gray">World Conference on Lung Cancer<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12214596633541486667" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:jtI9f0ekYq0C" class="gsc_a_at">Small cell lung cancer and other thoracic malignancies</a><div class="gs_gray">H Daga, H Murakami, N Yamamoto, T Shibata, M Endo, H Watanabe, ...</div><div class="gs_gray">Annals of Oncology 23 (suppl_9)<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6902106990319116532" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:zUl2_INMlC4C" class="gsc_a_at">Molecular Profiling As An Outcome Predictor In The GALAXY TRIALTM (NCT01348126): A Randomized IIB/III Study Of Ganetespib (Sta-9090) In Combination With Docetaxel Versus&nbsp;…</a><div class="gs_gray">R Rosell, SS Ramalingam, D Fennell, C Manegold, I El Hariry, V Vukovic, ...</div><div class="gs_gray">Annals of Oncology 23, ix529<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=836829804864144735" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:MGPUR4WVBMEC" class="gsc_a_at">Technical Advances</a><div class="gs_gray">C Conway, R Chalkley, A High, K Maclennan, S Berri, P Chengot, ...</div><div class="gs_gray">The Journal of Molecular Diagnostics 14 (2)<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=7011334662781648328" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:ovGv7akYl-cC" class="gsc_a_at">Small Cell Lung Cancer</a><div class="gs_gray">D Fennell</div><div class="gs_gray">Lancet, 1741-1755<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=18146962551345076004" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:aEW5N-EHWIMC" class="gsc_a_at">Cisplatin Resistant Nsclc Cells Block Acid Sphingomyelinase Dependent Caspase 8 Activation but Conserve Death Receptor Signalling</a><div class="gs_gray">I Paul, A Chacko, N Crawford, M Barr, KJ O'Byrne, DB Longley, ...</div><div class="gs_gray">Journal of Thoracic Oncology 6 (6), S934-S935<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10068877526878609129" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:nqdriD65xNoC" class="gsc_a_at">Obatoclax effects on MCL1 addiction in mesothelioma and activity in vivo.</a><div class="gs_gray">N McTavish, F McCoy, I Paul, S Busacca, DA Fennell</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), e13539-e13539<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=10028414517586378346" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:hQUaER0FWQ4C" class="gsc_a_at">BRCA1 expression and efficacy of vinorelbine in malignant mesothelioma.</a><div class="gs_gray">S Busacca, SG Gray, I Paul, N McTavish, KJ O'Byrne, JE Quinn, ...</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), e13541-e13541<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=228316252892353232" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:JWITY9-sCbMC" class="gsc_a_at">PP 56 Suitability of advanced non-small cell lung cancer biopsies for prospective, multiple molecular analyses in clinical trials</a><div class="gs_gray">D Fennell, M Nicolson, D Ferry, K O'Byrne, S Moore, S McErlean, ...</div><div class="gs_gray">European Journal of Cancer, S17-S18<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=17515718718829583537" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:lYAcb2jw7qUC" class="gsc_a_at">Expression of the receptor MST1R/RON and its ligand MSP in malignant pleural mesothelioma</a><div class="gs_gray">SG Gray, D Easty, AM Baird, I Opitz, D Nonaka, D Fennell, HI Pass, L Mutti, ...</div><div class="gs_gray">Lung Cancer 71, S18-S18<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2569309722567427516" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:pQTOvowfQioC" class="gsc_a_at">Development of expression based biomarkers in NSCLC: A study of intratumor heterogeneity using FFPE tissue.</a><div class="gs_gray">RJ Holt, T Davison, S Dibben, J Taylor, PJ Kelly, I Paul, P Kerr, ...</div><div class="gs_gray">Journal of Clinical Oncology 28 (15_suppl), e21024-e21024<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12513084825432965095" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:TaaCk18tZOkC" class="gsc_a_at">New Computer Vision Approach in the Classification of Adenocarcinoma and Squamous NSCLC using H&amp;E Tissue Images</a><div class="gs_gray">CW Wang, D Fennell, P Kelly, J James, P Hamilton</div><div class="gs_gray">Cellular Oncology 32, 235-235<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=6232979496281135507" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:c59VksA5Vz4C" class="gsc_a_at">Markov modelling of mitochondrial BAK activation kinetics during apoptosis</a><div class="gs_gray">C Grills, DA Fennell, SFC Shearer</div><div class="gs_gray">International Symposium on Stochastic Algorithms, 191-205<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=12555920135268706070" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:jmjb1lOE9QIC" class="gsc_a_at">Response to chemotherapy predicts longer survival in an individual patient meta-analysis of 1205 patients with mesothelioma</a><div class="gs_gray">DA Fennell, GL Ceresoli, B Castagneto, P Scullin, M O'Brien, M Parker, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 4 (9), S347-S348<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=14580587019669171563" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:X0DADzN9RKwC" class="gsc_a_at">P-405 Survivin and survival in malignant pleural mesothelioma</a><div class="gs_gray">A Klabatsa, J Steele, D Fennell, M Evans, R Rudd, M Sheaff</div><div class="gs_gray">Lung Cancer, S222<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=8355683962728967186" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:s85pQhAUCrAC" class="gsc_a_at">HA14-1, a small molecule Bcl-2 antagonist: Chemosensitization and pharmacodynamics in leukaemia.</a><div class="gs_gray">DA Fennell, M Corbo, A Pallaska, FE Cotter</div><div class="gs_gray">Blood 98 (11), 839A-840A<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=3653446033991088540" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:nPT8s1NX_-sC" class="gsc_a_at">A dynamical systems model to simulate the perturbation kinetics of gene expression by antisense oligonucleotides</a><div class="gs_gray">DA Fennell, FE Cotter</div><div class="gs_gray">Journal of theoretical biology 209 (1), 103-112<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=399376478326196663" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:LK8CI43ZvvMC" class="gsc_a_at">Activity of BCL-2 antisense molecule G3139 against, lymphoma/leukemia; Results from a phase I/IIA clinical trial and further developments.</a><div class="gs_gray">F Cotter, A Webb, D Cunningham, D Fennell, M Corbo, P Ross, J Walters, ...</div><div class="gs_gray">Blood 90 (10), 2289-2289<span class="gs_oph">, 1997</span></div></td><td class="gsc_a_c"><a href="https://scholar.google.com/scholar?oi=bibs&amp;hl=en&amp;cites=2104965117608743509" class="gsc_a_ac gs_ibl">1</a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1997</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:qSd0DAb9jMoC" class="gsc_a_at">Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy</a><div class="gs_gray">J Harber, T Kamata, C Pritchard, D Fennell</div><div class="gs_gray">Journal for ImmunoTherapy of Cancer 9 (9), e003032<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:RgznTc0nqo4C" class="gsc_a_at">CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition</a><div class="gs_gray">G Pinton, Z Wang, C Balzano, S Missaglia, D Tavian, R Boldorini, ...</div><div class="gs_gray">Frontiers in Oncology 11, 2505<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:KqW5X_olkfQC" class="gsc_a_at">Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment</a><div class="gs_gray">M Zhang, JL Luo, Q Sun, J Harber, AG Dawson, A Nakas, S Busacca, ...</div><div class="gs_gray">Nature Communications 12 (1), 1-1<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:koF6b02d8EEC" class="gsc_a_at">P24. 03 A Multicenter Randomized Phase III Trial of Dendritic Cell Maintenance Therapy After Chemotherapy in Mesothelioma; Denim Trial</a><div class="gs_gray">R Belderbos, P Baas, R Berardi, R Cornelissen, D Fennell, J Meerbeeck, ...</div><div class="gs_gray">Journal of Thoracic Oncology 16 (3), S378<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:lRPiJ3GhvscC" class="gsc_a_at">P198 Thoracic skeletal muscle loss is prognostic in malignant pleural mesothelioma</a><div class="gs_gray">AC Kidd, A Winter, L Miller, W Baird, C Dick, D Pearce, W Sloan, ...</div><div class="gs_gray">Thorax 76 (Suppl 1), A197-A197<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:9tXw7Op4-u0C" class="gsc_a_at">Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma</a><div class="gs_gray">E Aliagas, A Alay, M Martínez-Iniesta, M Hernandez-Madrigal, D Cordero, ...</div><div class="gs_gray">bioRxiv<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:jq04SsiGh3QC" class="gsc_a_at">Promising Investigational New Drugs for Mesothelioma: What Is the Next Stage of the Treatment for Advanced Mesothelioma?</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Malignant Pleural Mesothelioma, 279-289<span class="gs_oph">, 2021</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2021</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:h1pkognVyKwC" class="gsc_a_at">89P Dissecting tumour-immune interactions in mesothelioma for identifying responders to immune checkpoint blockade</a><div class="gs_gray">V Addala, S Sneddon, I Dick, D Fennell, JV Pearson, B Robinson, ...</div><div class="gs_gray">Annals of Oncology 31, S1453<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:U3qCfcK-7lkC" class="gsc_a_at">Mesothelioma is associated with ipsilateral thoracic muscle loss</a><div class="gs_gray">AC Kidd, A Winter, L Miller, W Baird, C Dick, D Pearce, W Sloan, ...</div><div class="gs_gray">European Respiratory Journal 56 (suppl 64)<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:uEM9VtRl8xsC" class="gsc_a_at">1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors</a><div class="gs_gray">F Morschhauser, P McKay, G Salles, S Stacchiotti, GK Schwartz, H Tilly, ...</div><div class="gs_gray">Annals of Oncology 31, S981-S982<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:cww_0JKUTDwC" class="gsc_a_at">EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilisation and accelerated migration through NEK9 and NEK7</a><div class="gs_gray">A Fry, L O'Regan, G Barone, R Adib, CG Woo, HJ Jeong, MW Richards, ...</div><div class="gs_gray">University of Leicester<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:jKT558fuBk8C" class="gsc_a_at">Protocol: Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended&nbsp;…</a><div class="gs_gray">E Lim, L Darlison, J Edwards, D Elliott, DA Fennell, S Popat, RC Rintoul, ...</div><div class="gs_gray">BMJ Open 10 (9)<span class="gs_oph">, 2020</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2020</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:KqnX2w3egDsC" class="gsc_a_at">A novel role of BAP1 in regulating the spindle assembly checkpoint and mitotic spindle assembly</a><div class="gs_gray">A Singh, D Fennell, A Fry</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 121, 1-1<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:cF7EPgIk0B4C" class="gsc_a_at">Molecularly Stratified Umbrella Study, Mesothelioma Stratified Therapy (MiST)</a><div class="gs_gray">D Fennell, S Mohammed, C Poile, A Gaba, C Richards, P Well-Jordan, ...</div><div class="gs_gray">TRIALS 20<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:nOiSByfp82kC" class="gsc_a_at">P2. 06-11 MEDUSA: Phylogenetic Analysis of Mesothelioma Tumours by Multiregional Sampling, Whole Exome Sequencing, and Copy Number Analysis</a><div class="gs_gray">E Hollox, L Brannan, A Nakas, M Jama, A Sharkey, A Dawson, ...</div><div class="gs_gray">Journal of Thoracic Oncology 14 (10), S759<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Cvh0bltMcLgC" class="gsc_a_at">ES03. 02 Targeting CDKN2A in Mesothelioma</a><div class="gs_gray">D Fennell</div><div class="gs_gray">Journal of Thoracic Oncology 14 (10), S18-S19<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:SWgZeABleR0C" class="gsc_a_at">Personalized circulating tumor DNA profiling in malignant pleural mesothelioma</a><div class="gs_gray">LJ Martinson, AJ Sharkey, AG Dawson, RK Hastings, G Wilson, D Waller, ...</div><div class="gs_gray">Cancer Research 79 (13 Supplement), 1349-1349<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:oAywNP-vUhwC" class="gsc_a_at">Mesothelioma phylogeny reveal MTAP as a solitary clonal deletion, exposing vulnerability to the PRMT5 perturbagen, quinacrine</a><div class="gs_gray">S Busacca, L Brannan, A Nakas, A Sharkey, C Riganti, D Waller, ...</div><div class="gs_gray">Cancer Research 79 (13 Supplement), 2908-2908<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:1xBWf43XMUgC" class="gsc_a_at">Selected Abstracts from the 2019 NCRI Cancer Conference of National Cancer Research Institute</a><div class="gs_gray">A Singh, D Fennell, A Fry</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:It0W0vAlS5QC" class="gsc_a_at">Unmet Needs and Future Outlook of Mesothelioma Management</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Mesothelioma, 331-340<span class="gs_oph">, 2019</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2019</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:E8ajGqO0XoUC" class="gsc_a_at">Клинические рекомендации по диагностике и ведению больных со злокачественной мезотелиомой плевры (часть 1-я)</a><div class="gs_gray">С Редакционная</div><div class="gs_gray">Пульмонология 28 (5), 531-557<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:_mQi-xiA4oYC" class="gsc_a_at">Abstract LB-169: Asbestos and anthelmintics: Repurposing drugs to prevent mesothelioma in high-risk populations</a><div class="gs_gray">BG Rogoyski, A Karmokar, S Khan, H Cai, FL Khanim, S Busacca, ...</div><div class="gs_gray">Cancer Research 78 (13 Supplement), LB-169-LB-169<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:wuD5JclIwkYC" class="gsc_a_at">基于基因表达谱筛选乳腺癌他莫昔芬耐药的生物标志物与治疗药物</a><div class="gs_gray">张晶晶， 赵拯， 刘赟心， 朱余兵， 樊宏伟</div><div class="gs_gray">临床与病理杂志 38 (7), 1392398-1391398<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:NU-BerS4NX4C" class="gsc_a_at">CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.</a><div class="gs_gray">DA Fennell, EV Kirkpatrick, K Cozens, S Danson, GG Hanna, JF Lester, ...</div><div class="gs_gray">Journal of Clinical Oncology 36 (15_suppl), TPS8586-TPS8586<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:oXKBmVzQOggC" class="gsc_a_at">Clinical guidelines on diagnosis and management of patients with malignant pleural mesothelioma. Part 2</a><div class="gs_gray">I Woolhouse, L Bishop, L Darlison, D De Fonseka, A Edey, J Edwards, ...</div><div class="gs_gray">Pulmonologiya 28 (6), 655-679<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:dhpJJ7xvgBgC" class="gsc_a_at">Clinical guidelines on diagnosis and management of patients with malignant pleural mesothelioma (рart 1)</a><div class="gs_gray">I Woolhouse, L Bishop, L Darlison, D De Fonseka, A Edey, J Edwards, ...</div><div class="gs_gray">Pulmonologiya 28 (5), 531-557<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:CCeGMaHljPEC" class="gsc_a_at">MiST3: a phase II study of oral selective AXL inhibitor bemcentinib (BGB324) incombination with pembrolizumab in pts with malignant mesothelioma</a><div class="gs_gray">MG Krebs, L Carter, S Villa, A King, C Massey, J Lorens, E Darlington, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:eFf2swCANGcC" class="gsc_a_at">Experience of immunotherapy treatment for non-small cell lung cancer within University Hospitals Leicester in patients treated both within and outside of a clinical trial</a><div class="gs_gray">HS Walter, E Dickens, SUI Muhammad, T Sridhar, D Fennell, S Ahmed</div><div class="gs_gray">Lung Cancer 115, S41<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:sJK75vZXtG0C" class="gsc_a_at">Recruitment and outcome of lung cancer patients to clinical trials within the Department of Medical Oncology at University Hospitals Leicester</a><div class="gs_gray">MR Abi Aoun, HS Walter, E Dickens, MO Mahgoub, B Varadhan, S Porter, ...</div><div class="gs_gray">Lung Cancer 115, S43-S44<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Nufq_to8ts0C" class="gsc_a_at">CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma</a><div class="gs_gray">G Hanna, G Griffiths, EV Kirkpatrick, K Cozens, M Kalevras, T Maishman, ...</div><div class="gs_gray">Lung Cancer 115 (Suppl 1), S84-S84<span class="gs_oph">, 2018</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2018</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:qPeb-qHga9sC" class="gsc_a_at">PUB035 CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma</a><div class="gs_gray">D Fennell, E Kirkpatrick, K Cozens, S Danson, G Hanna, J Lester, J Lord, ...</div><div class="gs_gray">Journal of Thoracic Oncology 12 (11), S2376<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Oo1CbQkBAzEC" class="gsc_a_at">FAK-PD1: a phase I/IIa trial of FAK (defactinib) &amp; PD-1 (pembrolizumab) inhibition</a><div class="gs_gray">S Symeonides, TRJ Evans, V Coyle, A Serrels, F Thomson, D Currie, ...</div><div class="gs_gray">Annals of Oncology 28, v426-v427<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:RVqaWcrwK10C" class="gsc_a_at">细胞凋亡药物</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">临床与病理杂志 35 (4), E73-E78-E7E78<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Ei5r6KrKXVQC" class="gsc_a_at">Stem Cells and Lung Cancer: In Vitro and InVivo</a><div class="gs_gray">DA Fennell, DM Jablons</div><div class="gs_gray">IASLC Thoracic Oncology E-Book 13, 117<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:cdwqcPQS8ssC" class="gsc_a_at">Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies</a><div class="gs_gray">N van Zandwijk, OT Brustugun, D Buergy, L Crino, AM Dingemans, ...</div><div class="gs_gray">Lippincott Williams &amp; Wilkins<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:mVC4hKzE2FoC" class="gsc_a_at">Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE)</a><div class="gs_gray">R di Maio, A Scherpereel, L Calabrò, J Aerts, SC Perez, A Bearz, ...</div><div class="gs_gray">The Lancet Oncology<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:X4-KO54GjGYC" class="gsc_a_at">P3. 03-021 When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?: Topic: Mesothelioma Transitional</a><div class="gs_gray">AM Baird, D Easty, M Jarzabek, L Shiels, A Soltermann, S Raeppel, ...</div><div class="gs_gray">Journal of Thoracic Oncology 12 (1), S1356-S1357<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Vr2j17o0sqMC" class="gsc_a_at">Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma</a><div class="gs_gray">A Baird, D Easty, BM Mohamed, M Jarzabek, L Shiels, A Soltermann, ...</div><div class="gs_gray">15th Annual British Thoracic Oncology Group Conference, S26<span class="gs_oph">, 2017</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2017</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:6ZzL7HXColQC" class="gsc_a_at">Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on&nbsp;…</a><div class="gs_gray">R Hassan, JJ Nemunaitis, JP van Meerbeeck, R Jennens, ...</div><div class="gs_gray">Cancer Research 76 (14 Supplement), CT083-CT083<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:yIeBiWEAh44C" class="gsc_a_at">Analysis Of Gene-Expression Changes In 3d Spheroids Highlights A Survival Role For Ass1 In Mesothelioma</a><div class="gs_gray">D Barbone, C Follo, L Van Dam, PV Jithesh, SD Zhang, WG Richards, ...</div><div class="gs_gray">C110. MESOTHELIOMA AND MALIGNANT PLEURAL DISEASE: FROM BENCH TO BEDSIDE TO&nbsp;…<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:RXiHnyRawswC" class="gsc_a_at">Genetics of Malignant Pleural Mesothelioma</a><div class="gs_gray">DA Fennell, AJ Sharkey, S Busacca</div><div class="gs_gray">Malignant Pleural Mesothelioma: Present Status and Future Directions, 155<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:2vr6o8x5NLkC" class="gsc_a_at">Genetics of mesothelioma</a><div class="gs_gray">DA FENNELL, S BUSACCA</div><div class="gs_gray">Textbook of Pleural Diseases, 80<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:HKviVsUxM5wC" class="gsc_a_at">Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, LeQuesne J, Klabatsa A, Edwards JM, Matchett KB, Luo JL, Pringle JH, El-Tanani M</a><div class="gs_gray">M MacFarlane, DA Fennell</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:zzCxg_vo7cAC" class="gsc_a_at">C110 MESOTHELIOMA AND MALIGNANT PLEURAL DISEASE: FROM BENCH TO BEDSIDE TO COMMUNITY: Analysis Of Gene-Expression Changes In 3d Spheroids Highlights A Survival Role For Ass1 In&nbsp;…</a><div class="gs_gray">D Barbone, C Follo, L Van Dam, PV Jithesh, S Zhang, WG Richards, ...</div><div class="gs_gray">American Journal of Respiratory and Critical Care Medicine 193, 1<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:hefNtdE4IMkC" class="gsc_a_at">86 When RON MET TAM: potential interventions for mesothelioma therapy</a><div class="gs_gray">A Baird, D Easty, BM Mohamed, MA Jarzabek, L Sheils, A Soltermann, ...</div><div class="gs_gray">Lung Cancer 91, S31<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:g_UdREhPGEoC" class="gsc_a_at">90 Accrual to clinical trials in mesothelioma</a><div class="gs_gray">RE Plant, M Chauhan, L Nelson, D Fennell, SI Ahmed</div><div class="gs_gray">Lung Cancer 1 (91), S32-S33<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:ifOnle78iJkC" class="gsc_a_at">82 Accrual to clinical trials–an update</a><div class="gs_gray">RE Plant, M Chauhan, L Nelson, D Fennell, SI Ahmed</div><div class="gs_gray">Lung Cancer 1 (91), S29-S30<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:yeL6HyUMUGUC" class="gsc_a_at">89 Experience of the treatment of malignant mesothelioma at a UK centre</a><div class="gs_gray">RE Plant, M Chauhan, FA Wright, L Darlison, S Porter, D Fennell, ...</div><div class="gs_gray">Lung Cancer 1 (91), S32<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:orDZ08hpP44C" class="gsc_a_at">24 The impact of an inpatient acute oncology service on new lung cancer diagnoses</a><div class="gs_gray">S Ayub, A Law, T Sridhar, L Aznar-Garcia, D Fennell, SI Ahmed</div><div class="gs_gray">Lung Cancer 1 (91), S9<span class="gs_oph">, 2016</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2016</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:AZju0d2GQJ0C" class="gsc_a_at">MEMBERSHIP AND ACKNOWLEDGEMENTS</a><div class="gs_gray">A Wilcock, MC Stonham, C Mulatero, DA Fennell, I Williamson, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:MDX3w3dAD3YC" class="gsc_a_at">A Phase 1 Dose Escalation Study of VS-5584, a PI3K/MTOR Inhibitor, Administered with VS-6063, a Focal Adhesion Kinase Inhibitor, in Mesothelioma</a><div class="gs_gray">U Banerji, DA Fennell, HL Kindler, MG Zauderer, M Keegan, J Horobin</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 10 (9), S630-S630<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:yY3RG6sOEgwC" class="gsc_a_at">BRCA1/OCT1/MAD2L1 Axis Regulates a Bifurcating Apoptotic Pathway Induced by Vinorelbine in Mesothelioma</a><div class="gs_gray">S Busacca, AJ Sharkey, D Waller, A Nakas, L O'Regan, K Kerr, M Sheaff, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 10 (9), S403-S403<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:QVtou7C4vgoC" class="gsc_a_at">The Small Molecule Inhibitor, LCRF004, Is Effective in Targeting the RON/MST1R Pathway in Malignant Pleural Mesothelioma</a><div class="gs_gray">AM Baird, KJ O'Byrne, D Easty, L Shiels, A Byrne, S Raeppel, B Stanfill, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 10 (9), S505-S505<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:cOfwuRB03ygC" class="gsc_a_at">COMMAND: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Defactinib as Maintenance Therapy in Subjects with Malignant Pleural Mesothelioma which&nbsp;…</a><div class="gs_gray">HL Kindler, D Fennell, P Baas, M Zauderer, AK Nowak, RJ Gralla, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:uAPFzskPt0AC" class="gsc_a_at">58: The prognostic significance of nodal metastatic burden on survival following radical surgery for malignant pleural mesothelioma</a><div class="gs_gray">A Sharkey, D Fennell, A Nakas, D Waller</div><div class="gs_gray">Lung Cancer, S23-S24<span class="gs_oph">, 2015</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:6VlyvFCUEfcC" class="gsc_a_at">Mezoteliomul pleural malign: Ghidul ESMO de practică clinică pentru diagnostic, tratament şi urmărire</a><div class="gs_gray">P Baas, D Fennell, KM Kerr, PE Van Schil</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2015</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Vno172sVVMwC" class="gsc_a_at">TARGETING THE RON/MST1R RECEPTOR USING LCRF004, MAY PROVIDE AN EFFECTIVE NOVEL INTERVENTIONAL STRATEGY IN MALIGNANT PLEURAL MESOTHELIOMA: 206</a><div class="gs_gray">AM Baird, K O'Byrne, D Easty, L Shiels, A Byrne, S Raeppel, ...</div><div class="gs_gray">Asia-pacific Journal of Clinical Oncology 10<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:e84hm74t-eoC" class="gsc_a_at">ASS1, ANXA4 and MVP underlie acquired multicellular resistance of mesothelioma 3D cell cultures</a><div class="gs_gray">D Barbone, L van Dam, SD Zhang, J Puthen, D Fennell, VC Broaddus</div><div class="gs_gray">Cancer Research 74 (19 Supplement), 696-696<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:QaSi33NTfwYC" class="gsc_a_at">Exploratory Analysis of Circulating Free Dna to Identify Biomarkers Predictive of Outcome in Galaxy-1, a Large Randomized Phase Iib Study of Ganetespib in Combination with&nbsp;…</a><div class="gs_gray">D Fennell, J Shaw, I El-Hariry, V Reichert, V Vukovic, LM Martins</div><div class="gs_gray">Annals of Oncology 25, iv69<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:rbGdIwl2e6cC" class="gsc_a_at">The difficulty of subtyping mesothelioma from biopsy material: the effects on surgical management and room for improvement</a><div class="gs_gray">A Sharkey, J Le Quesne, D Fennell, A Nakas, C Richards, D Waller, ...</div><div class="gs_gray">VIRCHOWS ARCHIV 465, S373-S373<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:ji7lAbPyDbYC" class="gsc_a_at">Pathological features of response to neoadjuvant chemotherapy in malignant pleural mesothelioma</a><div class="gs_gray">A Sharkey, J Le Quesne, D Fennell, A Nakas, C Richards, D Waller, ...</div><div class="gs_gray">VIRCHOWS ARCHIV 465, S373-S373<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:kUhpeDhEZMUC" class="gsc_a_at">O-104 DOES THE TIMING OF CHEMOTHERAPY AFFECT OUTCOME FOLLOWING RADICAL SURGERY FOR MALIGNANT PLEURAL MESOTHELIOMA?</a><div class="gs_gray">A Jane Sharkey, D Fennell, A Nakas, KJ O'Byrne, D Waller</div><div class="gs_gray">Interactive CardioVascular and Thoracic Surgery 18 (suppl_1), S27-S27<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:R22Rs3tN8aoC" class="gsc_a_at">ULTRA-DEEP SEQUENCING OF CIRCULATING FREE DNA TO IDENTIFY PREDICTIVE, MUTATED HSP90 CLIENTS IN GALAXY-1 (NCT01348126), A RANDOMIZED PHASE 2B STUDY OF GANETESPIB PLUS DOCETAXEL&nbsp;…</a><div class="gs_gray">D Fennell, J Shaw, I El-Hariry, VM Vukovic, V Reichert, LM Martins</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 9 (4), S19-S19<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:ehoypfNsBj8C" class="gsc_a_at">Tracking Genomic Cancer</a><div class="gs_gray">M Jamal-Hanjani, A Hackshaw, Y Ngai, J Shaw, C Dive</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:GJVTs2krol4C" class="gsc_a_at">Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed</a><div class="gs_gray">DA Fennell, SP Myrand, TS Nguyen, D Ferry, KM Kerr</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:WIXB4To3Tx4C" class="gsc_a_at">97 The experience of lung cancer patients seeking treatment through Accident and Emergency Departments (AED)</a><div class="gs_gray">J Crane, J Dunbar, A McIver, J Hughes, M Ledson, E Perkins</div><div class="gs_gray">Lung Cancer, S36<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:T8_be82Iz5gC" class="gsc_a_at">Predicting sensitivity to PI3K/mTOR inhibition in asbestos-induced malignant mesothelioma models Ian Powley1, Sara Galavotti1, Xiao-Ming Sun1</a><div class="gs_gray">T Chernova, A Nakas, J Le Quesne, H Pringle, D Fennell, M MacFarlane</div><div class="gs_gray">Abstracts/Toxicology Letters 229S 40 (S252), S153<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:i_7YvbSbtFEC" class="gsc_a_at">222 MesobanK–a UK based bioresource for malignant mesothelioma</a><div class="gs_gray">RC Rintoul, DM Rassl, N Maskell, J Gittins, PW Szlosarek, KM Kerr, ...</div><div class="gs_gray">Lung Cancer, S82<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:E7VqQtBCVmcC" class="gsc_a_at">41 Accrual to lung cancer clinical trials–a single centre experience</a><div class="gs_gray">R Plant, H Walter, D Samuel, DA Fennell, SI Ahmed</div><div class="gs_gray">Lung Cancer, S15-S16<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:KTwcwpFFj4wC" class="gsc_a_at">Predicting sensitivity to PI3K/mTOR inhibition in asbestos-induced malignant mesothelioma models</a><div class="gs_gray">I Powley, S Galavotti, XM Sun, T Chernova, A Nakas, J Le Quesne, ...</div><div class="gs_gray">Toxicology Letters, S153<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:L24QuVWYgZ0C" class="gsc_a_at">96 Impact of an acute oncology service in patients with a suspected new diagnosis of lung cancer at University Hospitals of Leicester</a><div class="gs_gray">HS Walter, R Plant, A Law, C Esler, T Sridhar, DA Fennell, SI Ahmed</div><div class="gs_gray">Lung Cancer, S36<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:qmtmRrLr0tkC" class="gsc_a_at">27 Risk of CNS progression in EGFR mutation positive NSCLC patients treated with TKI</a><div class="gs_gray">HS Walter, R Plant, M Chauhan, DA Fennell, SI Ahmed</div><div class="gs_gray">Lung Cancer, S11<span class="gs_oph">, 2014</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2014</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=200&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:37UQlXuwjP4C" class="gsc_a_at">P1 An analysis of 8,503 cases of mesothelioma from the National Lung Cancer Audit</a><div class="gs_gray">P Beckett, I Woolhouse, R Stanley, D Fennell, J Edwards, R Hubbard, ...</div><div class="gs_gray">Thorax 68 (Suppl 3), A75-A75<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:wGzT3bKASkAC" class="gsc_a_at">ASSOCIATION BETWEEN GENE EXPRESSION PROFILES AND CLINICAL OUTCOME OF PEMETREXED-BASED TREATMENT IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: EXPLORATORY&nbsp;…</a><div class="gs_gray">D Fennell, S Myrand, T Nguyen, D Ferry, KM Kerr, P Maxwell, S Moore, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 8, S329-S329<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:qsWQJNntlusC" class="gsc_a_at">THE RON (MST1R)/MSP PATHWAY IS A POTENTIAL THERAPEUTIC TARGET IN MALIGNANT PLURAL MESOTHELIOMA</a><div class="gs_gray">AM Baird, KO Byrne, D Easty, L Shiels, A Byrne, A Soltermann, D Nonaka, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 8, S502-S502<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:aDl3D7KC1E4C" class="gsc_a_at">MESOBANK: A UK BASED BIORESOURCE FOR MALIGNANT PLEURAL MESOTHELIOMA</a><div class="gs_gray">RC Rintoul, DM Rassl, NA Maskell, PW Szlosarek, KM Kerr, R Booton, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 8, S940-S940<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:PuOEWVtPfzwC" class="gsc_a_at">A RANDOMISED PHASE II TRIAL OF ORAL VINORELBINE AS SECOND-LINE THERAPY FOR PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) EXPRESSING BRAC1-VIM TRIAL</a><div class="gs_gray">D Fennell, A Casbard, J Lester, KA Roberts, G Griffiths</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 8, S941-S941<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:BAanoTsO0WEC" class="gsc_a_at">MALIGNANT PLEURAL MESOTHELIOMA IN THE UK NATIONAL LUNG CANCER AUDIT: AN ANALYSIS OF 8503 CASES</a><div class="gs_gray">MD Peake, P Beckett, I Woolhouse, R Stanley, D Fennell, J Edwards, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 8, S311-S311<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:eH23hyXCXa4C" class="gsc_a_at">A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF VS-6063 AS MAINTENANCE THERAPY IN SUBJECTS WITH MALIGNANT PLEURAL MESOTHELIOMA WHICH HAS NOT&nbsp;…</a><div class="gs_gray">M Keegan, P Baas, D Fennell, RJ Gralla, H Kindler, LM Krug, AK Nowak, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 8, S941-S942<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:M0leSnx2MbUC" class="gsc_a_at">TARGETING MCL1 AMPLIFICATION IN NSCLC THROUGH ANTHRACYCLINE-MEDIATED TRANSCRIPTIONAL SUPPRESSION</a><div class="gs_gray">S Busacca, E Law, K Gately, KJ O'Byrne, EF Smit, HJM Groen, J Harrison, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 8, S501-S502<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:uUvzmPk0f8oC" class="gsc_a_at">Ganetespib in combination with docetaxel versus docetaxel alone in second line adenocarcinoma patients with KRAS mutations and elevated LDH levels</a><div class="gs_gray">DA Fennell, GD Goss, Z Andric, I Bondarenko, B Zaric, T Ceric, ...</div><div class="gs_gray">EUROPEAN JOURNAL OF CANCER 49, S801-S801<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Azgs6IHzeyYC" class="gsc_a_at">Platelet counts (PLT) at baseline and on treatment as predictor for progression free survival (PFS) in patients with advanced malignant pleural mesothelioma (MPM): EORTC 08052&nbsp;…</a><div class="gs_gray">RM Gaafar, S Popat, JP Van Meerbeeck, P Baas, D Fennell, AG Pallis, ...</div><div class="gs_gray">Journal of Clinical Oncology 31 (15_suppl), 7585-7585<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:4Yq6kJLCcecC" class="gsc_a_at">Ultra-deep sequencing of circulating free DNA to identify predictive, mutated HSP90 clients in the GALAXY TrialTM (NCT01348126): a randomized phase IIB/III study of ganetespib&nbsp;…</a><div class="gs_gray">DA Fennell, LM Martins, I El-Hariry, V Vukovic, F Teofilovici, VL Reichert, ...</div><div class="gs_gray">Cancer Research 73 (8 Supplement), 2012-2012<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:SrKkpNFED5gC" class="gsc_a_at">HSSB1: An essential regulator of genomic integrity in lung cancer</a><div class="gs_gray">MN Adams, V Leong, N Paquet, E Bolderson, DA Fennell, K O'Byrne, ...</div><div class="gs_gray">15th World Conference on Lung Cancer, S444<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:U0iAMwwPxtsC" class="gsc_a_at">MicroRNA profiling and cisplatin-DNA interactions in an isogenic model of cisplatin resistant NSCLC cell lines [Conference Abstract]</a><div class="gs_gray">M Barr, S Gray, D Fennell, J O'Leary, D Richard, J Thomale, A Hoffmann, ...</div><div class="gs_gray">Lung Cancer 79 (S1), S1-S1<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:9shLKfS_uJEC" class="gsc_a_at">82 Inhibition of RON (MST1R) induces apoptosis and decreases the cellular migration and proliferation capacity of mesothelioma cells</a><div class="gs_gray">AM Baird, KJ O'Byrne, D Easty, A Soltermann, D Nonaka, DA Fennell, ...</div><div class="gs_gray">Lung Cancer, S29<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:QoJ_w57xiyAC" class="gsc_a_at">82P COMBINED MODALITY THERAPY OF ADVANCED NON-SMALL-CELL LUNG CANCER: A SINGLE INSTITUTION EXPERIENCE</a><div class="gs_gray">B Resuli</div><div class="gs_gray">Lung Cancer, S36-S37<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:WwIwg2wKZ0QC" class="gsc_a_at">19 A single centre experience of gefitinib in patients with EGFR mutation positive non small cell lung cancer</a><div class="gs_gray">HS Walter, DA Fennell, SI Ahmed</div><div class="gs_gray">Lung Cancer, S7<span class="gs_oph">, 2013</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2013</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:cSdaV2aYdYsC" class="gsc_a_at">VorINOStat Eliminates Multicellular Resistance Of Mesothelioma 3d Spheroids Via Restoration Of Noxa Expression</a><div class="gs_gray">VC Broaddus, D Barbone, P Cheung, S Battula, S Busacca, SG Gray, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:gmHTDCtJMcoC" class="gsc_a_at">THE GALAXY TRIAL (NCT01348126): A RANDOMIZED IIB/III STUDY OF GANETESPIB (STA-9090) IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE AS SECOND LINE THERAPY IN PATIENTS WITH&nbsp;…</a><div class="gs_gray">D Fennell, S Ramalingam, J Spicer, C Manegold, R Rosen, V Vukovic, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 7 (11), S446-S446<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:HqhvjgTjE9cC" class="gsc_a_at">Proteomic and Circulating Free DNA Analysis Outcome Predictors in the Galaxy Trialtm (NCT01348126): A Randomized Phase IIB/III Study of Ganetespib (STA-9090) in Combination&nbsp;…</a><div class="gs_gray">D Fennell, E Petricoin, J Shaw, I El Hariry, V Vukovic, F Teofilovici, ...</div><div class="gs_gray">Annals of Oncology 23, ix533-ix534<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:v_tt_AnqfNMC" class="gsc_a_at">High Expression of Macrophage Stimulating Protein (MSP) Correlates with Survival Benefit in Malignant Pleural Mesothelioma</a><div class="gs_gray">D Easty, A Baird, KJ O'Byrne, A Soltermann, D Nonaka, D Fennell, L Mutti, ...</div><div class="gs_gray">Annals of Oncology 23, ix495<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:xyvS_IvSCKsC" class="gsc_a_at">Met Activation by Autocrine Loop Rescues Colon Cancer Cells From Sensitivity to EGFR Inhibition</a><div class="gs_gray">T Troiani, D Vitagliano, S Napolitano, F Morgillo, A Capasso, V Sforza, ...</div><div class="gs_gray">Annals of Oncology 23, ix67<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:vnF2_uLGgtgC" class="gsc_a_at">Basic science</a><div class="gs_gray">G Bepler, Y Zhang, X Li</div><div class="gs_gray">Annals of Oncology 23 (suppl_9)<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:cBPnxVikjH8C" class="gsc_a_at">Microrna Profiling and CDDP-GPG DNA Adduct Formation Analysis in a Panel of Cisplatin Resistant Non-Small Cell Lung Cancer Cell Lines</a><div class="gs_gray">M Barr, SG Gray, DA Fennell, JJ O'Leary, D Richard, J Thomale, ...</div><div class="gs_gray">Annals of Oncology 23, ix68<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:nPTYJWkExTIC" class="gsc_a_at">BIOLOGY AND TARGETED APPROACHES</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 7 (6), S11-S11<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:rCNdntzdTkkC" class="gsc_a_at">Manipulating the Noxa/Bim axis undermines the multicellular resistance of 3D tumor spheroids</a><div class="gs_gray">D Barbone, P Cheung, TM Yang, DM Jablons, DJ Sugarbaker, R Bueno, ...</div><div class="gs_gray">Cancer Research 72 (8 Supplement), 5257-5257<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:6pF0wJmtdfAC" class="gsc_a_at">TMAX–a Database System Integrating Tissue Biomarker &amp; Genomic Data</a><div class="gs_gray">Y Wang, D Kieran, J Blayney, D McArt, K Savage, D Fennell, J James, ...</div><div class="gs_gray">1st Digital Pathology Application &amp; Development Conference in China<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:QeguYG95ZbAC" class="gsc_a_at">Whole Slide Imaging in Digital Pathology: The Impact of Image Compression</a><div class="gs_gray">D Kieran, Y Wang, D Fennell, J Quinn-O'Brien, WQ Yan, D Crookes, ...</div><div class="gs_gray">11th European Congress on Telepathology and 5th International Congress on&nbsp;…<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:TGkaJS32XoUC" class="gsc_a_at">842 FLIP as a Critical Target for Vorinostat in Mesothelioma</a><div class="gs_gray">I Stasik, JL Hurwitz, D Barbone, VC Broaddus, SG Gray, KJ O'Byrne, ...</div><div class="gs_gray">european journal of cancer, S202<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:I858iXPj1OkC" class="gsc_a_at">3 The establishment of an isogenic model of cisplatin resistance and the identification of a potential microRNA signature in non-small cell lung cancer</a><div class="gs_gray">M Barr, D Fennell, J O'Leary, R Stallings, S Gray, K O'Byrne</div><div class="gs_gray">Lung Cancer, S1-S2<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:pYKElYtJMmwC" class="gsc_a_at">64 Macrophage stimulating protein (MSP) up-regulates the Src kinases in malignant pleural mesothelioma</a><div class="gs_gray">AM Baird, D Easty, A Soltermann, D Nonaka, D Fennell, L Mutti, H Pass, ...</div><div class="gs_gray">Lung Cancer, S21<span class="gs_oph">, 2012</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2012</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:wyM6WWKXmoIC" class="gsc_a_at">Abstract B139: Arginine deprivation with pegylated arginine deiminase regulates key metabolic genes in RNA and DNA synthesis in ASS1-deficient malignant mesothelioma cells&nbsp;…</a><div class="gs_gray">B Delage, P Luong, M Phillips, M Chmielewska-Kassassir, R Cutts, ...</div><div class="gs_gray">Molecular Cancer Therapeutics 10 (11 Supplement), B139-B139<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:hNSvKAmkeYkC" class="gsc_a_at">VORINOSTAT IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA (MPM) WHO HAVE FAILED PRIOR PEMETREXED AND EITHER CISPLATIN OR CARBOPLATIN THERAPY: A PHASE III, RANDOMIZED&nbsp;…</a><div class="gs_gray">P Baas, H Kindler, H Calvert, C Manegold, A Tsao, D Fennell, ...</div><div class="gs_gray">Asia-pacific Journal of Clinical Oncology 7<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:u3T1itk59dMC" class="gsc_a_at">SAHA SENSITIZES MESOTHELIOMA SPHEROIDS TO BORTEZOMIB-INDUCED APOPTOSIS BY RESTORING LEVELS OF PRO-APOPTOTIC NOXA</a><div class="gs_gray">D Barbone, DB Longley, DA Fennell, VC Broaddus</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 6 (6), S939-S939<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:EBV337fEn3EC" class="gsc_a_at">BRCA1 REGULATES APOPTOSIS INDUCED BY VINORELBINE IN MALIGNANT MESOTHELIOMA</a><div class="gs_gray">S Busacca, I Paul, N Mctavish, KM Kerr, M Sheaff, JE Quinn, DA Fennell</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 6 (6), S747-S747<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:WWeOtg8bX_EC" class="gsc_a_at">THE RAB27A EFFECTOR MYRIP IS AN ESSENTIAL REGULATOR OF SURVIVAL IN NON-SMALL CELL LUNG CANCER CELLS</a><div class="gs_gray">A Chacko, P Jithesh, C Grills, N Crawford, I Paul, M Barr, KJ O'Byrne, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 6 (6), S774-S774<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:rLGzs9wiiwIC" class="gsc_a_at">FLIP AS A CRITICAL TARGET FOR VORINOSTAT IN MESOTHELIOMA</a><div class="gs_gray">JL Hurwitz, I Stasik, EM Kerr, C Holohan, KM Redmond, CS Fenning, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 6 (6), S1045-S1045<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:DXE8ND7PrJAC" class="gsc_a_at">THE MACROPHAGE STIMULATING PROTEIN (MSP)-RON/MST1R AXIS IN MALIGNANT PLEURAL MESOTHELIOMA</a><div class="gs_gray">SG Gray, D Easty, AM Baird, A Soltermann, D Nonaka, DA Fennell, L Mutti, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 6 (6), S766-S767<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:BOlwja0KXvYC" class="gsc_a_at">MITOCHONDRIAL VDAC2 IS TRANSCRIPTIONALLY REGULATED BY P63 AND CONFERS SHORTER SURVIVAL IN NON-SMALL CELL LUNG CANCER</a><div class="gs_gray">B Wilson, S Mcdade, C Grills, DA Fennell</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 6 (6), S1006-S1007<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:hHIA4WEVY-EC" class="gsc_a_at">The Rab27A effector MYRIP as a regulator of survival in non-small cell lung cancer cells.</a><div class="gs_gray">A Chacko, PV Jithesh, C Grills, I Paul, N Crawford, DA Fennell</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), e13537-e13537<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Kqc1aDSOPooC" class="gsc_a_at">Activation of the macrophage-stimulating protein (MSP)-RON axis in malignant pleural mesothelioma.</a><div class="gs_gray">D Easty, SG Gray, A Baird, A Soltermann, D Nonaka, DA Fennell, I Opitz, ...</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), e17508-e17508<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:m4fbC6XIj1kC" class="gsc_a_at">The effect of PARP inhibition on BAX/BAK independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.</a><div class="gs_gray">I Paul, K Savage, E Lamers, K Gately, KJ O'Byrne, JK Blayney, KM Kerr, ...</div><div class="gs_gray">Journal of Clinical Oncology 29 (15_suppl), e13519-e13519<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:ijdKiLOsEJMC" class="gsc_a_at">Apoptosis as a Tumor Suppressor Mechanism</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Malignant Mesothelioma 189, 149<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Oj-SLI0tZTcC" class="gsc_a_at">The generation and characterisation of cisplatin resistant non-small cell lung cancer cell lines that display stem-like features</a><div class="gs_gray">M Barr, DA Fennell, KJ O'Byrne</div><div class="gs_gray">LUNG CANCER 71, S2-S2<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:N6_Y7JlWxwsC" class="gsc_a_at">SP 119 synthetic lethal approaches and biomarker discovery related to radiation sensitization in prostate cancer</a><div class="gs_gray">R Bristow</div><div class="gs_gray">European Journal of Cancer, S1<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:C-Rn0OCouf8C" class="gsc_a_at">PP 44 Myeloid zinc finger 1 regulates thymidylate synthase expression in patients with metastatic colorectal cancer showing the same promoter gene polymorphism</a><div class="gs_gray">A Calascibetta, F Contino, S Feo, A Martorana, R Sanguedolce</div><div class="gs_gray">European Journal of Cancer, S12<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:q0uBw5dMOAkC" class="gsc_a_at">PP 15 BRCA1 expression is required for efficacy of vinorelbine and is a predictive biomarker in malignant mesothelioma</a><div class="gs_gray">S Busacca, M Sheaff, SG Gray, KJ O'Byrne, K Kerr, I Schmitt-Opitz, ...</div><div class="gs_gray">European Journal of Cancer, S12<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:QsKbpXNoaWkC" class="gsc_a_at">5 The generation and characterisation of cisplatin resistant non-small cell lung cancer cell lines that display stem-like features</a><div class="gs_gray">M Barr, DA Fennell, KJ O'Byrne</div><div class="gs_gray">Lung Cancer, S2<span class="gs_oph">, 2011</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2011</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:xGWFX6Gbr9MC" class="gsc_a_at">VDAC1 and prognosis in surgically resected non-small cell lung cancer.</a><div class="gs_gray">CM Grills, KJ O'Byrne, K Gately, DA Fennell</div><div class="gs_gray">Journal of Clinical Oncology 28 (15_suppl), 7029-7029<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:9NZAP19TdFAC" class="gsc_a_at">MST1R, a receptor tyrosine kinase expressed in malignant pleural mesothelioma.</a><div class="gs_gray">D Easty, SG Gray, A Soltermann, D Nonaka, DA Fennell, I Opitz, HI Pass, ...</div><div class="gs_gray">Journal of Clinical Oncology 28 (15_suppl), 10583-10583<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:EaFouW7jFu4C" class="gsc_a_at">Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer.</a><div class="gs_gray">JK Blayney, CM Grills, PV Jithesh, II Wistuba, M Jacobson, KJ O'Byrne, ...</div><div class="gs_gray">Journal of Clinical Oncology 28 (15_suppl), 1599-1599<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:gV6rEsy15s0C" class="gsc_a_at">Pegylated arginine deiminase induces mitochondrial apoptosis and synergizes with cisplatin in ASS1-negative malignant pleural mesothelioma</a><div class="gs_gray">B Delage, C Chelala, A Chacko, PV Jithesh, DA Fennell, NR Lemoine, ...</div><div class="gs_gray">Cancer Research 70 (8 Supplement), 4445-4445<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:idthP5jqfYAC" class="gsc_a_at">584 c-FLIP, a critical target for histone deacetylase inhibitors in mesothelioma</a><div class="gs_gray">J Hurwitz, K McLaughlin, E Kerr, D Fennell, D Longley</div><div class="gs_gray">Ejc Supplements 7 (8), 184<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:YPNY0knpFBYC" class="gsc_a_at">Evaluation of c-FLIP as a target for vorinostat in mesothelioma</a><div class="gs_gray">J Hurwitz, K Redmond, K McLaughlin, D Fennell, D Longley</div><div class="gs_gray">Lung Cancer, S1<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:OzeSX8-yOCQC" class="gsc_a_at">FAST AUTO-QUANTIFICATION OF IHC BIOMARKERS (BAK AND BAX) AND DISCOVERY OF NOVEL PROGNOSTICALLY SIGNIFICANT TUMOUR SUBSETS IN NSCLC</a><div class="gs_gray">CW Wang, D Fennell, I Paul, P Hamilton</div><div class="gs_gray">Cellular Oncology 32, 176-177<span class="gs_oph">, 2010</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2010</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:yTLRzDEmwhEC" class="gsc_a_at">Abstract B31: Multicellular resistance to bortezomib acquired by mesothelioma spheroids can be reversed by modulation of the Bcl‐2 repertoire</a><div class="gs_gray">D Barbone, DA Fennell, VC Broaddus</div><div class="gs_gray">Molecular Cancer Therapeutics 8 (12 Supplement), B31-B31<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:wLxue7F8ec0C" class="gsc_a_at">Abstract B30: Phosphorylation of c‐jun N terminal kinase (JNK) regulates induction of mitochondrial apoptosis by pro‐suvival BCL‐2 antagoinist obatoclax</a><div class="gs_gray">FGP McCoy, I Paul, JL Hurwitz, B O'Hagan, K Odrzywol, JT Murray, ...</div><div class="gs_gray">Molecular Cancer Therapeutics 8 (12 Supplement), B30-B30<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:WMtz-WDmgKQC" class="gsc_a_at">Multicellular resistance to bortezomib acquired by mesothelioma spheroids can be reversed by modulation of the Bcl-2 repertoire</a><div class="gs_gray">D Barbone, DA Fennell, VC Broaddus</div><div class="gs_gray">MOLECULAR CANCER THERAPEUTICS 8 (12)<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Nnq8S6OXqDYC" class="gsc_a_at">Phosphorylation of c-jun N terminal kinase (JNK) regulates induction of mitochondrial apoptosis by pro-suvival BCL-2 antagoinist obatoclax</a><div class="gs_gray">FGP Mccoy, I Paul, JL Hurwitz, B O'Hagan, K Odrzywol, JT Murray, ...</div><div class="gs_gray">MOLECULAR CANCER THERAPEUTICS 8 (12)<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:txeM2kYbVNMC" class="gsc_a_at">Resistance to the BH3 peptidomimetic obatoclax in non-small cell lung cancer associated with a block in BCL-2 family post-translational regulation</a><div class="gs_gray">F McCoy, J Hurwitz, AD Chacko, I Paul, F Liberante, B O'Hagan, G McKerr, ...</div><div class="gs_gray">Journal of Thoracic Oncology 4 (9, Sup), S592<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:KI9T_ytC6pkC" class="gsc_a_at">Role of the Bcl-2 repertoire in the acquired resistance to Bortezomib of mesothelioma spheroids</a><div class="gs_gray">D Barbone, A Chacko, S Busacca, P Jitesh, G Gaudino, DA Fennell, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 4 (9), S751-S752<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:J3LtWjKFLicC" class="gsc_a_at">Bortezomib resistance in mesothelioma is associated with NOXA downregulation: reversal by the MCL-1 antagonist obatoclax</a><div class="gs_gray">AD Chacko, S Busacca, D Barbone, N Crawford, S Al Rashid, P Bertino, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 4 (9), S363-S363<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:rOcdG6UcVlcC" class="gsc_a_at">Development of expression based biomarkers in NSCLC: a study of intratumor heterogeneity using FFPE tissue</a><div class="gs_gray">RJ Holt, DA Fennell, I Paul, K McManus, PJ Kelly, P Kerr, T Davison, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 4 (9), S622-S622<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:RMgMIBzvq-4C" class="gsc_a_at">Identification of VDAC1 as a putative inhibitor of TRAIL induced apoptosis in non-small cell lung cancer</a><div class="gs_gray">AD Chacko, F Liberante, I Paul, DA Fennell</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 4 (9), S613-S613<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:oTdOBqtIf_kC" class="gsc_a_at">Bcl-2 family proteins contribute to multicellular resistance in lung cancer</a><div class="gs_gray">Y Tsung-Ming, D Barbone, DA Fennell, C Broaddus</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 4 (9), S643-S644<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:sfnaS5RM6jYC" class="gsc_a_at">Restoration of absent mitochondrial death signals by an MCL-1 antagonist bypasses cisplatin resistance in non-small cell lung cancer</a><div class="gs_gray">N Crawford, AD Chacko, S Busacca, I Paul, F Liberante, G Gaudino, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 4 (9), S555-S555<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:7Frjd3zlGBUC" class="gsc_a_at">Deterministic Modelling of BAK Activation Kinetics</a><div class="gs_gray">C Grills, A Chacko, N Crawford, PG Johnston, DA Fennell, SFC O’Rourke</div><div class="gs_gray">AIP Conference Proceedings 1148 (1), 116-119<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:4n0clTBhZ78C" class="gsc_a_at">SRC as a Target</a><div class="gs_gray">D Fennell</div><div class="gs_gray">Journal of thoracic oncology: official publication of the International&nbsp;…<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Ej9njvOgR2oC" class="gsc_a_at">A pilot phase II clinical trial of the 20S proteasome inhibitor bortezomib in patients with relapsed malignant pleural mesothelioma</a><div class="gs_gray">DA Fennell, J Van Meerbeeck, KJ O'Byrne, P Donnellan, S O'Reilly, ...</div><div class="gs_gray">JOURNAL OF THORACIC ONCOLOGY 4 (9), S457-S458<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:PlWzFYVEG4EC" class="gsc_a_at">9080 Phase I trial of gemcitabine/carboplatin (GC), followed by pemetrexed/gemcitabine (PG) in chemonaïve patients (pts) with advanced NSCLC</a><div class="gs_gray">J Steele, G Patel, A Klabatsa, M Das, B Kalidas, C Nicoll, P Wells, ...</div><div class="gs_gray">EJC Supplements 2 (7), 529<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Og1tA8FjbJAC" class="gsc_a_at">Regulation of gene networks associated with mesothelioma cell growth in three dimensional culture</a><div class="gs_gray">P Jithesh, D Barbone, D Fennell, VC Broaddus</div><div class="gs_gray">Journal of thoracic oncology: official publication of the International&nbsp;…<span class="gs_oph">, 2009</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2009</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:g8uWPOAv7ggC" class="gsc_a_at">Obatoclax in SCLC: preclincal evaluation of a BH3 mimetic</a><div class="gs_gray">E Dean, M Ranson, D Fennell, A Roulston, J Viallet, M Berger, C Dive</div><div class="gs_gray">Ejc Supplements 6, 115-115<span class="gs_oph">, 2008</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2008</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:lg2tdxc6qMwC" class="gsc_a_at">P2-120: BH3 domain of BID induces potent and selective apoptosis of non-small cell lung cancer cells: mechanisms and implications for therapy</a><div class="gs_gray">A Chacko, N Crawford, G Coleman, B Greer, P Harriott, G McCartney, ...</div><div class="gs_gray">Journal of Thoracic Oncology 2 (8), S539<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:3A3nxV7CjKIC" class="gsc_a_at">cisplatin, and mitomycin in mesothelioma. Cancer 109: 93-99, No. 1, 1 Jan 2007 801061714</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Inpharma 1573, 3<span class="gs_oph">, 2007</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2007</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:0ngZmJvimKcC" class="gsc_a_at">Translational research</a><div class="gs_gray">J Laurence</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:UarirCmVI0EC" class="gsc_a_at">Novel treatments for mesothelioma</a><div class="gs_gray">F Blackhall, D Fennell, S Baka, S Danson, K O'Byrne, M Ranson</div><div class="gs_gray">Oxford Textbook of Mesothelioma<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:QKtdBID3u5MC" class="gsc_a_at">101 Inhibition of survivin and aurora B kinase radiosensitizes mesothelioma cells by enhancing mitotic arrests</a><div class="gs_gray">KW Kim, B Lu</div><div class="gs_gray">Lung Cancer, S24<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Gb6Hms-Uo9kC" class="gsc_a_at">10 ALA mediated fluorescence thoracoscopy in pleural diseases</a><div class="gs_gray">S Burgers, M Triesscheijn, R van Pel, F Stewart, M Aalders, P Baas</div><div class="gs_gray">Lung Cancer, S3<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:kO05sadLmrgC" class="gsc_a_at">112 Diffuse malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Experience of NCI of Milan</a><div class="gs_gray">M Deraco, S Kusamura, D Baratti, D Nonaka, AD Cabras, N Zaffaroni, ...</div><div class="gs_gray">Lung Cancer, S28<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:WzTVkKNmPSkC" class="gsc_a_at">100 Bax and Bak immunoreactivity in malignant pleural mesothelioma (MPM)</a><div class="gs_gray">A Klabatsa, S Bax, JPC Steele, RM Rudd, MT Sheaff, DA Fennell</div><div class="gs_gray">Lung Cancer, S24<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:Y9VhQm-5nPIC" class="gsc_a_at">483 POSTER Kinetic modelling of R8BH3BID induced BAX/BAK activation dynamics in Non-Small Cell Lung Cancer cells</a><div class="gs_gray">AD Chacko, N Crawford, E Hopkins, B Greer, P Harriott, SFC C'Rourke, ...</div><div class="gs_gray">EJC Supplements 12 (4), 147-148<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:TesyEGJKHF4C" class="gsc_a_at">84 Spontaneous regression of diffuse malignant pleural mesothelioma with no treatment: Two case reports</a><div class="gs_gray">A Klabatsa, MT Sheaff, JPC Steele, RM Rudd, DA Fennell</div><div class="gs_gray">Lung Cancer, S20<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:I8rxH6phXEkC" class="gsc_a_at">247 Spontaneous regression of diffuse malignant pleural mesothelioma (MPM) with no treatment: Two case reports</a><div class="gs_gray">A Klabatsa, MT Sheaff, JPC Steele, RM Rudd, DA Fennell</div><div class="gs_gray">Lung Cancer, S59-S60<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:x21FZCSn4ZoC" class="gsc_a_at">160 An apoptosis primer</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Lung Cancer, S39<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:9DLIHnF0jcYC" class="gsc_a_at">114 Phase II trial of vinorelbine chemotherapy in patients with malignant peritoneal mesothelioma</a><div class="gs_gray">JPC Steele, A Klabatsa, DA Fennell, RL Bowen, MT Sheaff, RA Reznek, ...</div><div class="gs_gray">Lung Cancer, S28-S29<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:m92CDrhVnKEC" class="gsc_a_at">Novel therapies for mesothelioma</a><div class="gs_gray">F Blackhall, D Fennell, S Baka, S Danson, K O’Byrne, M Ranson</div><div class="gs_gray">Malignant Pleural Mesothelioma, 363<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:sJPMR1oEGYQC" class="gsc_a_at">96 Bortezomib accelerates BAX BAK dependent mitochondrial depolarization in malignant pleural mesothelioma cells</a><div class="gs_gray">A Chacko, G Coleman, P Harriott, B Greer, G Gaudino, L Mutti, D Fennell</div><div class="gs_gray">Lung Cancer, S23-S24<span class="gs_oph">, 2006</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2006</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:In6cVmBjs0IC" class="gsc_a_at">Molecular and Immunological approaches</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">Lung cancer 49, S87<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:n3vGvpFsckwC" class="gsc_a_at">Expression and prognostic significance of activated caspase-3 (CASP3) in malignant pleural mesothelioma (MPM)</a><div class="gs_gray">A Klabatsa, DA Fennell, MT Evans, JPC Steele, J Shamash, RM Rudd, ...</div><div class="gs_gray">JOURNAL OF PATHOLOGY 205, 10-10<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:i91s68tWr-MC" class="gsc_a_at">Original Reports-LUNG CANCER-Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials</a><div class="gs_gray">DA Fennell, A Parmar, J Shamash, MT Evans, MT Sheaff, R Sylvester, ...</div><div class="gs_gray">Journal of Clinical Oncology 23 (1), 184-189<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:h168fVGZblEC" class="gsc_a_at">P-397 Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage</a><div class="gs_gray">D Fennell, J Steele, M Sheaff, M Evans, J Shamash, P Wells, R Rudd</div><div class="gs_gray">Lung Cancer, S219-S220<span class="gs_oph">, 2005</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2005</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:5LPo_wSKItgC" class="gsc_a_at">Malignant pleural mesothelioma: time for translational research–Authors' reply</a><div class="gs_gray">D Fennell, R Rudd</div><div class="gs_gray">The Lancet Oncology 10 (5), 591-592<span class="gs_oph">, 2004</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2004</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:lbI08cpqPnQC" class="gsc_a_at">Molecular cytogenetic markers in malignant pleural mesothelioma</a><div class="gs_gray">J Strefford, D Fennell, TM Lane, DM Lillington, J Steele, BD Young, ...</div><div class="gs_gray">JOURNAL OF MEDICAL GENETICS 40, S51-S51<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:3_LpOwP6eMYC" class="gsc_a_at">Expression and prognostic significance of hypoxia-inducible factor 1 alpha in malignant pleural mesothelioma</a><div class="gs_gray">A Klabatsa, DA Fennell, MT Evans, J Shamash, JPC Steele, RM Rudd, ...</div><div class="gs_gray">JOURNAL OF PATHOLOGY 201, 49A-49A<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:BJtnxTr0fRcC" class="gsc_a_at">P-577 Treatment of relapsed small cell lung cancer with irinotecan, cisplatin, and mitomycin C (IPM): A phase II study</a><div class="gs_gray">DA Fennell, SE Slater, JPC Steele, MT Evans, A Constantinidou, ...</div><div class="gs_gray">Lung Cancer, S237<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:GYcXSSpN504C" class="gsc_a_at"><i>Bcl-2</i> Antisense Oligonucleotides Therapy for Cancer</a><div class="gs_gray">FE Cotter, DA Fennell</div><div class="gs_gray">Oncogene-Directed Therapies, 453-468<span class="gs_oph">, 2003</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2003</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:kvJssbFybhEC" class="gsc_a_at">22 Bcl-2 Antisense Oligonucleotides</a><div class="gs_gray">FE Cotter, DA Fennell</div><div class="gs_gray">Oncogene-Directed Therapies, 453<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:oqD4_j7ulsYC" class="gsc_a_at">Ha14-1, a small molecule Bcl-2 antagonist: Chemosensitzation and pharmacodynamics in leukaemia</a><div class="gs_gray">DA Fennell, M Corbo, A Pallaska, FE Cotter</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 86, S16-S17<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:jlhcAiayVhoC" class="gsc_a_at">Structurally distinct small molecule Bak BH3 peptide mimetics exhibit comparable BCL-2 sensitive, pro-apoptotic efficacy</a><div class="gs_gray">DA Fennell, A Pallaska, M Corbo, FE Cotter</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 86, S115-S116<span class="gs_oph">, 2002</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2002</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:l6Q3WhenKVUC" class="gsc_a_at">PK11195, A SMALL MOLEULE FOR APOPTOSIS SENSITISATION, AS A NOVEL THERAPY FOR CLL</a><div class="gs_gray">R Auer, D Fennell, M Corbo, C Fegan, T Lister, F Cotter</div><div class="gs_gray">British Journal of Haematology-Supplement 113<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:3lUAU8Oskd0C" class="gsc_a_at">Pharmacological strategies for antagonising anti-apoptosis protein function in malignancy</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">University College London (University of London)<span class="gs_oph">, 2001</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2001</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=300&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:JH5k92_tO-AC" class="gsc_a_at">Targeting the mitochondrial redox state of leukemia and lymphoma cells with PK11195 for effective therapy.</a><div class="gs_gray">DA Fennell, M Corbo, A Pallaska, M Grootveld, FE Cotter</div><div class="gs_gray">BLOOD 96 (11), 461A-461A<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:H7nrzBkawXsC" class="gsc_a_at">PK11195, a mitochondrial benzodiazepine receptor antagonist, as a new therapy for CLL.</a><div class="gs_gray">RL Auer, DA Fennell, M Corbo, CD Fegan, A Lister, FE Cotter</div><div class="gs_gray">BLOOD 96 (11), 516A-516A<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:DQNrXyjhriIC" class="gsc_a_at">Preclinical pharmacology of a novel class of Bcl-2 resistant chemosensitiser with affinity for the mitochondrial benzodiazepine receptor</a><div class="gs_gray">DA Fennell, A Okaro, M Corbo, DE Banker, F Applebaum, FE Cotter</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 83, 22-22<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:ufKn5pxu7C0C" class="gsc_a_at">REVERSING BCL-2 FUNCTION VIA THE MITOCHONDRIAL BENZODAZEPINE RECEPTOR: A NEW SMALL MOLECULE STRATEGY FOR IN VIVO CHEMOSENSITISATION</a><div class="gs_gray">D Fennell, M Lawler, M Corbo, F Cotter</div><div class="gs_gray">British Journal of Haematology-Supplement 108<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:XDrR66g3YHsC" class="gsc_a_at">KINETIC MODELLING OF CHEMOTHERAPY INDUCED APOPTOSIS IN LYMPHOMA: MEDIAN RATE OF MITOCHONDRIAL PERMEABILITY TRANSITION AS AN INDEX OF CHEMOSENSITIVITY</a><div class="gs_gray">D Fennell, F Cotter</div><div class="gs_gray">British Journal of Haematology-Supplement 108<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:3_f9JqYsqVQC" class="gsc_a_at">Novel pharmacological strategies for antagonizing anti-apoptosis protein function in malignancy</a><div class="gs_gray">DA Fennell</div><div class="gs_gray">PQDT-Global<span class="gs_oph">, 2000</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">2000</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:tz746QTLzJkC" class="gsc_a_at">In vivo facilitation of VP16 in a leukaemia model by the isoquinoline carboxamide PK11195, a mitochondrial benzodiazepine receptor antagonist.</a><div class="gs_gray">DA Fennell, M Corbo, FE Cotter</div><div class="gs_gray">BLOOD 94 (10), 656A-656A<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:wSy_KLzO7YEC" class="gsc_a_at">In vivo suppression of Bcl-XL facilitates VP16 induced mitochondrial permeability transition and caspase activation in a leukaemia model.</a><div class="gs_gray">DA Fennell, MV Corbo, MN Dean, BP Monia, FE Cotter</div><div class="gs_gray">BRITISH JOURNAL OF CANCER 80, 11-11<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:lK9BDNCuzFgC" class="gsc_a_at">Designing a Clinical Antisense Study</a><div class="gs_gray">FE Cotter, D Fennell</div><div class="gs_gray">Manual of Antisense Methodology, 191-201<span class="gs_oph">, 1999</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1999</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:wUn16MOA3RoC" class="gsc_a_at">Validation of a mathematical model for improved antisense oligonucleotide therapy in haematological malignancies</a><div class="gs_gray">DA Fennell, M Corbo, B Kuss, F Dazzi, JM Goldman, FE Cotter</div><div class="gs_gray">British Journal of Haematology 102 (1-I)<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:oursBaop5wYC" class="gsc_a_at">In vivo modelling of gene silencing therapy in haematological malignancies: Apoptosis sensitisation approaches</a><div class="gs_gray">DA Fennell, M Corbo, B Kuss, FE Cotter</div><div class="gs_gray">British Journal of Haematology-Supplement 101 (1S)<span class="gs_oph">, 1998</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl">1998</span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:QtA78RmWg5MC" class="gsc_a_at">When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?</a><div class="gs_gray">T ISSAD, C Blanquart, U Malapelle, SG Gray, AM Baird, D Easty, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:wBLCggQE-ToC" class="gsc_a_at">Ion Torrent semiconductor sequencing detects gene mutations in circulating cell-free DNA of lung cancer patients</a><div class="gs_gray">C Rakhit, DA Fennell, J Shaw, A Antonov, I El-Hariry, V Reichert, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:3MwzVuqRcA0C" class="gsc_a_at">22nd European Conference on General Thoracic Surgery June 15-18, 2014, Copenhagen, Denmark</a><div class="gs_gray">S Raut, F Granato, L Kelly, A Kirk, M Scarci</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:CMvovTBb2okC" class="gsc_a_at">Tracking the Evolution of Non-Small-Cell Lung Cancer-DTU Orbit (24/05/2017)</a><div class="gs_gray">M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:VRfTbSk87rEC" class="gsc_a_at">vi Contents continued</a><div class="gs_gray">SA Smulders, F Smeenk, MLG Janssen-Heijnen, P Wielders, D de Munck, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:W2uZP3ddy8sC" class="gsc_a_at">Vol. 100, October 2016</a><div class="gs_gray">C Gibelin, S Couraud, F Vannucci, D Gonzalez-Rivas, AJ Sharkey, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:ndLnGcHYRF0C" class="gsc_a_at">11 Designing</a><div class="gs_gray">FE Cotter, D Fennell</div><div class="gs_gray">MANUAL OF ANTISENSE METHODOLOGY, 191<span class="gs_oph">, 0</span></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr><tr class="gsc_a_tr"><td class="gsc_a_t"><a href="/citations?view_op=view_citation&amp;hl=en&amp;user=IHT1G6gAAAAJ&amp;cstart=400&amp;pagesize=100&amp;citation_for_view=IHT1G6gAAAAJ:R-LXmdHK_14C" class="gsc_a_at">online at: http://contentsdirect. elsevier. com</a><div class="gs_gray">A Lavolé, M Wislez, M Antoine, C Mayaud, B Milleron, J Cadranel, X Hao, ...</div><div class="gs_gray"></div></td><td class="gsc_a_c"><a href="" class="gsc_a_ac gs_ibl"></a></td><td class="gsc_a_y"><span class="gsc_a_h gsc_a_hc gs_ibl"></span></td></tr></tbody></table><div id="gsc_a_sp" class=""></div><div id="gsc_a_err" class="gs_alrt">The system can't perform the operation now. Try again later.</div></div><div id="gsc_lwp"><span id="gsc_a_nn">Articles 1–418</span><div id="gsc_bpf"><button type="button" id="gsc_bpf_more" class="gs_btnPD gs_in_ib gs_btn_flat gs_btn_lrge gs_btn_lsu" disabled=""><span class="gs_wr"><span class="gs_ico"></span><span class="gs_lbl">Show more</span></span></button></div></div></form></div></div></div></div><div id="gs_ftr_sp" role="presentation"></div><div id="gs_ftr" role="contentinfo"><div id="gs_ftr_rt"><a href="/intl/en/scholar/about.html">Help</a><a href="//www.google.com/intl/en/policies/privacy/">Privacy</a><a href="//www.google.com/intl/en/policies/terms/">Terms</a></div></div></div></body></html>